ZA200702467B - Pyrazolo[1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor(CRF) receptor antagonists - Google Patents
Pyrazolo[1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor(CRF) receptor antagonists Download PDFInfo
- Publication number
- ZA200702467B ZA200702467B ZA200702467A ZA200702467A ZA200702467B ZA 200702467 B ZA200702467 B ZA 200702467B ZA 200702467 A ZA200702467 A ZA 200702467A ZA 200702467 A ZA200702467 A ZA 200702467A ZA 200702467 B ZA200702467 B ZA 200702467B
- Authority
- ZA
- South Africa
- Prior art keywords
- methyl
- pyrazolo
- phenyl
- amine
- dimethyl
- Prior art date
Links
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 title description 47
- 102100021752 Corticoliberin Human genes 0.000 title description 45
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 title description 44
- 229940044551 receptor antagonist Drugs 0.000 title description 26
- 239000002464 receptor antagonist Substances 0.000 title description 26
- 125000000714 pyrimidinyl group Chemical group 0.000 title description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 101
- 150000001875 compounds Chemical class 0.000 claims description 82
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 55
- -1 -NRgR 0 Chemical group 0.000 claims description 48
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 41
- 229910052799 carbon Inorganic materials 0.000 claims description 37
- 239000001257 hydrogen Substances 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 36
- 125000001188 haloalkyl group Chemical group 0.000 claims description 32
- 125000003545 alkoxy group Chemical group 0.000 claims description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 29
- 150000002431 hydrogen Chemical class 0.000 claims description 25
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 19
- 150000002367 halogens Chemical class 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- 208000019901 Anxiety disease Diseases 0.000 claims description 17
- 239000002769 corticotropin releasing factor antagonist Substances 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 150000001721 carbon Chemical group 0.000 claims description 14
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 13
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 claims description 11
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 229910052684 Cerium Inorganic materials 0.000 claims description 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 229940002612 prodrug Drugs 0.000 claims description 7
- 239000000651 prodrug Substances 0.000 claims description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 230000036506 anxiety Effects 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 5
- 229940122010 Corticotropin releasing factor antagonist Drugs 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- BZWZDARLLCYKHK-UHFFFAOYSA-N 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-n-[1-(1,3,4-oxadiazol-2-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound N=1N=COC=1C(CC)NC(N1N=C2C)=CC(C)=NC1=C2C1=CC=C(OC)C=C1C BZWZDARLLCYKHK-UHFFFAOYSA-N 0.000 claims description 2
- VKHVAUKFLBBZFJ-SFHVURJKSA-N 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-n-[(1s)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound N([C@@H](CC)C=1ON=C(C)N=1)C(N1N=C2C)=CC(C)=NC1=C2C1=CC=C(OC)C=C1C VKHVAUKFLBBZFJ-SFHVURJKSA-N 0.000 claims 1
- MUWSWQFNUQJBAQ-UHFFFAOYSA-N 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-n-[1-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropyl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound CC1=CC(OC)=CC=C1C1=C2N=C(C)C=C(NC3(CC3)C=3ON=C(C)N=3)N2N=C1C MUWSWQFNUQJBAQ-UHFFFAOYSA-N 0.000 claims 1
- VBGSRWZQVUWQFD-UHFFFAOYSA-N n-[(3-cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amine Chemical compound CC1=CC(OC)=CC=C1C1=C2N=C(C)C=C(NCC=3ON=C(N=3)C3CC3)N2N=C1C VBGSRWZQVUWQFD-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 222
- 239000000203 mixture Substances 0.000 description 130
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 79
- 235000019439 ethyl acetate Nutrition 0.000 description 78
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 76
- 239000000243 solution Substances 0.000 description 76
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- 239000007787 solid Substances 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 49
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 48
- 208000035475 disorder Diseases 0.000 description 45
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
- 108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 description 37
- 238000006243 chemical reaction Methods 0.000 description 36
- 238000000034 method Methods 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 239000003921 oil Substances 0.000 description 35
- 235000019198 oils Nutrition 0.000 description 35
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
- 230000015572 biosynthetic process Effects 0.000 description 29
- 238000003786 synthesis reaction Methods 0.000 description 27
- 239000000725 suspension Substances 0.000 description 26
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 24
- 238000004128 high performance liquid chromatography Methods 0.000 description 24
- 239000002904 solvent Substances 0.000 description 24
- 239000011541 reaction mixture Substances 0.000 description 23
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
- 239000010410 layer Substances 0.000 description 22
- 238000010898 silica gel chromatography Methods 0.000 description 22
- 239000012044 organic layer Substances 0.000 description 21
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- 239000012267 brine Substances 0.000 description 20
- 239000003153 chemical reaction reagent Substances 0.000 description 20
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 208000028017 Psychotic disease Diseases 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
- 230000035987 intoxication Effects 0.000 description 16
- 231100000566 intoxication Toxicity 0.000 description 16
- 229910052938 sodium sulfate Inorganic materials 0.000 description 16
- 235000011152 sodium sulphate Nutrition 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- 229910000104 sodium hydride Inorganic materials 0.000 description 15
- 125000000623 heterocyclic group Chemical group 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- 208000019022 Mood disease Diseases 0.000 description 13
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 239000012458 free base Substances 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical group N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 description 12
- 235000017557 sodium bicarbonate Nutrition 0.000 description 12
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 12
- 206010012218 Delirium Diseases 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
- 235000019341 magnesium sulphate Nutrition 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 10
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- AEXITZJSLGALNH-UHFFFAOYSA-N n'-hydroxyethanimidamide Chemical compound CC(N)=NO AEXITZJSLGALNH-UHFFFAOYSA-N 0.000 description 10
- 150000002923 oximes Chemical class 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 208000019116 sleep disease Diseases 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 7
- 102000030621 adenylate cyclase Human genes 0.000 description 7
- 108060000200 adenylate cyclase Proteins 0.000 description 7
- 239000002249 anxiolytic agent Substances 0.000 description 7
- 230000000949 anxiolytic effect Effects 0.000 description 7
- 238000000113 differential scanning calorimetry Methods 0.000 description 7
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 230000002085 persistent effect Effects 0.000 description 7
- 208000020016 psychiatric disease Diseases 0.000 description 7
- 208000020685 sleep-wake disease Diseases 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 7
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 201000001880 Sexual dysfunction Diseases 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 230000002124 endocrine Effects 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- 230000000147 hypnotic effect Effects 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000000932 sedative agent Substances 0.000 description 6
- 230000001624 sedative effect Effects 0.000 description 6
- 231100000872 sexual dysfunction Toxicity 0.000 description 6
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 5
- 206010013654 Drug abuse Diseases 0.000 description 5
- 206010026749 Mania Diseases 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 238000001069 Raman spectroscopy Methods 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 229940025084 amphetamine Drugs 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical class C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 208000011117 substance-related disease Diseases 0.000 description 5
- YCZQHXPIKQHABJ-UHFFFAOYSA-N 7-chloropyrazolo[1,5-a]pyrimidine Chemical compound ClC1=CC=NC2=CC=NN12 YCZQHXPIKQHABJ-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 208000022497 Cocaine-Related disease Diseases 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 208000003863 Marijuana Abuse Diseases 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 4
- 238000001237 Raman spectrum Methods 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 208000019906 panic disease Diseases 0.000 description 4
- 208000022821 personality disease Diseases 0.000 description 4
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 4
- 229950010883 phencyclidine Drugs 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 239000002287 radioligand Substances 0.000 description 4
- 238000006798 ring closing metathesis reaction Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 201000009032 substance abuse Diseases 0.000 description 4
- 238000001757 thermogravimetry curve Methods 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 208000031091 Amnestic disease Diseases 0.000 description 3
- 208000029197 Amphetamine-Related disease Diseases 0.000 description 3
- 208000000103 Anorexia Nervosa Diseases 0.000 description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 101800000414 Corticotropin Proteins 0.000 description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000004230 Gender Dysphoria Diseases 0.000 description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000026251 Opioid-Related disease Diseases 0.000 description 3
- 208000006199 Parasomnias Diseases 0.000 description 3
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
- 229960000258 corticotropin Drugs 0.000 description 3
- 230000003001 depressive effect Effects 0.000 description 3
- 235000014632 disordered eating Nutrition 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 3
- 239000000380 hallucinogen Substances 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 206010020765 hypersomnia Diseases 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000024714 major depressive disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Chemical group 0.000 description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 3
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 3
- 238000002600 positron emission tomography Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229910052717 sulfur Chemical group 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 238000004808 supercritical fluid chromatography Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 2
- FBZVZUSVGKOWHG-UHFFFAOYSA-N 1,1-dimethoxy-n,n-dimethylethanamine Chemical compound COC(C)(OC)N(C)C FBZVZUSVGKOWHG-UHFFFAOYSA-N 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N 1,3-di(propan-2-yl)urea Chemical compound CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- IXOPCMZOHYZDMX-UHFFFAOYSA-N 2-(4-methoxy-2-methylphenyl)acetonitrile Chemical compound COC1=CC=C(CC#N)C(C)=C1 IXOPCMZOHYZDMX-UHFFFAOYSA-N 0.000 description 2
- YWGKOEQZKMSICW-UHFFFAOYSA-N 2-chloro-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(Cl)=C1 YWGKOEQZKMSICW-UHFFFAOYSA-N 0.000 description 2
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 2
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 2
- 208000008811 Agoraphobia Diseases 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 208000032841 Bulimia Diseases 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- 241000218236 Cannabis Species 0.000 description 2
- 208000017781 Cocaine intoxication Diseases 0.000 description 2
- 206010012239 Delusion Diseases 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 2
- 206010013980 Dyssomnias Diseases 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- 208000017701 Endocrine disease Diseases 0.000 description 2
- 206010016754 Flashback Diseases 0.000 description 2
- 208000029810 Gender identity disease Diseases 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 101000868045 Homo sapiens Uncharacterized protein C1orf87 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QWCKQJZIFLGMSD-VKHMYHEASA-N L-alpha-aminobutyric acid Chemical compound CC[C@H](N)C(O)=O QWCKQJZIFLGMSD-VKHMYHEASA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 206010033888 Paraphilia Diseases 0.000 description 2
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 description 2
- 208000030047 Sexual desire disease Diseases 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 208000011963 Substance-induced psychotic disease Diseases 0.000 description 2
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 description 2
- 102100032994 Uncharacterized protein C1orf87 Human genes 0.000 description 2
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 201000001843 cannabis dependence Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000010549 co-Evaporation Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N ***e Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- GBONBLHJMVUBSJ-FAUHKOHMSA-N corticorelin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(C)C)C1=CNC=N1 GBONBLHJMVUBSJ-FAUHKOHMSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002447 crystallographic data Methods 0.000 description 2
- 231100000868 delusion Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000003826 endocrine responses Effects 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 208000029364 generalized anxiety disease Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000011331 hallucinogen-persisting perception disease Diseases 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 208000007100 phencyclidine abuse Diseases 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000000063 preceeding effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000003653 radioligand binding assay Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 108010086511 sauvagine Proteins 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 231100000736 substance abuse Toxicity 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229910052713 technetium Inorganic materials 0.000 description 2
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 2
- 229910052716 thallium Inorganic materials 0.000 description 2
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 2
- 125000004001 thioalkyl group Chemical group 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- LOCGPWGCRVKCFN-UHFFFAOYSA-N (2-chloro-4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C(Cl)=C1 LOCGPWGCRVKCFN-UHFFFAOYSA-N 0.000 description 1
- BKMMTJMQCTUHRP-GSVOUGTGSA-N (2r)-2-aminopropan-1-ol Chemical compound C[C@@H](N)CO BKMMTJMQCTUHRP-GSVOUGTGSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- RXNPEQZHMGFNAY-GEALJGNFSA-N (5R)-4-[(1S,6R)-5-[(2S)-2-(4-chlorophenyl)-3-(propan-2-ylamino)propanoyl]-2,5-diazabicyclo[4.1.0]heptan-2-yl]-5-methyl-6,8-dihydro-5H-pyrido[2,3-d]pyrimidin-7-one Chemical compound C[C@@H]1CC(=O)NC2=C1C(=NC=N2)N3CCN([C@H]4[C@@H]3C4)C(=O)[C@H](CNC(C)C)C5=CC=C(C=C5)Cl RXNPEQZHMGFNAY-GEALJGNFSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- OEBXWWBYZJNKRK-UHFFFAOYSA-N 1-methyl-2,3,4,6,7,8-hexahydropyrimido[1,2-a]pyrimidine Chemical group C1CCN=C2N(C)CCCN21 OEBXWWBYZJNKRK-UHFFFAOYSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical compound NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 1
- VGZWTKRISQVBRG-UHFFFAOYSA-N 2,2,2-trifluoro-n'-hydroxyethanimidamide Chemical compound ON=C(N)C(F)(F)F VGZWTKRISQVBRG-UHFFFAOYSA-N 0.000 description 1
- SFFUEHODRAXXIA-UHFFFAOYSA-N 2,2,2-trifluoroacetonitrile Chemical compound FC(F)(F)C#N SFFUEHODRAXXIA-UHFFFAOYSA-N 0.000 description 1
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 1
- 125000006069 2,3-dimethyl-2-butenyl group Chemical group 0.000 description 1
- RWELXDIUDWWGKU-UHFFFAOYSA-N 2-(2,4-dimethoxyphenyl)acetonitrile Chemical compound COC1=CC=C(CC#N)C(OC)=C1 RWELXDIUDWWGKU-UHFFFAOYSA-N 0.000 description 1
- PQXBQWKKJUWNDI-UHFFFAOYSA-N 2-(4-ethoxyphenyl)acetonitrile Chemical compound CCOC1=CC=C(CC#N)C=C1 PQXBQWKKJUWNDI-UHFFFAOYSA-N 0.000 description 1
- BKBQJEGATMJTIY-UHFFFAOYSA-N 2-(bromomethyl)benzoyl bromide Chemical compound BrCC1=CC=CC=C1C(Br)=O BKBQJEGATMJTIY-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DORSEMFXHOQANI-UHFFFAOYSA-N 2-[6-(dimethylamino)-4-methylpyridin-3-yl]-3-oxobutanenitrile Chemical compound CN(C)C1=CC(C)=C(C(C#N)C(C)=O)C=N1 DORSEMFXHOQANI-UHFFFAOYSA-N 0.000 description 1
- YEYUOWPIFKOKHW-UHFFFAOYSA-N 2-[6-(dimethylamino)-4-methylpyridin-3-yl]acetonitrile Chemical compound CN(C)C1=CC(C)=C(CC#N)C=N1 YEYUOWPIFKOKHW-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- XKXMVDRKJANBRI-UHFFFAOYSA-N 3-(2-chloro-4-methoxyphenyl)-2,5-dimethyl-n-[1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound N=1C(C)=NOC=1C(CC)NC(N1N=C2C)=CC(C)=NC1=C2C1=CC=C(OC)C=C1Cl XKXMVDRKJANBRI-UHFFFAOYSA-N 0.000 description 1
- XMUHXQFXXXJKNA-UHFFFAOYSA-N 3-(2-chloro-4-methylphenyl)-2,5-dimethyl-n-[1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound N=1C(C)=NOC=1C(CC)NC(N1N=C2C)=CC(C)=NC1=C2C1=CC=C(C)C=C1Cl XMUHXQFXXXJKNA-UHFFFAOYSA-N 0.000 description 1
- TYDFAFGBEDXXJZ-UHFFFAOYSA-N 3-(4-ethoxyphenyl)-n-(2-methoxyethyl)-2,5-dimethyl-n-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound C1=CC(OCC)=CC=C1C1=C2N=C(C)C=C(N(CCOC)CC=3ON=C(C)N=3)N2N=C1C TYDFAFGBEDXXJZ-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- 125000006027 3-methyl-1-butenyl group Chemical group 0.000 description 1
- ORLGLBZRQYOWNA-UHFFFAOYSA-N 4-methylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 description 1
- RXCVUHMIWHRLDF-HXUWFJFHSA-N 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one Chemical compound ClC1=C2CCN(C(C2=C(C(=C1)[C@@H](C1COC1)OC)Cl)=O)CC=1C(NC(=CC=1OC)C)=O RXCVUHMIWHRLDF-HXUWFJFHSA-N 0.000 description 1
- HWQBQKWBLFACPJ-UHFFFAOYSA-N 5-(3-amino-5-methyl-1h-pyrazol-4-yl)-n,n,4-trimethylpyridin-2-amine Chemical compound C1=NC(N(C)C)=CC(C)=C1C1=C(C)NN=C1N HWQBQKWBLFACPJ-UHFFFAOYSA-N 0.000 description 1
- TYVGWSPFCRINNQ-SFHVURJKSA-N 5-[(2s)-1-[3-(2,4-dimethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]pyrrolidin-2-yl]-3-methyl-1,2,4-oxadiazole Chemical compound COC1=CC(OC)=CC=C1C1=C2N=C(C)C=C(N3[C@@H](CCC3)C=3ON=C(C)N=3)N2N=C1C TYVGWSPFCRINNQ-SFHVURJKSA-N 0.000 description 1
- WPSFOIQTQNCLRY-UHFFFAOYSA-N 6-(dimethylamino)-4-methylpyridine-3-carbaldehyde Chemical compound CN(C)C1=CC(C)=C(C=O)C=N1 WPSFOIQTQNCLRY-UHFFFAOYSA-N 0.000 description 1
- GHEPYZLVGBIRPV-UHFFFAOYSA-N 7-pyrrolidin-1-ylpyrazolo[1,5-a]pyrimidine Chemical compound C1CCCN1C1=CC=NC2=CC=NN12 GHEPYZLVGBIRPV-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 206010001605 Alcohol poisoning Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 206010002859 Anxiety disorder due to a general medical condition Diseases 0.000 description 1
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 206010004716 Binge eating Diseases 0.000 description 1
- 208000021500 Breathing-related sleep disease Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- QCMHGCDOZLWPOT-FMNCTDSISA-N COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 Chemical compound COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 QCMHGCDOZLWPOT-FMNCTDSISA-N 0.000 description 1
- 208000004652 Cardiovascular Abnormalities Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000027691 Conduct disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 206010012225 Delirium tremens Diseases 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000021663 Female sexual arousal disease Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000010235 Food Addiction Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 206010017389 Frotteurism Diseases 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000016619 Histrionic personality disease Diseases 0.000 description 1
- 101000895481 Homo sapiens Corticoliberin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000016588 Idiopathic hypersomnia Diseases 0.000 description 1
- 206010021750 Infantile Spasms Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000001271 Inhalant Abuse Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 206010026864 Masochism Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 206010027944 Mood disorder due to a general medical condition Diseases 0.000 description 1
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 1
- YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 1
- 108010065338 N-ethylglycine Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000027120 Narcissistic personality disease Diseases 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 208000000224 Night Terrors Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- GZMYLSJUNSCMTD-MOPGFXCFSA-N OC[C@@H](C)NC1=NC(=CC(=C1)C=1C=C(C=CC=1C)NC(=O)N1C[C@@H](CC1)CC(F)(F)F)N1CCOCC1 Chemical compound OC[C@@H](C)NC1=NC(=CC(=C1)C=1C=C(C=CC=1C)NC(=O)N1C[C@@H](CC1)CC(F)(F)F)N1CCOCC1 GZMYLSJUNSCMTD-MOPGFXCFSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 208000032769 Pedophilia Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
- 208000034592 Polysubstance dependence Diseases 0.000 description 1
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 1
- 101000895495 Rattus norvegicus Corticoliberin Proteins 0.000 description 1
- 206010039367 Sadism Diseases 0.000 description 1
- 208000030988 Schizoid Personality disease Diseases 0.000 description 1
- 208000020186 Schizophreniform disease Diseases 0.000 description 1
- 208000024791 Schizotypal Personality disease Diseases 0.000 description 1
- 208000029901 Sexual arousal disease Diseases 0.000 description 1
- 208000029899 Sexual aversion disease Diseases 0.000 description 1
- 208000019568 Shared Paranoid disease Diseases 0.000 description 1
- 208000028810 Shared psychotic disease Diseases 0.000 description 1
- 206010063910 Sleep disorder due to a general medical condition Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 206010041347 Somnambulism Diseases 0.000 description 1
- 206010042135 Stomatitis necrotising Diseases 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 108010059705 Urocortins Proteins 0.000 description 1
- 102000005630 Urocortins Human genes 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 201000006791 West syndrome Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- NPUXORBZRBIOMQ-RUZDIDTESA-N [(2R)-1-[[4-[[3-(benzenesulfonylmethyl)-5-methylphenoxy]methyl]phenyl]methyl]-2-pyrrolidinyl]methanol Chemical compound C=1C(OCC=2C=CC(CN3[C@H](CCC3)CO)=CC=2)=CC(C)=CC=1CS(=O)(=O)C1=CC=CC=C1 NPUXORBZRBIOMQ-RUZDIDTESA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 1
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 208000006246 alcohol withdrawal delirium Diseases 0.000 description 1
- 208000028505 alcohol-related disease Diseases 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 description 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- DVHXJLRODLTJOD-UHFFFAOYSA-N aminoazanium;bromide Chemical compound Br.NN DVHXJLRODLTJOD-UHFFFAOYSA-N 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 229950011175 aminopicoline Drugs 0.000 description 1
- 201000002472 amphetamine abuse Diseases 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 208000024823 antisocial personality disease Diseases 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000009910 autonomic response Effects 0.000 description 1
- 208000022804 avoidant personality disease Diseases 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000030963 borderline personality disease Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229940045348 brown mixture Drugs 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 201000009322 cannabis abuse Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- KFUIXDNQSMKKJQ-ZLFMSJRASA-N chembl439883 Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)CNC(=O)[C@H]2NC(=O)CC2)CCC1 KFUIXDNQSMKKJQ-ZLFMSJRASA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960003920 ***e Drugs 0.000 description 1
- 201000001272 ***e abuse Diseases 0.000 description 1
- 201000006145 ***e dependence Diseases 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 208000030964 dependent personality disease Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000005077 diacylhydrazine group Chemical group 0.000 description 1
- 125000004342 dicyclopropylmethyl group Chemical group [H]C1([H])C([H])([H])C1([H])C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- JIVGSHFYXPRRSZ-UHFFFAOYSA-N dimethoxybenzaldehyde Natural products COC1=CC=CC(C=O)=C1OC JIVGSHFYXPRRSZ-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 1
- HHIOOBJZIASBFF-UHFFFAOYSA-N ethyl 3-aminobutanoate Chemical compound CCOC(=O)CC(C)N HHIOOBJZIASBFF-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 125000005469 ethylenyl group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000003481 exhibitionism Diseases 0.000 description 1
- 208000014840 female orgasmic disease Diseases 0.000 description 1
- 206010016531 fetishism Diseases 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- UIWYJDYFSGRHKR-AHCXROLUSA-N gadolinium-153 Chemical compound [153Gd] UIWYJDYFSGRHKR-AHCXROLUSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 201000002270 hallucinogen abuse Diseases 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 201000004197 inhibited female orgasm Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- OCVXZQOKBHXGRU-UHFFFAOYSA-N iodine(1+) Chemical compound [I+] OCVXZQOKBHXGRU-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005468 isobutylenyl group Chemical group 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- VXGRMCZTYDXKQW-YFKPBYRVSA-N methyl (2s)-2-aminopentanoate Chemical compound CCC[C@H](N)C(=O)OC VXGRMCZTYDXKQW-YFKPBYRVSA-N 0.000 description 1
- MBAHGFJTIVZLFB-SNAWJCMRSA-N methyl (e)-pent-2-enoate Chemical compound CC\C=C\C(=O)OC MBAHGFJTIVZLFB-SNAWJCMRSA-N 0.000 description 1
- AHAQQEGUPULIOZ-UHFFFAOYSA-N methyl 2-aminobutanoate;hydrochloride Chemical compound Cl.CCC(N)C(=O)OC AHAQQEGUPULIOZ-UHFFFAOYSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- STSLIPZQSYMYNW-UHFFFAOYSA-N methyl 3-aminopentanoate Chemical compound CCC(N)CC(=O)OC STSLIPZQSYMYNW-UHFFFAOYSA-N 0.000 description 1
- QAWFLJGZSZIZHO-UHFFFAOYSA-N methyl 4-bromobutanoate Chemical compound COC(=O)CCCBr QAWFLJGZSZIZHO-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- OPENCMFJZQABIY-UHFFFAOYSA-N n'-hydroxybutanimidamide Chemical compound CCCC(N)=NO OPENCMFJZQABIY-UHFFFAOYSA-N 0.000 description 1
- OMCUPXRCMTUDHI-UHFFFAOYSA-N n'-hydroxycyclopropanecarboximidamide Chemical compound ON=C(N)C1CC1 OMCUPXRCMTUDHI-UHFFFAOYSA-N 0.000 description 1
- RLZPCFQNZGINRP-UHFFFAOYSA-N n'-hydroxypropanimidamide Chemical compound CCC(N)=NO RLZPCFQNZGINRP-UHFFFAOYSA-N 0.000 description 1
- WODKXQZRQNZRDW-UHFFFAOYSA-N n,n,4-trimethylpyridin-2-amine Chemical compound CN(C)C1=CC(C)=CC=N1 WODKXQZRQNZRDW-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 201000008585 noma Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 description 1
- 201000000988 opioid abuse Diseases 0.000 description 1
- 208000024196 oppositional defiant disease Diseases 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- QEEJLLNYQOBRRM-KSHGRFHLSA-N ovine crf Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CN=CN1 QEEJLLNYQOBRRM-KSHGRFHLSA-N 0.000 description 1
- 150000004866 oxadiazoles Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 208000024817 paranoid personality disease Diseases 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000005470 propylenyl group Chemical group 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 201000005814 sexual masochism Diseases 0.000 description 1
- 208000027599 sexual masochism disease Diseases 0.000 description 1
- 201000005841 sexual sadism Diseases 0.000 description 1
- 208000027596 sexual sadism disease Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 201000006152 substance dependence Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000001958 sympathoadrenomedullary effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 208000016686 tic disease Diseases 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N trans-decahydronaphthalene Natural products C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
- 201000005142 transvestism Diseases 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 239000000777 urocortin Substances 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 206010046947 vaginismus Diseases 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 208000008918 voyeurism Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
PYRAZOLO (1,5-ALPHA) PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING
FACTOR (CRF) RECEPTOR ANTAGONISTS
This application claims the benefit of U.S. Provisional Application No. 60/620.060 filed October 19, 2004 and GB 0519957.5 field 30 September 2005, which is hereby incorporated by reference in its entirety.
This invention relates generally to CRF receptor antagonists, and to methods of treating disorders by administration of such antagonists to a warm-blooded marnmal in need thereof.
The first corticotropin-releasing factor (CRF) was isolated from ovine hypothalami and identificd as a 41-amino acid peptide (Vale et al, Science 213:1394- 1397, 1981). Subsequently, sequences of human and rat CRF were isolated and determined to be identical but different from ovine CRF in 7 of the 41 amino acid residues (Rivier et al., Proc. Natl. Acad. Sci. USA 80:4851, 1983; Shibahara et al., EMBO J. 2.775, 1983). -—
CREF has been found to produce profound alterations in endocrine, nervous and immune system function. CRF is believed to be the major physiological regulator of the basal and stress-release of adrenocorticotropic hormone ("ACTH"), 8-endorphin, and other pro-opiomelanocortin ("POMC")-derived peptides from the anterior pituitary (Vale et al., Science 213:1394-1397, 1981). Briefly, CRF is believed to initiate its biological effects by binding to a plasma membrane receptor which has been found to be distributed throughout the brain (DeSouza et al., Science 224:1449-1451, 1984), pituitary (DeSouza et al, Methods Enzymol. 124:560, 1986, Wynn et al, Biochem. Biophys. Res. Comm. 110:602-608, 1983), adrenals (Udelsman et al., Nature 319:147-150, 1986) and spleen (Webster, E L., and E.B. DeSouza, Endocrinology 122:609-617, 1988). The CRF receptor is coupled to 2 GTP-binding protein (Perrin et al.. Endocrinology 118:1171-1179, 1986) which mediates CRF-stimulated increase in intracellular production of cAMP (Bilezikjian,
L.M., and W.W. Vale, Endocrinology 113:6571-662, 1983). The receptor for CRF has now been cloned from rat (Perrin et al., Endo 133(6):3058-3061, 1993), and human brain (Chen et al., PNAS 90(19):8967-8971, 1993; Vita et al, FEBS 335(1):1-5, 1993). This receptor is a 415 amino acid protein comprising seven membrane spanning domains. A comparison of identity between rat and human sequences shows a high degree of homology (97%) at the amino acid level.
In addition to its role in stimulating the production of ACTH and POMC,
CRF is also believed to coordinate many of the endocrine, autonomic, and behavioral responses to stress, and may be involved in the pathophysiology of affective disorders.
Moreover, CRF is believed to be a key intermediary in communication between the immune, central nervous, endocrine and cardiovascular systems (Crofford et al., J. Clin.
Invest. 90:2555-2564, 1992; Sapolsky et al., Science 238:522-524, 1987; Tilders et al.,
Regul. Peptides 5:77-84, 1982). Overall, CRF appears to be one of the pivotal central nervous system neurotransmitters and plays a crucial role in integrating the body's overall response to stress.
Administration of CRF directly to the brain elicits behavioral, physiological, and endocrine responses identical to those observed for a mammal exposed to a stressful environment. For example, intracerebroventricular injection of CRF results in behavioral activation (Sutton et al., Nature 297:331, 1982), persistent activation of the electroencephalogram (Ehlers et al., Brain Res. 278:332, 1983), stimulation of the sympathoadrenomedullary pathway (Brown et al., Endocrinology 110:928, 1982), an increase of heart rate and blood pressure (Fisher et al., Endocrinology 110:2222, 1982), an increase in oxygen consumption (Brown et al., Life Sciences 30:207, 1982), alteration of gastrointestinal activity (Williams et al., Am. J. Physiol. 253:G582, 1987), suppression of food consumption (Levine et al., Neuropharmacology 22:337, 1983), modification of sexual behavior (Sirinathsinghji et al., Nature 305:232, 1983), and immune function compromise (Irwin et al., Am. J. Physiol. 255:R744, 1988). Furthermore, clinical data suggests that CRF may be hypersecreted in the brain in depression, anxiety-related disorders, and anorexia nervosa. (DeSouza, Ann. Reports in Med. Chem. 25:215-223, 1990). Accordingly, clinical data suggests that CRF receptor antagonists may represent novel antidepressant and/or anxiolytic drugs that may be useful in the treatment of the neuropsychiatric disorders manifesting hypersecretion of CRF.
The first CRF receptor antagonists were peptides (see, e.g., Rivier et al,
U.S. Patent No. 4,605,642; Rivier et al., Science 224:889, 1984). While these peptides established that CRF receptor antagonists can attenuate the pharmacological responses to
CRF, peptide CRF receptor antagonists suffer from the usual drawbacks of peptide therapeutics including lack of stability and limited oral activity.
CRF antagonists comprising compounds having a pyrazolo-[1,5a}- pyrimidine core are disclosed in the following patents and published applications:
W09720109, US6313124, W09803510, WO9938868, WO09808847, JP2000038350,
EP1097709 and US6664261. Further, this core is disclosed in application W09535298 for analgesics, in application JP10101672 for adenosine reinforcement agents, in application JP10101671 for nitrogen monooxide synthase inhibitors, in application
W02001023387 for neuropeptide Y1 antagonists, in application WO02000044754 for fat accumulation inhibitors, and in application WO02003101993 for hepatitis C virus replication inhibitors.
Due to the physiological significance of CRF, the development of biologically-active small molecules having significant CRF receptor binding activity and which are capable of antagonizing the CRF receptor remains a desirable goal. Such CRF receptor antagonists may be useful in the treatment of endocrine, psychiatric and neurological conditions or illnesses, including stress-related disorders in general.
While significant strides have been made toward achieving CRF regulation through administration of CRF receptor antagonists, there remains a need in the art for effective small molecule CRF receptor antagonists. There is also a need for pharmaceutical compositions containing such CRF receptor antagonists, as well as methods relating to the use thereof to treat, for example, stress-related disorders. The present invention fulfills these needs, and provides other related advantages.
This invention is generally directed to CRF receptor antagonists, and more specifically to CRF receptor antagonists having the following general structure (I):
Ry So
Rie Sy _ Het
No =
N
AR), and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein:
R, is hydrogen, alkyl, substituted alkyl, haloalkyl, substituted haloalkyl,
S alkoxyalkyl, substituted alkoxyalkyl, arylalkyl, substituted arylalkyl, heterocyclealkyl, or substituted heterocyclealkyl;
R,s and Ry are independently hydrogen, C,-Cs alkyl, substituted C-Ce alkyl, C;-Cs haloalkyl, substituted C;-Cs haloalkyl, arylalkyl, substituted arylalkyl, C,-Ce alkoxyalkyl, substituted C,-Cs alkoxyalkyl, alkylsulfonylalkyl, aminoalkyl, monoalkylaminoalky! or dialkylaminoalkyl; or :
R, together with the nitrogen to which it is attached and either Ra, or Ry together with the carbon to which Ry and Ry, are attached form a 4-7 membered heterocyclic ring; or
Ra, and Ry together with the carbon atom to which they are attached form a ring of 3-7 members optionally containing within the ring -O-, -S- or -N(R3)-;
Rs is alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, acyl, -C(O)ORg, -C(O)NRgR 0, or S(O)R11;
Y at each occurrence is independently a direct bond or -C(R4;Rap)m-: mis lor2;
Rus and Rep are independently hydrogen, C;-Cs alkyl, substituted C;-Cs alkyl, arylalkyl, substituted arylalkyl, C,-Cs alkoxyalkyl, substituted C,-Ce alkoxyalkyl, alkylsulfonylalkyl, aminoalkyl, monoalkylaminoalkyl or dialkylaminoalkyl; or
Ra, and Ry, together with the carbon atom to which they are attached form a ring of 3-7 members optionally containing within the ring -O-, -S- or -N(R3)-;
Het is
R syn. XT wo Wo or Ve
Rs is hydrogen, halogen, C,-Cs alkyl, substituted C,-Cg alkyl, C-Cg alkoxy, substituted C,-Cs alkoxy, amino, alkylamino or dialkylamino;
Rs at each occurrence is independently halogen, C;-Cs¢ alkyl or substituted
C,-Cs alkyl; n is an integer from 0-3 inclusive;
Ar is phenyl or pyridyl;
R; at each occurrence is independently halogen, alkyl, substituted alkyl, C,-
Cg alkoxy, substituted C,-Ce alkoxy, -NRoR 0. alkylsulfonyl or substituted alkylsulfonyl; o is an integer from 0-3 inclusive; and each of Rs, Re, Rio and Ry; is hydrogen, C,-Ce alkyl, substituted C;-Ce alkyl, arylalkyl, substituted arylalkyl, C,-C¢ alkoxyalkyl, substituted C,-C¢ alkoxyalkyl, alkylsulfonylalkyl, aminoalkyl, monoalkylaminoalkyl or dialkylaminoalkyl.
These and other aspects of the invention will be apparent upon reference to the following detailed description. To this end, various references are set forth herein which describe in more detail certain procedures, compounds and/or compositions, and are hereby incorporated by reference in their entirety.
Figure 1 shows X-Ray powder diffraction data obtained for polymorph Form 1 of {3-(4-
Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-ylJ-[(S)-1-(3- methyl-[1,2,4)oxadiazol-5-yl)-propyl])-amine as described before. Form 1 is characterised by having an XRPD pattern with signals substantially as listed in Table 1.
Figure 2 shows the Raman spectrum of polymorph Form 1 of [3-(4-
Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1 ,5-a]pyrimidin-7-yl]-[(8)-1-(3- methyl-[1,2,4]oxadiazol-5-yl)-propyl]-amine.
Figure 3 shows a Differential Scanning Calorimetry (DSC) thermogram of polymorph Form 1 of [3-(8-Methoxy-2-methyl-pheny})-2,5-dimethyl-pyrazolo{1,5- alpyrimidin-7-yl]-[(S)-1-(3-methyl-[1,2,4]oxadiazol-5-y!)-propyl]-amine.
Figure 4 shows X-Ray powder diffraction data obtained for polymorph
Form 2 of [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolof1,5-alpyrimidin-7-yl]- [(S)-1-(3-methyl-[ 1,2 4]oxadiazol-5-yl)-propyl}-amine as described before. Form 1 is characterised by having an XRPD pattern with signals substantially as listed in Table 1.
Figure 5 shows the Raman spectrum of polymorph Form 2 of [3-(4-
Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolof 1,5-alpyrimidin-7-y1}-{(S)-1-(3- methyi-[1,2,4Joxadiazol-5-yl)-propyl]-amine.
Figure 6 shows a Differential Scanning Calorimetry (DSC) thermogram of polymorph Form 2 of [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5- a]pyrimidin-7-yl}-[(S)-1-(3-methyi-[1 ,2,4]oxadiazol-5-yl)-propyl]-amine.
The present invention is directed generally to compounds useful as corticotropin-releasing factor (CRF) receptor antagonists. In a first embodiment, the CRF receptor antagonists of this invention have the following structure (I):
R Ye P Het “NNT Sy
NN =~
Mr), and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein:
R, is hydrogen, alkyl, substituted alkyl, haloalkyl, substituted haloalkyl, alkoxyalkyl, substituted alkoxyalkyl, arylalkyl, substituted arylalkyl, heterocyclealkyl, or substituted heterocyclealkyl;
Raz, and Ry, are independently hydrogen, C,-Cs alkyl, substituted C;-Cs alkyl, C;-Cs haloalkyl, substituted C,-Cs haloalkyl, arylalkyl, substituted arylalkyl, C;-Cs alkoxyalkyl, substituted C,;-Cs alkoxyalkyl, alkylsulfonylalkyl, aminoalkyl, monoalkylaminoalkyl or dialkylaminoalkyl; or
R, together with the nitrogen to which it is attached and either Ra, or Ray together with the carbon to which Ry and Rap are attached form a 4-7 membered heterocyclic ring; or
Ra, and Ry, together with the carbon atom to which they are attached form a ring of 3-7 members optionally containing within the ring -O-, -S- or -N(R3)-;
Rj is alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, acyl, -C(O)ORg, -C(O)NRgR 10, or S(O)R 11;
Y at each occurrence is independently a direct bond or -C(R4aRap)m-; mis 1 or 2;
Rs and Ry, are independently hydrogen, C,-C¢ alkyl, substituted C,-C¢ alkyl, arylalkyl, substituted arylalkyl, C,-Cs alkoxyalkyl, substituted C,-Cs alkoxyalkyl, alkylsulfonylalkyl, aminoalkyl, monoalkylaminoalkyl or dialkylaminoalkyl; or .
Raa and Ry, together with the carbon atom to which they are attached form a ring of 3-7 members optionally containing within the ring -O-, -S- or -N(R3)-;
Het is
X
FT re
HSH
Rs is hydrogen, halogen, C,-Cg alkyl, substituted C,-Cg alkyl, C,-Cg alkoxy, substituted C,-Cs alkoxy, amino, alkylamino or dialkylamino;
Rg at each occurrence is independently halogen, C,-Cg alkyl or substituted
C-Cg alkyl; n is an integer from 0-3 inclusive;
Ar is phenyl or pyridyl;
R7 at each occurrence is independently halogen, alkyl, substituted alkyl, C,-
Cs alkoxy, substituted C,-Cg alkoxy, -NRgR , alkylsulfonyl or substituted alkylsulfonyl;
o is an integer from 0-3 inclusive; and cach of Rs, Ro, Ryo and Ry; is hydrogen, Ci-Cs alkyl, substituted C,-Cq alkyl, arylalkyl, substituted arylalkyl, C;-Cs alkoxyalkyl, substituted C,-Cs alkoxyalkyl, alkylsulfonylalkyl, aminoalkyl, monoalkylaminoalkyl or dialkylaminoalkyl.
The CRF receptor antagonists of this invention have utility over a wide range of therapeutic applications, and may be used to treat a variety of disorders or illnesses, including stress-related disorders. Such methods include administering an effective amount of a CRF receptor antagonist of this invention, preferably in the form of a pharmaceutical composition, to a mammal in need thereof. Accordingly, in another embodiment, pharmaceutical compositions are disclosed containing one or more CRF receptor antagonists of this invention in combination with a pharmaceutically acceptable carrier and/or diluent.
As used herein, the above terms have the following meaning: “Alkyl” means a straight chain or branched, noncyclic or cyclic, unsaturated or saturated aliphatic hydrocarbon containing from 1 to 10 carbon atoms, while the terms “lower alkyl” and “C;-Cg alkyl” have the same meaning as alkyl but contain 1 to 6 carbon atoms. Representative saturated straight chain alkyls include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, and the like; while saturated branched alkyls include isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, and the like. Representative saturated cyclic alkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -CH- cyclopropyl, -CHa-cyclobutyl, -CH;-cyclopentyl, -CH,-cyclohexyl, and the like; while unsaturated cyclic alkyls include cyclopentenyl and cyclohexenyl, and the like. Cyclic alkyls, also referred to as “homocyclic rings,” include di- and poly-homocyclic rings such as decalin and adamantyl. Unsaturated alkyls contain at least one double or triple bond between adjacent carbon atoms (referred to as an “alkenyl” or “alkynyl”, respectively).
Representative straight chain and branched alkenyls include ethylenyl, propylenyl, 1- butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-2- butenyl, 2,3-dimethyl-2-butenyl, and the like; while representative straight chain and branched alkynyls include acetylenyl, propynyl, 1-butynyl, 2-butynyl, l-pentynyl, 2- pentynyl, 3-methyl-1 butynyl, and the like.
“Aryl” means an aromatic carbocyclic moiety such as phenyl or naphthyl.
“Arylalkyl” means an alkyl having at least one alkyl hydrogen atom replaced with an aryl moiety, such as benzyl (i.e., -CHz-phenyl), -CH,-(1- or 2-naphthy}), -(CHa),phenyl, -(CHz)sphenyl, -CH(phenyl),, and the like.
“Heteroaryl” means an aromatic heterocycle ring of 5- to 10-members and having at least one heteroatom selected from nitrogen, oxygen and sulfur, and containing at least 1 carbon atom, including both mono- and bicyclic ring systems.
Representative heteroaryls include (but are not limited to) furyl, benzofuranyl, thiophenyl, benzothiophenyl, pyrrolyl, indolyl, isoindolyl, azaindolyl, pyridyl, quinolinyl, isoquinolinyl, oxazolyl, isooxazolyl, benzoxazolyl, pyrazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, quinazolinyl and oxadiazolyl.
“Heteroarylalkyl” means an alkyl having at least one alkyl hydrogen atom replaced with a heteroaryl moiety, such as -CH,-pyridinyl, -CH,-pyrimidiny}, and the like.
“Heterocycle” (also referred to herein as a “heterocycle ring”) means a 5- to 7-membered monocyclic, or 7- to 14-membered polycyclic, heterocycle ring which is either saturated, unsaturated or aromatic, and which contains from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized, including bicyclic rings in which any of the above heterocycles are fused to a benzene ring as well as tricyclic (and higher) heterocycle rings.
The heterocycle may be attached via any heteroatom or carbon atom.
Heterocycles include heteroaryls as defined above.
Thus, in addition to the aromatic heteroaryls listed above, heterocycles also include (but are not limited to) morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperizinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyrany!, tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl,
and the like.
“Heterocyclealkyl” means an alkyl having at least one alkyl hydrogen atom replaced with a heterocycle, such as -CHz-morpholinyl, and the like.
“Haloalkyl” means an alkyl group having at least one alkyl hydrogen atom replaced with a halogen, such as CHC], CHCl, CCl, CHF, CF, and the like. “C-Cs haloalkyl” has the same definition as “haloalkyl” but contains 1 to 6 carbon atoms.
The term “substituted” as used herein means that at least one hydrogen atom on any of the groups described herein (e.g. alkyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle or heterocyclealkyl) is replaced with a substituent. In the case of an oxo substituent (“(=0)") two hydrogen atoms are replaced. “Substituents” within the context of this invention include halogen, hydroxy, cyano, nitro, amino, alkylamino, dialkylamino, alkyl, substituted alkyl, alkoxy, thioalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxy, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -NR,Rs, -NR,C(=O)Rs, -NR,C(=O)NR,Rs, -NR,C(=0)ORs -NR:SO:Rp, -OR,, -C(=O)R, -C(=O)OR,, -C(=O)NR,R;, -OC(=O)NR,Rp, -SH, -SR,, -S(=O)R,, -S(=O):R., -OS(=O)R,, -S(=0);0R,, wherein R, and Ry, are the same or different and independently hydrogen, alkyl, haloalkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl. “Halogen” means fluoro, chloro, bromo or iodo. “Alkoxy” means an alkyl moiety attached through an oxygen bridge (i.e., -O-alkyl) such as —O-methyl, -O-ethyl, and the like. “Cy-Cs alkoxy” has the same definition as alkoxy but contains 1 to 6 carbon atoms. “Haloalkoxy” means an alkoxy having at least one hydrogen atom replaced with halogen, such as trifluoromethoxy and the like. “Alkoxyalkyl” means an alkyl having at least one hydrogen atom replaced with alkoxy, such as methoxymethyl and the like. “Ci-Cs alkoxyalkyl” has the same definition as “alkoxyalkyl” where the alkoxy group has 1 to 6 carbon atoms. “Thioalkyl” means an alkyl moiety attached through a sulfur bridge (i.e., -S-alkyl) such as —S-methyl, -S-ethyl, and the like. “Alkylamino” and “dialkylamino” mean one or two alkyl moieties attached through a nitrogen bridge (i.e, -NHalkyl or —N(alkyl)(alkyl)) such as methylamino, ethylamino, dimethylamino, dicthylamino, and the like.
“Hydroxyalkyl” means an alkyl substituted with at least one hydroxyl group. “Mono- or di(cycloalkyl)methyl” represents a methyl group substituted with one or two cycloalkyl groups, such as cyclopropylmethyl, dicyclopropylmethyl, and the like. “Alkyicarbonylalkyl” represents an alkyl substituted with a -C(=O)alkyl group. “Alkylcarbonyloxyalkyl” represents an alkyl substituted with a -C(=0)Oalkyl group or a -OC(=0)alkyl group. “Alkylthioalkyl” represents a alkyl substituted with a -S-alkyl group. “Mono- or di(alkyl)aminoalkyl” represents an alkyl substituted with a mono- or di(alkyl)amino. "Acyl" represents alkyl-C(=0)-.
Embodiments of the invention presented herein are for purposes of example and not for purposes of limitation. In one embodiment of this invention, R; may represent hydrogen, alkyl, substituted alkyl, haloalkyl, substituted haloalkyl, alkoxyalkyl, substituted alkoxyalkyl, arylalkyl, substituted arylalkyl, heterocyclealkyl, or substituted heterocyclealkyl. Thus, representative compounds of this invention include, for example, the following structure (lla) where R; is hydrogen, structure (IIb) where R; is methyl, structure (IIc) where R; is methoxymethyl, structure (IId) where R; is benzyl, and structure (Ile) where R; is pyrid-2-yl-methyl:
Kn ne AS
Y)., Yn Y).
NSS, NPs EL
Aw, “wy, ay, (a) (Ib) (Ic)
R R R R
A 5%
Het Het
Baas of
A
Me. wy), (Id) (Tle)
In further embodiments of the invention, Raz, and Ry, are independently hydrogen, C;-Cs alkyl, substituted C,-Cs alkyl, C,-Cs haloalkyl, substituted C;-Cs haloalkyl, arylalkyl, substituted arylalkyl, C,-C¢ alkoxyalkyl, substituted C;-C¢ alkoxyalkyl, alkylsulfonylalkyl, aminoalkyl, monoalkylaminoalkyl or dialkylaminoalkyl.
Thus, representative compounds of this invention include the following structure (Ila) where R,, and Ry, are hydrogen. Further representative compounds wherein Rap is : hydrogen include structure (IIb) where R2, is alkyl exemplified by methyl, structure (IIc) where Rg, is arylalkyl exemplified by benzyl, structure (IlId) where Ry, is alkoxyalkyl exemplified by methoxymethyl, structure (Ille) where Ra 1s alkylsulfonylalkyl exemplified by methylsulfonylmethyl, and structure (IIIf) where Rj, is aminoalkyl exemplified by aminomethyl. c ¢ {
H Het Het
VA LN SR 1 —N N, N
NSS NSS Nee = ~~ 0) a ~~ (] a ~~
N N
A As,
Sw, \®p, ew, (Ta) (IIb) (IIc) ! 8 r Co cr
Het H Het
Rio” Novy” ANP el Roy” Avs =z —N, N, ~—N
NSS NSS WET
Nn = \ = _ =
NT N
Mey, Me, Mey, (Id) (Ie) (If)
In further embodiments of the invention, R, together with the nitrogen to which it is attached and either Ra, or Rap together with the carbon to which Rj, and Ry, are attached form a 4-7 membered heterocyclic ring exemplified in structure (IVa) as the 7- pyrrolidin-1-yl-pyrazolo[1,5-a]pyrimidine and in structure (IVb) as the 7-piperidin-1-yl- pyrazolo[1,5-a}pyrimidine.
Het @ Het $ vw a wl 1 wf JO
Ary, Ara, (IVa) (IVb)
In further embodiments of the invention, Ra, and Ry, together with the carbon atom to which they are attached form a ring of 3-7 members exemplied by cyclopropyl in the following structure (Va) and by ring "A" in the following structure (Vb) wherein ring "A" optionally contains -O-, -S- or -N(R3)- and Rj is alkyl, substituted alkyl, aryalkyl, substituted arylalkyl, acyl, -C(O)ORs, -C(O)NRgR 1, or S(O)2R 11. et x. Xi wt Re, GY we 3 NN Zz NN wr LS CID nN x 8 = v Cor ®Rs)s Ry), (Va) (Vb)
In further embodiments of the invention, Y at each occurrence is independently a direct bond or -C(RasRab)m-, Where m is 1-2 inclusive and Ry, and Ryy, are independently hydrogen, C,-C¢ alkyl, substituted C-Cs alkyl, arylalkyl, substituted arylalkyl, C,-C¢ alkoxyalkyl, substituted C-C; alkoxyalkyl, alkylsulfonylalkyl, aminoalkyl, monoalkylaminoalky! or dialkylaminoalkyl. Thus, representative compounds of this invention include for example the following structure (VIa) when Y is a direct bond and structure (VIb) when Y is -C(R4:Rap) »- and mis 1.
R R we 5 Het
R
Het 40 4b
A wy, Mero, (V1a) (Vib)
In another embodiment of the invention, Ri, and Ry, together with the
S carbon atom to which they are attached form a ring of 3-7 members optionally containing within the ring -O-, -S- or -N(R3)-. Thus, representative compounds of this invention include for example the following structure (VIIa) when Ra and Rg, together with the carbon atom to which they are attached form a cyclopropyl ring, and structure (VIIb) when
Raa and Rg, together with the carbon atom to which they are attached form ring "B" wherein ring "B" optionally contains -O-, -S- or -N(Rj)-. ! " Ry Het
Het Ry,
YX ~
EOSIN &
Mwy), A, (Va) (VIIb)
In another embodiment of the invention, Het is one of three oxadiazoles exemplified in the following structures (VIIIa)-(VIIIc) wherein RS is hydrogen, halogen,
C,-Cs alkyl, substituted C,-Cs alkyl, C,-Cs alkoxy, substituted C,-C¢ alkoxy, amino, alkylamino or dialkylamino.
pb
Ra Ry N Ra Ry TH, Ra Ry,
R fA R ( 0 Nes
A A
Ry), Rs a (Ry), (Villa) (VIIIb) (VIIc)
In another embodiment of the invention, Rs at each occurrence is 5S independently independently halogen, C;-Cs alkyl or substituted C,-Cs alkyl, and n is 0-3 inclusive. Thus, representative compounds of this invention include for example the following structures (IXa — IXh) wherein Ry independently occupies all possible combinations of positions 2, 5 and 6 of the pyrazolo-[1,5a}-pyrimidines core:
R CN He R y Het R ne™ Xe 0 TO oO
Ry Re 1 Tr tr
Ry, ®R;), (Ry), R,), (IXa) (IXb) (Xe) (IXd)
Ry, R R, Ry Rp R \/® a N a
Rm Ky he R oH Re Ky oH R y He
R, R
CO 0 0 1 § vo roo iy (Ry), (R,), (Ry), (Ry), (IXe) (IXf) (IXg) (IXh)
In another embodiment of the invention, Ar is phenyl or pyridyl, R, at each occurrence is independently halogen, C,-Co alkyl, substituted C,-C)q alkyl, C,-Cs alkoxy, substituted C,-Cg alkoxy, -NRgR 0, alkylsulfonyl or substituted alkylsulfonyl, and o is 0-3 inclusive. Thus, representative compounds of the invention include for example the following structure (Xa) when Ar is phenyl and structure (Xb) when Ar is pyridyl.
Fa J Ry Ra
R y t R N\ y Ne
Re; C10 (Ro); CO & @
R7)o R7)o (Xa) (Xb)
Compounds of the present invention include: [1-(3-Cyclopropyl-[1 2.4)oxadiazol-5-yl)-propyl]-[3-(4-methoxy-2-methyl- phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a}pyrimidin-7-yl]-amine (Ex. 11-1); [1-(3-Isopropyl-[1,2,4]oxadiazol-5-y1)-propyl]-{3(4-methoxy-2-methyl- phenyl)-2,5-dimethyl-pyrazolo[ 1.5-alpyrimidin-7-yl}-amine (Ex. 11-2); : [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo{1,5-a]pyrimidin-7- y1]-{1-(3-methyl-[1,2,4]oxadiazol-5-y})-2-phenyl-ethyl]-amine (Ex. 11-3); [1-(3-Isopropyl-[1,2 4]oxadiazol-5-y1)-propyl]-[3-(4-methoxy-2-methyl- phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7-yl}-amine (Ex. 1 1-4); [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo{1,5-a]pyrimidin-7- yl}-[1-(3-methyl-[1,2,4]oxadiazol-5-yl)-butyl]-amine (Ex. 11-5); [3-(4-Methoxy-2-meth yl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a] pyrimidin-7- yl)-(3-methyl-[1,2.4]oxadiazol-5-ylmethyl)-amine (Ex. 11-6); (3-Cyclopropyl-[1,2,4]oxadiazol-5-ylmethyl)-[3-(4-methoxy-2-methyl- phenyl)-2,5-dimethyl-pyrazolo{ 1,5-a]pyrimidin-7-yl]-amine (Ex. 11-7), . (3-Isopropyl-[1,2.4]oxadiazol-5-ylmethyl)-[3-(4-methoxy-2-methyl- phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7-yl]-amine (Ex. 11-8); [2-(3-Cyclopropyl-[1,2,4]oxadiazol-5-yl)-(R)-1-methyl-ethyl}-[3-(4- methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7-yl]-amine (Ex. 11- 9) [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7- ylJ-{(R)-1-methyl-2-(3-methyl-[1,2,4]oxadiazol-5-yl)-ethyl}-amine (Ex. 11-10); [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7- yl]-[1-(3-trifluoromethyl-[1,2 4]oxadiazol-5-yl)-propyl}-amine (Ex. 11-11);
(1-(3-Cyclopropyl-[1.2,4]oxadiazol-5-yl)-cyclopropyl}-{3-(4-methoxy-2- methyl-phenyl)-2,5-dimethyl-pyrazolo{1,5-a]pyrimidin-7-yl]-amine (Ex. 11-12); [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethy}-pyrazolo[1,5-alpyrimidin-7- y1}-[1-(3-methyl-(} 2,4)oxadiazol-5-yl)<cyclopropyl] -amine (Ex. 11-13); [1-(3-Ethyl-[1,2,4]oxadiazol-5-yl)-cyclopropyl}-[3-(4-methoxy-2-methyl- phenyl)-2,5-dimethyl-pyrazolo[1,5-alpyrimidin-7-yl}-amine (Ex. 11-14); [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimeth yl-pyrazolo[1,5-a]pyrimidin-7- yl}-(3-propyi-[1 2 4Joxadiazol-5-ylmethyl)-amine (Ex. 1 1-15); [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethy}-pyrazolo{1,5-a]pyrimidin-7- yl)-[1-33 -trifluoromethyl-{1 2.4]oxadiazol-5-y!)-cyclopropyl]-amine (Ex. 11-16); [2-(3-Ethyl-[1,2,4]oxadiazol-5-yl)-(R)-1-methyl-ethyl}-(3-(4-methoxy-2- methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a}pyrimidin-7-yl]-amine (Ex. 11-17); [3-(6-Dimethylamino-4-methyl-pyridin-3-y1)-2,5-dimethyl-pyrazolo[1,5- alpyrimidin-7-yl}-{3-methyl-(R)-1-(3-methyl-[1,2.4Joxadiazol-5-yl)-butyl]-amine (Ex. 11- 18); 3-(2,4-Dimethoxy-phenyl)-2,5-dimethyl-7-[(S)-2-(3-methyl- [1,2,4]oxadiazol-5-yl)-pyrrolidin-1-yl]-pyrazolo[1,5-a]pyrimidine (Ex. 11-19); - [3-(2,4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a}pyrimidin-7-yl}- [1-(3-methyl-[ 1,2,4Joxadiazol-5-y1)-propyl]-amine (Ex. 11-20); [3-(2,4-Dimethox y-phenyl)-2,5-dimethyl-pyrazolo(1 ,5-a)pyrimidin-7-yl}- {1-(3-methyl-[1,2,4]oxadiazol-5-yl)-ethyl}-amine (Ex. 11-21); (3-(2,4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a)pyrimidin-7-yl]- [1-(3-methyl-[1,2,4]oxadiazol-5-yl)-butyl]}-amine (Ex. 11-22); (3-(2,4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo{1,5-alpyrimidin-7-yl]- [3-methyl-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-butyl}-amine (Ex. 11-23); [3-(2,4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo(1,5-a}pyrimidin-7-yl]- methyl-(3-methyl-[1,2,4]oxadiazol-5-yimethyl)-amine (Ex. 11-24);
Benzyl-[3-(6-dimethylamino-4-methyl-pyridin-3-yl)-2,5-dimethyl- pyrazolo[1,5-a)pyrimidin-7-yl]-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-amine (Ex. 11- 25); [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyri midin-7- yl]-[1-(3-methyl-[1,2 4]oxadiazol-5-y})-propyl]-amine (Ex. 11-26);
[3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethy]-pyrazolo( 1 ,5-a)pyrimidin-7- yl]-[ 1-methyl-2-(3-methyl-[1,2,4]oxadiazol-5-yl)-ethyl)-amine (Ex. 12-1);
Benzyl-[3-(4-methoxy-2-methyl-phen yl)-2,5-dimethyl-pyrazolo[1.5- alpyrimidin-7-yl]-(3-methyl-[1,2 4Joxadi azol-5-ylmethyl)-amine (Ex. 12-2); [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-alpyrimidin-7- y1J-(2,2,2-trifluoro-1-(3-methyl-{1,2.4]oxadiazol-5-ylmethyl)-ethyl]-amine (Ex. 12-3); [2-(3-Cyclopropyl-{1 ,2,4]Joxadiazol-5-yl)- 1-methyl-ethy!]-[3-(4-methoxy- 2-methyl-phenyl)-2,5-dimethyl-pyrazolo 1,5-a]pyrimidin-7-yl}-amine (Ex. 124); [2-(3-1sopropyl-[1,2,4]oxadiazol-5-y1)-1-methyl-ethyl]-[3-(4-methoxy-2- methyl-phenyl)-2,5-dimethyl-pyrazolo{1,5-a]pyrimidin-7-yl]-amine (Ex. 12-5); [2-(3-Cyclopropyl-[1,2,4]oxadiazol-5-yl)-(S)- 1-methyl-ethyl}-[3-(4- methoxy-2-methyl-phenyl)-2,5-dimethy-pyrazolo[1,5-alpyrimidin-7-yl}-amine (Ex. 12- 6), [2<(3-Isopropy}-{1,2.4]oxadiazol-5-y1)-(S)-1-methyl-ethyl}-{3-(4-methoxy- 2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-amine (Ex. 12-7); (3-(4-Methoxy-2-meth yl-phenyl)-2,5-dimethyl-pyrazolo[1 ,5-a)pyrimidin-7- y1)-[(S)-1-methyl-2-(3-methyl-{1,2,4]oxadiazo}-5-yl)-ethyl]-amine (Ex. 12-8); [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1 ,5-a)pyrimidin-7- yl]-[1-(3-methyl-[1 2 4Joxadiazol-5-ylmethyl)-propyl}-amine (Ex. 12-9); [1-(3-Cyclopropyl-[1,2,4]oxadi azol-5-ylmethyl)-propyl}-[3-(2.4- dimethoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-alpyrimidin-7-yl]-amine (Ex. 12-10); [3-(2,4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a}pyrimidin-7 -yl}- [1-(3-methyl-[1 .2.4)oxadiazol-5-ylmethyl)-propyl]-amine (Ex. 12-11); [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1 ,5-a}pyrimidin-7- y1}-[(S)-1-(3-methyl-[1,2.4]oxadiazol-5-yl)-butyl]-amine (Ex. 13-1); [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7- y1]-[2.2.2-trifluoro(S)-1-(3-methyl-[ 1.2 4]oxadiazol-5-yimethyl)-ethyl]-amine (Ex. 13-2); [3-(4-Methoxy-2-methyi-phenyl)-2,5-dimethyl-pyrazolo[ 1 ,5-a]pyrimidin-7- yl]-[1-methyl-2-(3-trifluoromethyl-{1,2,4]oxadiazol-5-yl)-ethyl}-amine (Ex. 13-3); [3-(2-Chloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7- yl}-{2,2,2-trifluoro~(S)-1-(3-methyi-[ 1,2 4Joxadiazol-5-ylmethyl)-ethyl)-amine (Ex. 13-4);
[3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo{ 1,5-a)pyrimidin-7- yI}-{(R)-1-methyl-2-(3-trifluoromethyl-[1,2,4]oxadiazol-5-yl)-ethyl]-amine (Ex. 13-5); [3-(2-Chloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo{1,5-alpyrimidin-7- yI]-{(R)-1-methyl-2-(3-trifluoromethyl-[1,2 4Joxadiazol-5-yl)-ethyl)-amine (Ex. 13-6); [3-2 4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo(1 ,5-a)pyrimidin-7-yl]- [(R)-1-methyl-2-(3-trifluoromethyl-[1,2,4Joxadiazol-5-yl)-ethyl]-amine (Ex. 13-7); [3-(2,4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo{1,5-alpyrimidin-7-yl}- [2,2.2-trifluoro-(S)-1-(3-methyl-{1,2.4]oxadiazol-5-ylmethyl)-cthy}-amine (Ex. 13-8); [3-(2.4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo[ 1 5-a]pyrimidin-7-yl- [2,2,2-rifluoro-(S)-1-(3-trifluoromethyl-[1,2 4Joxadiazol-5-ylmethy))-ethyl]-amine (Ex. 13-9); [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo{ 1,5-a]pyrimidin-7- yl]-{(S)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-propyl}-amine (Ex. 14-1); [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo{1,5-a]pyrimidin-7- yl}-[(R)-1-(3-methyl-{1,2,4]oxadiazol-5-yl)-propyl]-amine (Ex. 14-2); 3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-7-[(S)-2-(3-methyl- [1,2,4]oxadiazol-5-ylmethyl)-pyrrolidin-1-yl]-pyrazolo[1,5-a}pyrimidine (Ex. 14-3); [3-(2-Chloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7- yI]-[(S)-1-(3-methyl-[1,2 4]oxadiazol-5-yl)-propyl}-amine (Ex. 14-4); [3-(2,4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo{1 ,5-a)pyrimidin-7-yl]- (2-methoxy-ethyl)-(3-methyi-[ 1,2,4)oxadiazol-5-ylmethyl)-amine (Ex. 15- 1); (5-{2,5-Dimethyl-7-[(S)-2-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrrolidin-1- yl]-pyrazolo[1,5-a}pyrimidin-3-yl }-4-methyl-pyridin-2-yl)-dimethyl-amine (Ex. 15-2); [3-(6-Dimethylamino-4-methyl-pyridin-3-y1)-2,5-dimeth yl-pyrazolo[1,5- aJpyrimidin-7-yl]-(2-methoxy-ethyl)-(3-methyl-[1,2 4]oxadiazol-5-ylmethyl)-amine (Ex. 15-3); [3-(4-Ethoxy-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7-yl]-(2- methoxy-ethyl)-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-amine (Ex. 15-4); (3-(2.4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7-yl]- (2-methoxy-ethyl)-[3-(3-methyl-[1,2,4]oxadiazol-5-y!)-propyl]-amine (Ex. 16-1); [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-ajpyrimidin-7- yl)-[(R)-1-methyl-2-(5-methyl-[1,2 4]oxadiazol-3-y!)-cthyl]-amine (Ex. 17-1);
[3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-alpyrimidin-7- yl1-{(S)-1-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-propy!]-amine (Ex. 17-2); [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethy! -pyrazolo[1,5-a}pyrimidin-7- yll-[(R)-1 -(5-methyl-{1,2,4]oxadiazol-3-ylmethyl)-propyl}-amine (Ex. 17-3); [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7- y1]-[(S)-1-methyl-2-(5-methyl-{1 .2.4]oxadiazol-3-yl)-ethyl]-amine (Ex. 17-4); [(R)-2-(5-Cyclopropyl-[1,2,4]Joxadiazol-3-yl)- 1-methyl-ethyl]-[3-(4- methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo{ 1,5-a}pyrimidin-7-yl]-amine (Ex. 18- 1) [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo( 1 ,5-a}pyrimidin-7- yl]-{(R)-1-methyl-2-(5-trifluoromethyl-[1,2,4]oxadiazol-3-yl)-ethyl]-amine (Ex. 18-2); [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7- ylI-[(S)-2,2.2-trifluoro-1-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-ethyl}-amine (Ex. 19-1),
Ethyl-[3-(4-methoxy-2-methyl-pheny!)-2,5-dimethyl-pyrazolo{1 5- alpyrimidin-7-yl]-(3-methyl-[1,2,4Joxadiazol-5-ylmethyl)-amine (Ex. 20-1); 3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-7-[2-(3-methyl- [1,2,4)oxadiazol-5-ylmethyl)-piperidin-1 -yl}-pyrazolo[ 1,5-alpyrimidine (Ex. 20-2), [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7- yl]-(1-[1,3,4]oxadiazol-2-yl-propyl)-amine (Ex. 21-1); [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl -pyrazolo(1,5-a]pyrimidin-7- yl]-[1-(5-methyl-[1 ,3,4Joxadiazol-2-yl)-propyl]-amine (Ex. 22-1); [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7- yl}-[1-methyl-2-(5-methy!-[1,3,4Joxadiazol-2-yl)-ethyl]-amine (Ex. 23-1); [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolof 1,5-a}pyrimidin-7- yl}-[1-methyl-2-(5-trifluoromethyl-[1,3,4)oxadiazol-2-yl)-ethyl]-amine (Ex. 23-2); [3-(2-Chloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7- yl]-[1-(3-methyl-[1 ,2,4]oxadiazol-5-yl)-propyl]-amine (Ex. 24-1); [3-(4-Chloro-2-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1 ,5-ajpyrimidin-7- yl]-[1-(3-methyl-[1,2 4]oxadiazol-5-yl)-propyl]-amine (Ex. 24-2); [3-(3-Chloro-4-fluoro-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7- yi]-[1-(3-methyl-[1,2,4]oxadiazol-5-yl)-propyl]-amine (Ex. 24-3);
[3-(4-Chloro-2-methyl-phenyl)-2,5-dimethyl-pyrazolof 1,5-a]pyrimidin-7- yl]-[1-(3-methyl-[1 2.4]oxadiazol-5-yl)-propyl}-amine (Ex. 24-4); [3-(2-Chloro-4-trifluoromethyl-phenyl)-2,5-dimethyl-pyrazolo(1,5- alpyrimidin-7-yl]-[ 1-(3-methyl-[1,2,4]oxadiazol-5-yl)-propyl]-amine (Ex. 24-5); and [3-(2-Chloro-4-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7- yl]-[1-(3-methyl-{1,2,4)oxadiazol-5-yl)-propyl]-amine (Ex. 24-6).
In another embodiment of the present invention, polymorphs of [3-(4-
Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7-yl]-{(S)-1-(3- methyl-[1,2,4]Joxadiazol-5-yl)-propyl]-amine (Example 14-1) are reported. Polymorph
Form 1 exhibits a predominant endotherm peak at about 108.3 °C and exhibits a X-ray powder diffraction spectrum as shown in Figure 1. The X-ray powder diffraction pattern of polymorph Form 1 as shown in Figure 1 exhibits predominant peaks (expressed in degrees 268 (+/- 0.15 degrees 26) at one or more of the following positions: 6.721, 11.757, 13.323, 18.222, 21.426 and 21.974. More specifically, such characteristic peaks are at 11.757 and 21.974, and further at 6.721 and further at 13.323, 18.222, and 21.426.
Polymorph Form 2 exhibits a predominant endotherm peak at about 115.1 °C as shown in
Figure 6 and exhibits a X-ray powder diffraction spectrum having peaks as shown as shown in Figure 4.
In another embodiment, [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl- pyrazolo[1,5-a]pyrimidin-7-yl]-[(S)-1-(3-methyl-[1,2,4]Joxadiazol-5-yl)-propyl]-amine is . in the form of a composition or mixture of polymorph Form 1 along with one or more other crystalline, solvate, amorphous, or other forms. More specifically, the composition may comprise from trace amounts up to 100% polymorph Form 1, or any amount in between — for example, the composition may comprise less than 0.1%, 0.5%, 1%, 2%, 5%, 10%, 20%. 30%, 40% or 50% by weight of polymorph Form 1 based on the total amount of [3-(4-Methoxy-2-methyl-phenyl)-2,5-di methyl-pyrazolo[1,5-a]pyrimidin-7-yl]-[(S)-1- (3-methyl-[1,2,4)oxadiazol-5-yl)-propyl}-amine in the composition. Altematively, the composition may comprise at least 50%, 60%, 70%, 80%, 90%, 95%, 97%, 98%, 99%, 99.5% or 99.9% by weight of polymorph Form 1 based on the total amount of [3-(4-
Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-[(S)-1-(3- methyl-[1,2,4]Joxadiazol-5-yl)-propyl}-amine in the composition.
In another embodiment, [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl- pyrazolo[1,5-alpyrimidin-7-yl}-[(S)-1-(3-methyl-{1,2,4Joxadiazol-5-yl)-propyl]-amine is in the form of a composition or mixture of polymorph Form 2 along with one or more other crystalline, solvate, amorphous, or other forms. More specifically, the composition may comprise from trace amounts up to 100% polymorph Form 2, or any amount in between — for example, the composition may comprise less than 0.1%, 0.5%, 1%, 2%, 5%, 10%, 20%, 30%, 40% or 50% by weight of polymorph Form 2 based on the total amount of [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7-yl}-{(S)-1- (3-methyl-[1,2,4]Joxadiazol-5-yl)-propyl]-amine in the composition. Alternatively, the composition may comprise at least 50%, 60%, 70%, 80%, 90%, 95%, 97%, 98%, 99%, 99.5% or 99.9% by weight of polymorph Form 2 based on the total amount of [3-(4-
Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-[(S)-1-(3- methyl-[1,2,4Joxadiazol-5-yl)-propyl]-amine in the composition.
The compounds of the present invention may generally be utilized as the free base. Alternatively, the compounds of this invention may be used in the form of acid addition salts. Acid addition salts of the free base amino compounds of the present invention may be prepared by methods well known in the art, and may be formed from organic and inorganic acids. Suitable organic acids include maleic, fumaric, benzoic, ascorbic, succinic, methanesulfonic, acetic, oxalic, propionic, tartaric, salicylic, citric, gluconic, lactic, mandelic, cinnamic, aspartic, stearic, palmitic, glycolic, glutamic, and benzenesulfonic acids. Suitable inorganic acids include hydrochloric, hydrobromic, sulfuric, phosphoric, and nitric acids. Thus, the term “pharmaceutically acceptable salt” of structure (I) is intended to encompass any and all acceptable salt forms.
In general, the compounds of structure (I) may be made according to the organic synthesis techniques known to those skilled in this field, as well as by the representative methods set forth in the Examples. For example, the synthesis of structure (I) may generally proceed according to the following Reaction Scheme 1 through Reaction
Scheme 6, which schemes are presented for purposes of exemplification and not limitation.
Reaction Scheme 1 $ 2» NeH Ry Ro \
EL» ner he i XL ) - Hy (R oO; pA — wf 10 wf 0
T
» a by « A
Rado (Ry),
Reaction of 7-chloro-pyrazolo-[1,5a}-pyrimidine a with amino acid ester under anhydrous conditions affords amino acid ester b. Reaction of Cmpd b with NaH and substituted amidoxime under anhydrous conditions affords the 5-yl-[1,2,4)oxadiazole
Cmpd c.
Reaction Scheme 2 1 ps Ry ron ne
Roz H LiOH
LY wD
Ar : ®) b A
H, 5 R;),
NDA hg fog er aN \
L AN pyridine er 3 l R ~N A ” (RY: DIC, HOBT " worl TC wD $ (R,), [4 Ar be A (Ry), (Ry),
Reaction of 7-chloro-pyrazolo-[1,5a)-pyrimidine a with amino acid ester under anhydrous conditions affords amino acid ester b. Compound b is de-esterified in the presence of LiOH to afford amino acid b’. Reaction of Cmpd b' with amidoxime in the presence of DIC and HOBT affords Cmpd b'' which undergoes ring closure upon incubation in pyridine at elevated temperature to afford the 5-yl-[1,2,4]oxadiazole Cmpd c.
Reaction Scheme 3
Ra 1]
COH
RY LS %
L ] ( - i \ r XN A a (Ry, b » ~~" Ry), 3
R Rzs \
XL (Ve ty is pyridine Y
R A "
DIC, HOBT wef JO (Re)z « ¥ b" v Ry),
Ry),
Reaction of 7-chloro-pyrazolo-[1,5a]-pyrimidine a with amino acid affords amino acid b'. Reaction of Cmpd b' with amidoxime in the presence of DIC and HOBT affords Cmpd b" which undegoes ring closure upon incubation in pyridine at elevated temperature to afford the 5-yl-(1,2,4Joxadiazole Cmpd c.
Reaction Scheme 4 1 : Rm =
Rex -— (Re n 8 a r d r a, ao . Ry Rn ’
C R
Soe com FR ol oC ” — X oF wf OT (Ry); b r a, < a do
Reaction of 7-chloro-pyrazolo-[1,5a]-pyrimidine a with substituted amine affords Cmpd d, which reacts with bromo ester to afford amino acid ester b. Compound b reacts with amidoxime in the presence of NaH to afford the 5-yl-[1,2,4]oxadiazole Cmpd c.
Reaction Scheme 5
R R
I SL ow
ZN J CVC A EL
: * ~N — = —~N (Ro); ~ J ZN 2 ZN IN
N A NSS Cl A a 4 N (Ry), Ar Ar © dh r®),
R OH N—5
NaCN Fay 0 oN R, Ry N° Ra
K,CO, ws No » Pi “5 A )
DMF Me pnonHO WNT Nil NH: pul bua vy, N
ZZ —~N * —— N ( N ZN Z NTN
N NS Sy \N SY a N nr N Ar s 1) i . ®, ®),
Reaction of 7-chloro-pyrazolo-{1,5a)-pyrimidinc a with aminol and triethylamine (TEA) in acetonitrile affords aminol e which can be mesylated by p- toluenesulfonyl chloride in the presence of TEA to afford Cmpd f. Cyano functionality can be introduced into Cmpd f affording Cmpd g, which can react with hydroxylamine to give Cmpd h. Compound h undergoes ring closure in the presence of DMA-DMA to afford the the 3-yl-[1,2,4]oxadiazole Cmpd i.
Reaction Scheme 6 ey SL
R OR, YY, © nN
H,NNH, os =e O10 b 4 I ®y, ~* Rae
R R
“223 we I ethyl R YY, TsCl R YY, formate H DBU ——— reer
Ro; $8, Re SN, k 0 rr
Ry), ®R,),
Reaction of 7-chloro-pyrazolo-[1,5a]-pyrimidine amino acid ester b with hydrazine giving Cmpd j followed by reaction with ethyl formate giving Cmpd k and ring closure with TsCl and DBU affords the 5-yl-[1,3,4]oxadiazole Cmpd 1.
Reaction Scheme 7 t]
Ra J nS \
L] feo: L LJ]
I" SE
ET) Log Tad
Suzuki : - ’ a «I
Ry), ®,),
Reaction of 3-bromo-7-amino-pyrazolo-[1,5a)-pyrimidine amino acid ester m with arylboronic acid under conditions of the Suzuki reaction affords the 3-aryl-7- amino-pyrazolo-[1,5a)-pyrimidine amino acid ester b which reacts with NaH and substituted amidoxime to afford Cmpd c.
The effectiveness of a compound as a CRF receptor antagonist may be determined by various assay methods. CRF antagonists of this invention may be capable
IS of inhibiting the specific binding of CRF to its receptor and antagonizing activities associated with CRF. A compound of structure (I) may be assessed for activity as a CRF antagonist by one or more generally accepted assays for this purpose, including (but not limited to) the assays disclosed by DeSouza etal. (J. Neuroscience 7.88, 1987) and
Battaglia et al. (Synapse 1:572, 1987). As mentioned above, CRF antagonists of this invention include compounds which demonstrate CRF receptor affinity. CRF receptor affinity may be determined by binding studies that measure the ability of a compound to inhibit the binding of a radiolabeled CRF (e.g., ['®I)tyrosine-CFR) to its receptor (e.g, receptors prepared from rat cerebral cortex membranes). The radioligand binding assay described by DeSouza et al. (supra, 1987) provides an assay for determining a compound's affinity for the CRF receptor. Such activity is typically calculated from the ICso as the concentration of a compound necessary to displace 50% of the radiolabeled ligand from the receptor, and is reported as a “K;" value calculated by the following equation: where L = radioligand and Kp = affinity of radioligand for receptor (Cheng and Prusoff,
Biochem. Pharmacol. 22:3099, 1973).
In addition to inhibiting CRF receptor binding, a compound's CRF receptor antagonist activity may be established by the ability of the compound to antagonize an activity associated with CRF. For example, CRF is known to stimulate various biochemical processes, including adenylate cyclase activity. Therefore, compounds may be evaluated as CRF antagonists by their ability to antagonize CRF-stimulated adenylate cyclase activity by, for example, measuring CAMP levels. The CRF-stimulated adenylate cyclase activity assay described by Battaglia et al. (supra, 1987) provides an assay for determining a compound's ability to antagonize CRF activity. Accordingly, CRF receptor antagonist activity may be determined by assay techniques which generally include an initial binding assay (such as disclosed by DeSouza (supra, 1987)) followed by a cAMP screening protocol (such as disclosed by Battaglia (supra, 1987).
With reference to CRF receptor binding affinities, CRF receptor antagonists of this invention may have a K; of less than 10 pM. In one embodiment of this invention, a CRF receptor antagonist has a K; of less than 1uM, and in a another embodiment the K; is less than 0.25 pM (i.e., 250 nM). As set forth in greater detail below, the K; values may be assayed by the methods set forth in Example 25. CRF receptor antagonists of the present invention having a K; of less than 0.10 pM (i.e., 100 nM) include Examples 11-1, 11-2, 11-3, 11-4, 11-5, 11-6, 11-9, 11-10, 11-11, 11-13, 11- 17, 11-18, 11-20, 11-23, 11-26, 12-1, 12-2, 12-3, 12-4, 12-5, 12-9, 12-10, 12-11, 13-1, 13- 2, 13-3, 13-4, 13-5, 13-6, 13-7, 13-8, 13-9, 14-1, 14-2, 14-3, 14-4, 15-1, 17-1, 17-2, 17-3, 18-1, 18-2, 19-1, 20-1, 20-2, 21-1, 22-1, 23-2, 24-1, 24-2, 24-4, and 24-6.
CRF receptor antagonists of the present invention may demonstrate activity at the CREF receptor site, and may be used as therapeutic agents for the treatment of a wide range of disorders or illnesses including endocrine, psychiatric, and neurological disorders or illnesses. More specifically, CRF receptor antagonists of the present invention may be useful in treating physiological conditions or disorders arising from the hypersecretion of
CRF. Because CRF is believed to be an important neurotransmitter that activates and coordinates the endocrine, behavioral and automatic responses to stress, CRF receptor antagonists of the present invention may be useful in the treatment of neuropsychiatric disorders. Neuropsychiatric disorders which may be treatable by the CRF receptor antagonists of this invention include affective disorders such as depression; anxiety-related disorders such as generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, abnormal aggression, cardiovascular abnormalities such as unstable angina and reactive hypertension; and feeding disorders such as anorexia nervosa, bulimia, and irritable bowel syndrome. CRF antagonists may also be useful in treating stress-induced immune suppression associated with various diseases states, as well as stroke. Other uses of the CRF antagonists of this invention include treatment of inflammatory conditions (such as rheumatoid arthritis, uveitis, asthma, inflammatory bowel disease and G.I motility), pain, Cushing's disease, infantile spasms, epilepsy and other seizures in both infants and adults, and various substance abuse and withdrawal (including alcoholism).
Within the context of the present invention, the following terms describing the indications used herein are classified in the Diagnostic and Statistical Manual of
Mental Disorders, 4th Edition, published by the American Psychiatric Association (DSM-
IV) and/or the Intemational Classification of Diseases, 10th Edition (ICD-10). The various subtypes of the disorders mentioned herein are contemplated as part of the present invention. Numbers in brackets after the listed diseases below refer to the classification code in DSM-IV.
Within the context of the present invention, the term “psychotic disorder” includes :-
Schizophrenia including the subtypes Paranoid Type (295.30),
Disorganised Type (295.10), Catatonic Type (295.20), Undifferentiated Type (295.90) and
Residual Type (295.60); Schizophreniform Disorder (295.40); Schizoaffective Disorder (295.70) including the subtypes Bipolar Type and Depressive Type; Delusional Disorder (297.1) including the subtypes Erotomanic Type, Grandiose Type, Jealous Type,
Persecutory Type, Somatic Type, Mixed Type and Unspecified Type; Brief Psychotic
Disorder (298.8); Shared Psychotic Disorder (297.3); Psychotic Disorder Due to a General
Medical Condition including the subtypes With Delusions and With Hallucinations;
Substance-Induced Psychotic Disorder including the subtypes With Delusions (293.81) and With Hallucinations (293.82); and Psychotic Disorder Not Otherwise Specified (298.9).
The compounds of the present invention including salts and pharmaceutically acceptable solvates thereof may also be of use in the treatment of the following disorders:- i
Depression and mood disorders including Major Depressive Episode,
Manic Episode, Mixed Episode and Hypomanic Episode; Depressive Disorders including
Major Depressive Disorder, Dysthymic Disorder (300.4), Depressive Disorder Not
Otherwise Specified (311); Bipolar Disorders including Bipolar I Disorder, Bipolar II
Disorder (Recurrent Major Depressive Episodes with Hypomanic Episodes) (296.89),
Cyclothymic Disorder (301.13) and Bipolar Disorder Not Otherwise Specified (296.80);
Other Mood Disorders including Mood Disorder Due to a General Medical Condition (293.83) which includes the subtypes With Depressive Features, With Major Depressive- like Episode, With Manic Features and With Mixed Features), Substance-Induced Mood
Disorder (including the subtypes With Depressive Features, With Manic Features and
With Mixed Features) and Mood Disorder Not Otherwise Specified (296.90):
Anxiety disorders including Social Anxiety Disorder, Panic Attack,
Agoraphobia, Panic Disorder, Agoraphobia Without History of Panic Disorder (300.22),
Specific Phobia (300.29) including the subtypes Animal Type, Natural Environment Type, . Blood-Injection-Injury Type, Situational Type and Other Type), Social Phobia (300.23),
Obsessive-Compulsive Disorder (300.3), Posttraumatic Stress Disorder (309.81), Acute
Stress Disorder (308.3), Generalized Anxiety Disorder (300.02), Anxiety Disorder Due to a General Medical Condition (293.84), Substance-Induced Anxiety Disorder and Anxiety
Disorder Not Otherwise Specified (300.00):
Substance-related disorders including Substance Use Disorders such as
Substance Dependence, Substance Craving and Substance Abuse; Substance-Induced
Disorders such as Substance Intoxication, Substance Withdrawal, Substance-Induced
Delirium, Substance-Induced Persisting Dementia, Substance-Induced Persisting
Amnestic Disorder, Substance-Induced Psychotic Disorder, Substance-Induced Mood
Disorder, Substance-Induced Anxiety Disorder, Substance-Induced Sexual Dysfunction,
Substance-Induced Sleep Disorder and Hallucinogen Persisting Perception Disorder (Flashbacks); Alcohol-Related Disorders such as Alcohol Dependence (303.90), Alcohol
Abuse (305.00), Alcohol Intoxication (303.00), Alcohol Withdrawal (291.81), Alcohol
Intoxication Delirium, Alcohol Withdrawal Delirium, Alcohol-Induced Persisting
Dementia, Alcohol-Induced Persisting Amnestic Disorder, Alcohol-Induced Psychotic
Disorder, Alcohol-Induced Mood Disorder, Alcohol-Induced Anxiety Disorder, Alcohol-
Induced Sexual Dysfunction, Alcohol-Induced Sleep Disorder and Alcohol-Related
Disorder Not Otherwise Specified (291.9); Amphetamine (or Amphetamine-Like)-Related
Disorders such as Amphetamine Dependence (304.40), Amphetamine Abuse (305.70),
Amphetamine Intoxication (292.89), Amphetamine Withdrawal (292.0), Amphetamine
Intoxication Delirium, Amphetamine Induced Psychotic Disorder, Amphetamine-Induced
Mood Disorder, Amphetamine-Induced Anxiety Disorder, Amphetamine-Induced Sexual
Dysfunction, Amphetamine-Induced Sleep Disorder and Amphetamine-Related Disorder
Not Otherwise Specified (292.9); Caffeine Related Disorders such as Caffeine Intoxication (305.90), Caffeine-Induced Anxiety Disorder, Caffeine-Induced Sleep Disorder and
Caffeine-Related Disorder Not Otherwise Specified (292.9); Cannabis-Related Disorders such as Cannabis Dependence (304.30), Cannabis Abuse (305.20), Cannabis Intoxication (292.89), Cannabis Intoxication Delirium, Cannabis-Induced Psychotic Disorder,
Cannabis-Induced Anxiety Disorder and Cannabis-Related Disorder Not Otherwise
Specified (292.9); Cocaine-Related Disorders such as Cocaine Dependence (304.20),
Cocaine Abuse (305.60), Cocaine Intoxication (292.89), Cocaine Withdrawal (292.0),
Cocaine Intoxication Delirium, Cocaine-Induced Psychotic Disorder, Cocaine-Induced
Mood Disorder, Cocaine-Induced Anxiety Disorder, Cocaine-Induced Sexual
Dysfunction, Cocaine-Induced Sleep Disorder and Cocaine-Related Disorder Not
Otherwise Specified (292.9); Hallucinogen-Related Disorders such as Hallucinogen
Dependence (304.50), Hallucinogen Abuse (305.30), Hallucinogen Intoxication (292.89),
Hallucinogen Persisting Perception Disorder (Flashbacks) (292.89), Hallucinogen
Intoxication Delirium, Hallucinogen-Induced Psychotic Disorder, Hallucinogen-Induced
Mood Disorder, Hallucinogen-Induced Anxiety Disorder and Hallucinogen-Related
Disorder Not Otherwise Specified (292.9); Inhalant-Related Disorders such as Inhalant
Dependence (304.60), Inhalant Abuse (305.90), Inhalant Intoxication (292.89), Inhalant
Intoxication Delirium, Inhalant-Induced Persisting Dementia, Inhalant-Induced Psychotic
Disorder, Inhalant-Induced Mood Disorder, Inhalant-Induced Anxiety Disorder and
Inhalant-Related Disorder Not Otherwise Specified (292.9); Nicotine-Related Disorders such as Nicotine Dependence (305.1), Nicotine Withdrawal (292.0) and Nicotine-Related
Disorder Not Otherwise Specified (292.9); Opioid-Related Disorders such as Opioid
Dependence (304.00), Opioid Abuse (305.50), Opioid Intoxication (292.89), Opioid
Withdrawal (292.0), Opioid Intoxication Delirium, Opioid-Induced Psychotic Disorder,
Opioid-Induced Mood Disorder, Opioid-Induced Sexual Dysfunction, Opioid-Induced
Sleep Disorder and Opioid-Related Disorder Not Otherwise Specified (292.9); . Phencyclidine (or Phencyclidine-Like)-Related Disorders such as Phencyclidine
Dependence (304.60), Phencyclidine Abuse (305.90), Phencyclidine Intoxication (292.89),
Phencyclidine Intoxication Delirium, Phencyclidine-Induced Psychotic Disorder,
Phencyclidine-Induced Mood Disorder, Phencyclidine-Induced Anxiety Disorder and
Phencyclidine-Related Disorder Not Otherwise Specified (292.9); Sedative-, Hypnotic-, or
Anxiolytic-Related Disorders such as Sedative, Hypnotic, or Anxiolytic Dependence (304.10), Sedative, Hypnotic, or Anxiolytic Abuse (305.40), Sedative, Hypnotic, or
Anxiolytic Intoxication (292.89), Sedative, Hypnotic, or Anxiolytic Withdrawal (292.0),
Sedative, Hypnotic, or Anxiolytic Intoxication Delirium, Sedative, Hypnotic, or
Anxiolytic Withdrawal Delirium, Sedative-, Hypnotic-, or Anxiolytic-Persisting
Dementia, Sedative-, Hypnotic-, or Anxiolytic- Persisting Amnestic Disorder, Sedative-,
Hypnotic-, or Anxiolytic-Induced Psychotic Disorder, Sedative-, Hypnotic-, or Anxiolytic-
Induced Mood Disorder, Sedative-, Hypnotic-, or Anxiolytic-Induced Anxiety Disorder
Sedative-, Hypnotic-, or Anxiolytic-Induced Sexual Dysfunction, Sedative-, Hypnotic-, or
Anxiolytic-Induced Sleep Disorder and Sedative-, Hypnotic-, or Anxiolytic-Related
Disorder Not Otherwise Specified (292.9); Polysubstance-Related Disorder such as
Polysubstance Dependence (304.80); and Other (or Unknown) Substance-Related
Disorders such as Anabolic Steroids, Nitrate Inhalants and Nitrous Oxide:
Sleep disorders including primary sleep disorders such as Dyssomnias such as Primary Insomnia (307.42), Primary Hypersomnia (307.44), Narcolepsy (347),
Breathing-Related Sleep Disorders (780.59), Circadian Rhythm Sleep Disorder (307.45) and Dyssomnia Not Otherwise Specified (307.47); primary sleep disorders such as
Parasomnias such as Nightmare Disorder (307.47), Sleep Terror Disorder (307.46),
Sleepwalking Disorder (307.46) and Parasomnia Not Otherwise Specified (307.47); Sleep
Disorders Related to Another Mental Disorder such as Insomnia Related to Another
Mental Disorder (307.42) and Hypersomnia Related to Another Mental Disorder (307.44),
Sleep Disorder Due to a General Medical Condition; and Substance-Induced Sleep
Disorder including the subtypes Insomnia Type, Hypersomnia Type, Parasomnia Type and
Mixed Type:
Eating disorders such as Anorexia Nervosa (307.1) including the subtypes
Restricting Type and Binge-Eating/Purging Type; Bulimia Nervosa (307.51) including the subtypes Purging Type and Nonpurging Type; Obesity; Compulsive Eating Disorder; and
Eating Disorder Not Otherwise Specified (307.50):
Autistic Disorder (299.00); Attention-Deficit Hyperactivity Disorder including the subtypes Attention-Deficit Hyperactivity Disorder Combined Type (314.01), Attention-Deficit /Hyperactivity Disorder Predominantly Inattentive Type (314.00), Attention-Deficit /Hyperactivity Disorder Hyperactive-Impulse Type (314.01) and Attention-Deficit Hyperactivity Disorder Not Otherwise Specified (314.9);
Hyperkinetic Disorder; Disruptive Behaviour Disorders such as Conduct Disorder including the subtypes childhood-onset type (321.81), Adolescent-Onset Type (312.82) and Unspecified Onset (312.89), Oppositional Defiant Disorder (313.81) and Disruptive
Behaviour Disorder Not Otherwise Specified; and Tic Disorders such as Tourette's
Disorder (307.23):
Personality Disorders including the subtypes Paranoid Personality Disorder (301.0), Schizoid Personality Disorder (301.20), Schizotypal Personality Disorder (301,22), Antisocial Personality Disorder (301.7), Borderline Personality Disorder (301,83), Histrionic Personality Disorder (301.50), Narcissistic Personality Disorder (301,81), Avoidant Personality Disorder (301.82), Dependent Personality Disorder
(301.6), Obsessive-Compulsive Personality Disorder (301.4) and Personality Disorder Not
Otherwise Specified (301.9):
Enhancement of cognition including the treatment of cognition impairment in other diseases such as schizophrenia, bipolar disorder, depression, other psychiatric disorders and psychotic conditions associated with cognitive impairment, e.g. Alzheimer's disease: and
Sexual dysfunctions including Sexual Desire Disorders such as Hypoactive
Sexual Desire Disorder (302.71), and Sexual Aversion Disorder (302.79); sexual arousal disorders such as Female Sexual Arousal Disorder (302.72) and Male Erectile Disorder (302.72); orgasmic disorders such as Female Orgasmic Disorder (302.73), Male Orgasmic
Disorder (302.74) and Premature Ejaculation (302.75); sexual pain disorder such as
Dyspareunia (302.76) and Vaginismus (306.51); Sexual Dysfunction Not Otherwise
Specified (302.70); paraphilias such as Exhibitionism (302.4), Fetishism (302.81),
Frotteurism (302.89), Pedophilia (302.2), Sexual Masochism (302.83), Sexual Sadism (302.84), Transvestic Fetishism (302.3), Voyeurism (302.82) and Paraphilia Not . Otherwise Specified (302.9); gender identity disorders such as Gender Identity Disorder in
Children (302.6) and Gender Identity Disorder in Adolescents or Adults (302.85); and
Sexual Disorder Not Otherwise Specified (302.9).
All of the various forms and sub-forms of the disorders mentioned herein are contemplated as part of the present invention. “Treatment” includes prophylaxis, where this is appropriate for the relevant condition(s).
In another embodiment of the invention, pharmaceutical compositions containing one or more CRF receptor antagonists are disclosed. For the purposes of administration, the compounds of the present invention may be formulated as pharmaceutical compositions. Pharmaceutical compositions of the present invention include a pharmaceutically effective amount of a CRF receptor antagonist of the present invention (i.e., a compound of structure (I)) and a pharmaceutically acceptable carrier or diluent. Thus, the CRF receptor antagonist is present in the composition in an amount which is effective to treat a particular disorder. In one embodiment of the invention, the pharmaceutical compositions of the present invention may include a CRF receptor antagonist in an amount from 0.1 mg to 250 mg per dosage depending upon the route of administration. In another embodiment the dosage may be from 1 mg to 60 mg. In other embodiments, the dosage may be, for example, 5 mg, 10 mg, 15 mg or 20 mg.
Appropriate concentrations and dosages can be readily determined by one skilled in the art.
Pharmaceutically acceptable carrier and/or diluents are familiar to those skilled in the art. For compositions formulated as liquid solutions, acceptable carriers and/or diluents include saline and sterile water, and may optionally include antioxidants, buffers, bacteriostats and other common additives. The compositions can also be formulated as pills, capsules, granules, or tablets which contain, in addition to a CRF receptor antagonist, diluents, dispersing and surface active agents, binders, and lubricants.
One skilled in this art may further formulate the CRF receptor antagonist in an appropriate manner, and in accordance with accepted practices, such as those disclosed in Remington's - Pharmaceutical Sciences, Gennaro, Ed., Mack Publishing Co., Easton, PA 1990.
In addition, prodrugs are also included within the context of this invention.
Prodrugs are any covalently bonded carriers that release a compound of structure (I) in vivo when such prodrug is administered to a patient. Prodrugs are generally prepared by : modifying functional groups in a way such that the modification is cleaved, either by routine manipulation or in vivo, yielding the parent compound.
With regard to stereoisomers, the compounds of structure (I) may have chiral centers and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers. All such isomeric forms are included within the present invention, including mixtures thereof. Furthermore, some of the crystalline forms of the compounds of structure (I) may exist as polymorphs, which are included in the present invention. In addition, some of the compounds of structure (I) may also form solvates with water or other organic solvents. Such solvates are similarly included within the scope of this invention.
In another embodiment, the present invention provides a method for treating a variety of disorders or illnesses, including endocrine, psychiatric and neurological disorders or illnesses. Such methods include administering of a compound of the present invention to a mammal (e.g., a person) in an amount sufficient to treat the disorder or illness. Such methods include systemic administration of a pharmaceutical composition containing a pharmaceutically effective amount of a CRF receptor antagonist of this invention. As used herein, systemic administration includes oral and parenteral methods of administration. For oral administration, suitable pharmaceutical compositions of CRF receptor antagonists include powders, granules, pills, tablets, and capsules as well as liquids, syrups, suspensions, and emulsions. These compositions may also include flavorants, preservatives, suspending, thickening and emulsifying agents, and other pharmaceutically acceptable additives. For parental administration, the compounds of the present invention can be prepared in aqueous injection solutions which may contain, in addition to the CRF receptor antagonist, buffers, antioxidants, bacteriostats, and other additives commonly employed in such solutions.
In another embodiment, the present invention permits the diagnostic visualization of specific sites within the body by the use of radioactive or non-radioactive pharmaceutical agents Use of a compound of the present invention may provide a physiological, functional, or biological assessment of a patient or provide disease or pathology detection and assessment. Radioactive pharmaceuticals are employed in .15 scintigraphy, positron emission tomography (PET), computerized tomography (CT), and single photon emission computerized tomography (SPECT). For such applications, radioisotopes are incorporated of such elements as iodine (I) including '®1 (PET), "#1 (SPECT), and "*'1, technetium (Tc) including %Tc (PET), phosphorus (P) including sip and 3?P, chromium (Cr) including 31Cr, carbon (C) including Ne, fluorine (F) including '®F, thallium (Tl) including 20171 and like emitters of positron and ionizing radiation.
Non-radioactive pharmaceuticals are employed in magnetic resonance imaging (MRI), fluoroscopy, and ultrasound. For such applications, isotopes are incorporated of such elements as gadolinium (Gd) including 153Gd, iron (Fe), barium (Ba), manganese (Mn), and thallium (T1). Such entities are also useful for identifying the presence of particular target sites in a mixture and for labeling molecules in a mixture.
The following examples are provided for purposes of illustration and not for purposes of limitation.
The CRF receptor antagonists of this invention may be prepared by the methods disclosed in the Examples. Example 25 presents a method for determining the receptor binding affinity, and Example 26 discloses an assay for screening compounds of this invention for CRF-stimulated adenylate cyclase activity.
Abbreviations:
AcCN, MeCN: acetonitrile
AcCN: Acetonitrile
DBU: Diaminobutyric acid
DCM: Dichloromethane
DEAD: diethylazodicarboxylate
DIC: N,N'-Diisopropylcarbodiimide
DIU: N,N'-diisopropylurea
DMA-DMA: N,N-dimethylacetamide dimethyl acetal
DME: 1,2-dimethoxyethane
DMEF: Dimethylformamide
DMF-DMA: N,N-dimethylformamide dimethyl acetal
EAA: Ethyl acetoacetate ;
HOBT: 1-Hydroxybenzotriazole
LC/MS: liquid chromatography-mass spectroscopy
MDA: Malondialdehyde bis-dimethylacetal
MsCl: Methanesulfonyl chloride
NaBH(OAc);: Sodium Triacetoxyborohydride
Pd-C: Palladium (10 %) on Carbon
TEA: Tricthylamine
TFA: Trifluoroacetic acid
THF: Tetrahydrofuran
TosMIC: Tosylmethyl isocyanide
TsCl: p-tolunesulfonyl chloride
TsOH: p-Toluenesulfonic acid
Prep. HPLC-MS
Gilson HPLC-MS equipped with Gilson 215 auto-sampler/fraction collector, an UV detector and a ThermoFinnigan AQA Single QUAD Mass detector (electrospray); ‘
HPLC column: BHK ODS-O/B, 5 yu, 30x75 mm
HPLC gradients: 35 mL/min, 10 % acetonitrile in water to 100 % acetonitrile in 7 min, maintaining 100 % acetonitrile for 3 min.
Analytical Method 1 -- High Performance Liquid Chromatography (HPLC-MS)
Platform: HP 1100 series: equipped with an auto-sampler, an UV detector (220 nM and 254 nM), a MS detector (electrospray);
Column: Phenomenex SynergiMAX-RP, 4 micron, 2x 50 mm;
Mobile phase: A=water, 0.025 % TFA; B=acetonitrile, 0.025% TFA;
Flow rate: 1.0 mL/min;
Gradient; 5% B/95% A to 95% B/5% A over 13 min, then hold 2.5 min;
Analytical Method 2 -- Supercritical Fluid Chromatography (SFC)
Platform: Berger FCM1200 SFC pump, Agilent Diode Array Detector,
Agilent Model 220 Microplate autosampler, Agilent Model 1946 MSD (APCI interface);
Column: Berger Pyridine 60A, 4 micron, 3x 150 mm;
Solvents: SFC Grade CO,, Optima-grade methanol with 1.5% water and 0.025% ethanesulfonic acid;
Flow rate: 4.0 mL/min, 120 Bar backpressure;
Gradient: 5-55% methanol/CO; in 2.4 min.
Analytical Method 3 -- Analytical HPLC-MS (LC-MS)
Platform: HP 1100 series: equipped with an auto-sampler, a UV detector (220 nM and 254 nM), and an MS detector (APCI);
Column: Waters XTerra 3 x 250 mm;
Solvent A: water with 0.025 % TFA
Solvent B: acetonitrile with 0.025% TFA
Flowrate: 1.0 mL/min;
Gradient: 5% B for 1.55 min, then 101090 % B over 46 min (47.55 min total)
Analytical Method 4 -- Analytical HPLC-MS (LC-MS),
Platform: HP/Agilent 1100 series: equipped with an auto-sampler, a UV detector (220 nM and 254 nM), and an MS detector (APCI),
Column: Phenomonex Synergymax RP 2.0 x 50 mm;
Flowrate: 1.0 mL/min;
Solvent A: 0.05% TFA in water
Solvent B: 0.05% TFA in acetonitrile
Gradient: 5 % B for 0.25 min, then from 5% B to 90 % B from 0.25t02.25 min, then 90% B from 2.25 to 3.25 min.
EXAMPLE 1
SYNTHESIS OF REAGENT [5-(7-CHLORO-2,5-DIMETHYL-PYRAZOLO[ 1,5-A]PYRIMIDIN-3-YL)- 4-METHYL-PYRIDIN-2-YL}-DIMETHYL-AMINE
B H 4
H,CO 7 \ NaBH,CN Br ome C \
AcCN
H,0 1a ib 1c 2 Ac,0 — // ~
TosMIC NaH, THF H 1-BuOK EtOAc ZR H,NNH, HBr 1d le if
POCL,
EAA 7 \ MeCN 3 ———— 1g 1h
Step tA:
To a mixture of 2-amino-4-picoline (33 g), NaBH;CN (57 g), formaldehyde (37% aq. solution, 240 mL) in acetonitrile (1 L) and water (200 mL) was added dropwise acetic acid (60 mL) at 0 °C in 2 hr. The resultant solution was stirred at RT for 7 days and then concentrated in vacuo. The residue was basified with solid NaOH to pH 10 and extracted with hexanes (3x 700 mL). The combined extract was washed with IN aq.
NaOH and brine, dried over Na;SO,4 and evaporated in vacuo 10 give 2-dimethylamino-4- methylpyridine as a colorless oil (Cmpd 1a, 36 g, 88%). 'H NMR (CDCl): 2.26 (s, 3H), 3.07 (s, 6H), 6.33 (s, 1H), 6.40 (d, 1H), 8.02 (d, 1H); MS (CI) m/e 137 (MH).
Step 1B:
A mixture of Cmpd 1a (32 g), Na,CO; (30 g) in DCM (50 mL) and water (400 mL) was treated dropwise with a solution of bromine (13 mL) in DCM (50 mL) at 0°C in 0.5 hr. The resultant light brown suspension was stirred at 0 °C for 0.5 hr. The resultant was extracted with hexanes (2x 600 mL,) and the combined extract was washed with brine, dried over Na,SO, and evaporation in vacuo. The crude resultant was purified by chromatography on silica gel with 1:5 ethyl acetate/hexanes to give 5-bromo-2- dimethylamino-4-methylpyridinc as a tan solid (Cmpd 1b, 78% yield). 'H NMR (CDCl): 2.30 (s, 3H), 3.04 (s, 6H), 6.38 (s, 1H), 8.14 (s, LH); MS (CI) m/e 216 (MH).
Step 1C: :
Into a suspension of magnesium (11.3 g) in THF (20 mL) was added a quarter portion of a solution of Cmpd 1b (48.5 g) from Step 1B in THF (100 mL). The reaction was initiated with 5 drops of 1,2-dibromoethane with slightly heating. After initiation of the reaction 10 mL of THF was added. The rest of the solution of Cmpd 1b was added dropwise to maintain a gentle reflux. After completion of addition the mixture was stirred at RT for 0.5 hr before DMF (1.5 eq.) was slowly injected at 0 °C. The resultant mixture was stirred at RT overnight and quenched with saturated aq. NH.Cl. The resultant was extracted with ether (2 x 500 mL) and the combined extract was washed with brine, dried over MgSO, filtered and concentrated in vacuo. The resultant was purified by chromatography on silica gel with 1:5 ethyl acetate/hexanes to afford 2-dimethylamino- 4-methyl-5-formylpyridine as a tan solid (Cmpd 1c, 77% yield). The analytic sample was obtained by crystallization from ether/hexanes. 'H NMR (CDCl): 2.57 (s, 3H), 3.11 (s, 6H), 6.28 (s, 1H), 8.43 (s, 1H), 9.87 (s, 1H); MS (CI) m/e 165 (MH).
Step 1D:
Into a suspension of tBUOK (12.5 g) in DME (70 mL) at -30 °C was added dropwise a solution of TosMIC (15.6 g) in DME (70 mL). The brown solution was stirred at -50 °C for 10 min before a solution of Cmpd 1c (11 g) in DME (70 mL) was added dropwise. The resultant mixture was stirred at -50 °C for 0.5 hr and quenched with methanol (70 mL). This mixture was heated to reflux for 1 hr and the solvent was evaporated and partitioned in ethyl acetate-water. The organic layer was washed with brine, dried over MgSO; and filtered through a silica gel pad with ethyl acetate. This work-up gave 2-dimethylamino-4-methyl-5-(cyanomethyl)pyridine as a yellow solid (Cmpd 1d, 9.5 g, 80%). IH NMR (CDCl3): 2.31(s, 3H), 3.08 (s, 6H), 3.54 (s, 2H), 6.36 (s, 1H), 7.99 (s, 1H); MS (CI) m/e 176 MH")
Step 1E:
Into a suspension of Cmpd 1d (40 g, 0.23 mol) and NaH (2.5 eq.) in THF (100 mL) was added about 5 mL of ethyl acetate. The mixture was stirred at RT until an exothermic reaction started and hydrogen evolved vigorously. Ethyl acetate (50 mL) was then added dropwise to maintain a gentle reflux. The mixture was stirred at RT for 2 hr before it was quenched with water (100 mL). The organic phase was separated and the aqueous phase was washed several times with ethyl ether. The aqueous phase was then acidified with acetic acid, and the resultant was extracted with ethyl acetate (5 x 800 mL).
The combined extract was washed with brine (50 mL) and dried over MgSOs.
Concentration in vacuo gave the keto form 1-cyano-1-(6-dimethylamino-4-methylpyridin- 3-yl)acetone and the 3-hydroxy-but-2-enenitrile enol form (Cmpd 1e) as a brown solid (40 g, 80% yield). "TH NMR (CDCl): 1:1 mixture of enol and ketone form, 2.24 (s, 1.5x3H), 2.32 (s, 0.5x3H), 2.88 (s, 0.5x6H), 3.09 (s, 0.5x6H), 4.50 (brs, 0.5x1H), 4.62 (s, 0.5x1H), 6.13 (s, 0.5x1H), 6.35 (s, 0.5x1H), 7.60 (s, 0.5x1H), 8.05 (s, 0.5x1H); MS (CI) m/e 218 (MH"). : ©
Step IF:
A mixture of Cmpd 1e (30 g) and hydrazine hydrobromide (62 g) in ethanol (150 mL) and water (20 mL) was heated to reflux for 1 hr. Ethanol was removed in vacuo and the residue was diluted with water (50 mL). The aqueous phase was basified with solid Na;CO; and the resultant was extracted with ethyl acetate. The extract was dried over MgSO, filtered and concentrated in vacuo to give 3-amino-4-(6-dimethylamino-4- methylpyridin-3-yl)-5-methylpyrazole as a brownish oil (Cmpd 1f, 30g, 93% yield.) which was crystallized from ether-hexanes. 'H NMR (CDCl): 2.07 (s, 3H), 2.14 (s, 3H), 3.10 (s, 6H), 4.10 (brs, 3H), 6.45 (s, 1H), 7.92 (s, 1H); MS (CI) m/e 232 (MH)
Step 1G:
A solution of Cmpd 1f (29.5 g) and ethyl] acetoacetate (2.5 eq.) in dioxane (100 mL) was heated to reflux for 20 hr. The suspension was cooled, and ether (200 mL) was added. The solid was collected by vacuum filtration and 2,5-dimethyl-3-(6- dimethylamino-4-methylpyridin-3-y1)-7-hydroxypyrazolo[ 1,5-a]pyrimidine was obtained as a tan solid (Cmpd 1g, 23.5 g, 62% yield). The filtrate was concentrated in vacuo and the residue was dissolved in water (50 mL). This aqueous phase was extracted with ether (3x 300mL) to remove starting material and impurity. The product was then extracted with DCM (5x 300 mL) affording another 6 g (total yield 78%) of Cmpd 1g. '"H NMR (CDCl): 2.10 (s, 3H), 2.20 (s, 3H), 2.33 (s, 3H), 2.91 (s, 6H), 5.64 (s, 1H), 6.24 (s, 1H), 7.65 (s, 1H). MS (CI) m/e 298 (MH")
Step 1H:
A suspension of Cmpd 1g (11 g) and POC]; (2 eq.) in acetonitrile (50 mL) was heated to reflux for 8 hr. The reaction was quenched with ice and basified with
Na,CO;. The product was extracted with ethyl acetate (2x 200 mL). The extract was dried over MgSO,, filtrated through a silica gel pad and concentrated in vacuo to give [5- (1-Chloro-2,5-dimethyl-pyrazolo(1,5-a]pyrimidin-3-yl)-4-methyl-pyridin-2-yl]-dimethyl- amine as a yellowish solid (Cmpd 1h, 11.5 g, 99% yield). 'H NMR (CDCl3): 2.13 (s, 3H), 2.43 (s, 3H), 2.53 (s, 3H), 3.11 (s, 6H), 6.49 (s, 1H), 6.78 (s, 1H), 8.01 (s, 1H); MS (CD) m/e 316 MH")
EXAMPLE 2
SYNTHESIS OF REAGENT (2,4-DIMETHOXY-PHENYL)-ACETONITRILE
NY
H
TosMIC t-BuOK 2
Step2:
Into a suspension t-BuOK (47.3 g) in DME (150 mL) at -30 OC (dry ice/acetone bath) was added dropwise a solution of TosMIC (58.8 g) in DME (150 mL), keeping the temperature of the mixture below -30 °C. The solution was stirred and allowed to cool to —60 °C over 10 minutes before a solution of 24- dimethoxybenzaldehyde (SO gl) in DME (150 mL) was added dropwise, keeping the temperature of the reaction mixture below —50 °C. The reaction mixture was stirred at -50 to —60 °C for 1hr, then methanol (200 mL) was added. This mixture was heated to reflux for 2hr. The solvent was evaporated and the residue was partitioned between ethyl acetate and water with acetic acid (40 mL) added. The aqueous layer was extracted with one additional portion of ethyl acetate, then the combined ethyl acetate layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography, eluting with 1:1 hexanes/ethyl acetate to provide 2 (48.8 g).
EXAMPLE 3
SYNTHESIS OF REAGENTS 2-CHLORO-4-METHOXY-BENZALDEHYDE AND (2-CHLORO-4-
METHOXY-PHENYL)-ACETONITRILE
XN
Hi Hi
I Kk,co, rosMiC !
Mel t-BuOK
H 3a 3»
Step 3A: 2-chloro-4-hydrox ybenzaldehyde (9.56 g) and K>CO; (25.3 g) were stirred with DMF (30 mL) at RT for 30 min. Iodomethane (4.0 mL) was added, the reaction vessel was sealed, and thc mixture was stirred at RT for 16 hr. 300 mL of 2:1 hexanes/ethyl acetate was added, after which the mixture was washed 3 times with water and once with brine. The organic layer was dried over sodium sulfate, filtered then evaporated to a volume of about 50 mL. The precipitate which formed was filtered and washed with hexanes to provide Cmpd 3a as a tan solid (6.0 g).
Step 3B:
Formation of the acetonitrile Cmpd 3b followed the procedure of Step 2 employing t-BuOK and TosMIC in DME.
EXAMPLE 4
SYNTHESIS OF REAGENT 7-CHLORO-3-(4-METHOX Y-2-METHYL-PHENY L)-2,5-DIMETHYL-
PYRAZOLO[1,5-A]PYRIMIDINE 0 /
NaH
THF H,NNH, HBr rr ————— ———————
EtOAc a da 4 / OH | , )
EAA POC), dioxane > MeCN CO ————— —————— 4 ] 4d
J
J
Step 4A:
Sodium hydride (12.0 g of 60% suspension in oil) was added to a solution of 4-methoxy-2-methylphenylacetonitrile (30 g) in anhydrous THF (300 mL) at RT under nitrogen. About 2 mL of ethyl acetate was added and the mixture was heated gradually to an internal temperature of 66 °C. After about 10 minutes a vigorous reaction ensued, and heating was discontinued while additional ethyl acetate (75 mL) was added dropwise over about 20 minutes to maintain reflux. Vigorous hydrogen evolution was observed. By the end of the ethyl acetate addition, the reaction mixture began to cool, and the mixture was stirred and allowed to cool over 3 hr. 150 mL water was added followed by 300 mL ether.
The aqueous layer was washed with two additional portions of ether. The ether extracts were discarded. The aqueous layer was acidified with 20 mL concentrated hydrochloric acid (pH ~5), then the mixture was extracted with three portions of ethyl acetate. The combined cthyl acetate extracts were dried over sodium sulfate, filtered and evaporated to give crude ketonitrile 4a as a slightly amber oil (39 g) which was camied forward without further purification.
Altemate Step 4A:
Sodium hydride (35.44 g of 60% suspension in oil, 1.48 mol) was added to a solution of 4-methoxy-2-methylphenylacetonitrile (148.8 g, 0.92 mol) in anhydrous THF (2 L) at rt. EtOAc (30 mL) was added and the mixture was heated gradually to an intemal temperature of 70.1 °C. Reaction initiated, and heating was discontinued immediately by removing the heating mantle completely. EtOAc (374 mL, total 4.14 mol) was added dropwise to maintain reflux. Vigorous hydrogen evolution was observed and the reaction was stirred for 2 hours after complete EtOAc addition. Water (750 mL) was added, followed by hexane (750 mL) with vigorous stirring and the aqueous layer was separated and acidified with conc. HCI to pH ~2. The aqueous layer was extracted with EtOAc (3 x 400 mL) and the combined extracts dried (MgSOs) and concentrated in vacuo to afford 4a as an amber colored oil (183.8 g, 0.90 mol, 98 %, 99 % purity).
Step 4B:
A mixture of crude 4a (37.8 g) and hydrazine monohydrobromide (23.1 g) was suspended in absolute ethanol (225 mL) and water (25mL). The mixture was refluxed for approximately 3 hr. The reaction mixture was allowed to cool, then the solvent was evaporated. Ethyl acetate was added, and the mixture neutralized by addition of saturated aq. NaHCO; (200 mL), and the mixture was extracted with ethyl acetate (4x 100 mL).
The combined organic layers were washed with brine (100 mL), dried over magnesium sulfate, filtered and evaporated to give crude Cmpd 4b as a pale orange oil (45 g) which was carried forward without further purification.
Alternate Step 4B:
Compound 4a (183.8 g, 0.9 mol) was dissolved in EtOH (1.09 L) and water (109 mL) and hydrazine hydrobromide (112.39 g, 0.99 mol) was added. The mixture was refluxed (90 °C bath temperature) for 2.5 h, at which time LC/MS monitoring showed complete reaction. The reaction mixture was allowed to cool and concentrated in vacuo to remove
EtOH and partitioned between NaHCO3 (950 mL, sat. aq.) and EtOAc (400 mL). The aqueous layer was separated and extracted further with EtOAc (3 x 400 mL) and the combined organic layers were washed with brine (400 mL), dried (MgSO,) and concentrated in vacuo to give the crude aminopyrazole 4b as an amber colored oil (168.8, 80 % pure), which was carried on without further purification.
Step 4C;
Ethyl acetoacetate (EAA) (28.4 mL) was added to a solution of 4b (40.2 g, 0.18 mol) in dry dioxane (180 mL). The mixture was refluxed at 115 °C for about 20 h, during which time pyrazolopyrimidine 4c precipitated from solution as a white solid. The reaction mixture was cooled and the precipitate was filtered and washed with cold ether.
The precipitate was then dried in vacuo to yield 22.5 g (0.079 mol, 42.7%) of Cmpd 4c as an off-white solid.
Alternative Step 4C:
Ethyl acetoacetate (EAA) (200 mL) was added to a solution of the crude 4b (180 g, 0.62 mol) in absolute ethanol (500 mL) and glacial acetic acid (500 mL). The mixture was heated to reflux for 2 h, during which time pyrazolopyrimidine 4c precipitated from solution as a white solid. The reaction mixture was cooled and the precipitate was filtered and washed with cold ether. The precipitate was then dried in vacuo to yield 131 g (0.46 mol, 75%) of Cmpd 4c as an off-white solid.
Step 4D:
Phosphorous oxychloride (12 mL) was added to a suspension of 4¢ (12.1 g) in anhydrous acetonitrile (60 mL) at RT. The mixture was heated at 80 °C for 30 h, at which point the reaction mixture was a clear, deep-red solution. The reaction mixture was poured onto 300 mL of ice/water, and the reaction flask was rinsed with 100 mL ethyl acetate. The mixture was then stirred and neutralized with sat. aq. sodium carbonate. The red mixture became yellow upon neutralization. The layers were separated and the aqueous layer was extracted with ethyl acetate (4x 100 mL). The combined organic layers were washed with brine (100 mL), dried over magnesium sulfate, filtered, and concentrated to give a clear brown oil. The crude product was chromatographed on silica gel using 2:1 hexanes/ethyl acetate, giving Cmpd 4d (12.1 g , 94%) as a clear yellow oil, which solidifed upon standing. )
Alternate Step 4D:
To a suspension of pyrazolopyrimidine 4c (235.1 g, 0.83 mol) in anhydrous acetonitrile (1.2 L) was added phosphorous oxychloride (232 mL, 2.49 mol) at rt. The mixture was heated to 80 °C and stirred for 20 h and allowed to cool and concentrated in vacuo to approximately 1/4 the volume. Ice chips and water were carefully added with stirring to make the total volume up to 1 L. Ensuring the temperature was always below 5 °C using an ice bath and adding more ice chips to the mixture, the pH was brought to around 6-7 using NaOH (2 M, aq.). The resulting cold suspension was extracted with
EtOAc (3 x 500 mL) and the combined organic layers dried (MgSO,) and concentrated in
S vacuo to give chloropyrimidine 4d as a red waxy crystalline solid (258.3 g, 93 % purity), which was used directly for the next step.
Also prepared by this method were: de 2,5-dimethyl-3-(2 4-dimethox yphenyl)-7-chloropyrazolo[1,5-a}- pyrimidine (starting from 2); af 2,5-dimethyl-3-(2-chloro-4-methoxyphenyl)-7-chloropyrazolo[ 1 5- a]-pyrimidine (starting from 3b); and 4g 2,5-dimethyl-3-(4-cthoxyphenyl)-7-chloropyrazolo(1,5-a}- pyrimidine (starting from 4-ethoxyphenylacetonitrile).
EXAMPLE 5
SYNTHESIS OF REAGENT 2-(3-BROMO-2,5-DIMETHYL-PYRAZOLO{ 1,5-A]PYRIMIDIN-7-
YLAMINO)-BUTYRIC ACID METHYL ESTER
PH POC], !
Et,N
JO-—==- L007 —
H,
Sa 5b
Br, iy -_ = oO AcCN sc CO 5d Br
Step SA:
A solution of 3-amino-S-methylpyrazole (20.0 g), ethyl acetoacetate (32.0 g), acetic acid (6 mL), and dioxane (150 mL) was refluxed for 16hr. A white solid precipitated, which was collected by filtration. The filter cake was washed with ether to provide Sa (29.0 g, 86 %) as a white solid.
Step 5B:
To a suspension of Sa (5.0 g) in 1,4-dioxane (30 mL) was added triethylamine (8.50 mL) and phosphorous oxychloride (7.4 mL). The reaction was heated under nitrogen at 100°C for 2 hr. The reaction mixture was cooled in an ice bath then treated successively with water and aq. sodium bicarbonate solution (final pH 8).
Dichloromethane was added and the mixture was washed three times with water. The combined organic layers were dried over magnesium sulfate, filtered, and concentrated to a dark brown oil. The crude resultant was purified by silica gel chromatography using 30% ethyl acetate in hexanes as eluant, providing Sb (3.8, 70%) as a white solid.
LC/MS: 182.0 MH")
Step 5C:
Bromine (0.51 mL) was added to a solution of Sb (1.5 g) in 1:1 .15 methanol/water (40 mL) at 10 °C. After 10 min, the mixture was filtered to collect the precipitate that had formed. The filter cake was washed with cold MeOH/H;O (1:1) until the filtrate ran clear and was then dried under vacuum to yield Sc (3.0 g) as an off-white solid, which was used immediately without further purification.
Step SD:
To compound Sc (prepared above) was added (RS) methyl 2-amino butyrate hydrochloride (1.3 g) followed by acetonitrile (40 mL) and 4 angstrom molecular sieves. The reaction mixture was heated at 110 °C for 5 h. Ethyl acetate and aq. sodium bicarbonate were added to the cooled reaction mixture, then the organic layer was washed three times with brine. The organic layer was dried over magnesium sulfate, filtered, and evaporated to give a crude yellow solid. Purification by silica gel chromatography using 30% ethyl acetate/hexanes as eluant provided 5d (800 mg, 28%) as an off white solid.
EXAMPLE 6
SYNTHESIS OF REAGENT N-HYDROXY-ACETAMIDINE
Va H,NOHHCI BY
NaOH
H,0 H, 6
MeOH
Step6:
Sodium hydroxide (39 g of a 50% aq. solution) was added to a suspension of hydroxylamine hydrochloride (34 g) in methanol (100 mL) at RT. Acetonitrile (20 g) was added and the mixture was heated at 60 °C for 15 hr. The mixture was cooled and the solvents evaporated, then 300 mL ethanol was added to the residue. The solid was filtered off and rinsed with 200 mL ethanol, then the filtrate was evaporated to a volume of 75 mL.
The resulting precipitate was collected by filtration, rinsed with ethanol, then dried under vacuum to provide acetamide oxime 6a (19.5 g) as a white solid.
Also prepared by this method were: 6b: propionamide oxime and 6c: butyramide oxime.
EXAMPLE 7
SYNTHESIS OF REAGENT 2,2,2-TRIFLUORO-N-HYDROXY -ACETAMIDINE
Fy 3 7
Step 7:
Sodium methoxide solution (35.9 mL of a 25 % w/w solution in methanol) was added to a suspension of hydroxylamine hydrochloride (10.9 g) in methanol (200 mL) at RT. The mixture was stirred for 10 min then filtered, and the solid was rinsed with methanol. The filtrate was cooled and stirred in an ice bath, then trifluoroacetonitrile gas (16.7 g) was bubbled into the solution over 30 min. The reaction mixture was allowed to warm to RT then was evaporated to a volume of 100 mL and filtered to remove solids.
The filtrate was evaporated to provide a crude waxy solid (18 g). A portion of this was further purified by bulb-to-bulb vacuum distillation, affording Cmpd 7 as a tan waxy solid.
SYNTHESIS OF REAGENT (S)-4.4 4- TRIFLUORO-3-METHYL-BUTYRIC ACID ETHYL ESTER
Et Et = Poe pe CQ HCI Et
Jo En Ether ge
PhMe No solvent RT : Dean-Stark ) 3 } 3
P “Me Ph 3 8a 8b 8c
Step 8A: (R)-alpha-methyl benzylamine (16.0 g) was added to a solution of ethyl 4,4 A-triflucrobutyrate (24.4 g) in toluene (75 mL). p-Toluenesulfonic acid hydrate (630 mg) was added, and the mixture was heated to reflux with removal of water via Dean-
Stark trap. After 2 hr, the mixture was cooled, ethyl acetate (100 mL) was added, and the solution was washed with ag. sodium bicarbonate followed by brine. The organic layer was dried over sodium sulfate, filtered and evaporated to a yellow oil. The oil was subjected to vacuum distillation (collection at 102-110 °C, ca. 5 mm Hg), providing 175¢ of Cmpd 8a as a colorless oil.
Step 8B:
DBU (18.1 mL) was added to 8a (17.44 g), and the brown mixture was heated at 70 °C for 12 hr. The cooled mixture was applied to a plug of silica gel, eluting with 4:1 hexanes/ethyl acetate to provide Cmpd 8b (14.5 g) as a yellow oil.
Step 8C:
Hydrochloric acid (7.0 mL, 2N) was added to a solution of Cmpd 8b (800 mg) in ether (10 mL). The mixture was stirred vi gorously at RT for 15 hr, then the layers were separated. The aqueous layer was washed three times with ether then was evaporated to dryness. The residue was co-evaporated twice with toluene, then dried under vacuum to provide Cmpd 8c (410 mg) as a gum.
EXAMPLE 9
SYNTHESIS OF REAGENT 3-AMINO-PENTANOIC ACID METHYL ESTER oA
PA(OH),/C ————— —————
MeOH EtOH
NS »
Step 9A:
S Benzylamine (2.51 mL) was added to a solution of methyl trans-2- pentenoate (2.62 g) in methanol (10 mL). The reaction vessel was sealed and the solution was heated at 85 °C for 3 hr. The solvent was evaporated, and the residue was chromatographed on silica gel, eluting with 3:1 hexanes/ethyl acetate to provide 9a (2.9 g) as a yellow oil.
Step 9B:
A mixture of 9a (2.3 g), 20% palladium hydroxide on charcoal (530 mg), and ethanol (10 mL) was stirred at RT under a hydrogen atmosphere (1 atm, balloon) for 17 hr. The reaction mixture was sparged with nitrogen then filtered and evaporated. The residue was dissolved in DCM, dried over sodium sulfate, filtered and evaporated to provide Cmpd 9b (1.7 g) as a colorless oil, contaminated with approximately 20% of the comresponding ethyl ester.
EXAMPLE 10
SYNTHESIS OF REAGENT (S)-NORVALINE METHYL ESTER HYDRLCHLORIDE
HCI
H MeOH reflux ————— “rN CH, “nN 10
Step 10:
Acetyl chloride (3.0 mL) was added to methanol (60 mL) with stirring in an ice bath. (S)-norvaline (3.0 g) was added to the methanol solution, and the mixture was heated to reflux for 19 hr. The cooled solution was evaporated to dryness, then the residue was co-evaporated three times With toluene, then dried under vacuum to provide Cmpd 10 (4.3 g) as a white solid.
EXAMPLE 11
SYNTHESIS OF [1-(3-CYCLOPROPYL-{1 2. 4]OXADIAZOL-5-Y1.)-PROPYL]-{3-(4-METHOXY-2-
METHYL-PHENYL)-2,5-DIMETHYL-PYRAZOLO[ 1 ,5-AJPYRIMIDIN-7-YL]-AMINE \V,
A , 3 ) © 4d H
Ch (MN wm °
AON \
C) 11a 0 C) 11-1 10 .
Step 11A; (RS)-Methyl-2-aminobutyrate hydrochloride salt (0.81 g) was added to a solution of Cmpd 4d (0.800 g) in anhydrous acetonitrile (4 mL). Triethylamine (0.74 mL) was added, and the mixture was heated in a sealed tube in a microwave reactor at 150 °C for 35 min. The solvent was evaporated, then the crude residue was purified by silica gel chromatography using 2:1 hexanes/ethyl acetate as eluant to provide Cmpd 11a (0.585 g, 58%) as a slightly yellow solid.
Step 11B:
Sodium hydride (7 mg of a 60% suspension in mineral oil) was added to a suspension of N-Hydroxycyclopropanecarboxamidine (20 mg) in anhydrous THF (1 mL).
The mixture was stirred at RT for 45 min, then a solution of 11a (50 mg) in anhydrous
THF (0.5 mL) was added, and the mixture was heated at 75 °C for 1 hr. The mixture was cooled and concentrated, then the residue was purified by silica gel chromatography, using 2:1 hexanes/ethyl acetate as eluant to provideCmpd 11-1 (20 mg) as a yellow oil.
Depending on the pyrazolo-{1,5a}-pyrimidine, amino acid ester and oxime reagent, the compounds in the following table were prepared:
Table 1.
R N
.
R
$04 . ey, .
Ri, Rp rat
HPLC
Cmpd Ss Aw, Method ~h~ 4 432.52 | 433.0 7
BFEEIEEER
\ 468.56 | 4692 | 6.122 +
Efe]
S
R,. Ry \ A HPLC
A MW
Cmpd 2 ®y, Method 4 . 11-6 4 g! 378.43 | 3790 | 4316 [Ge] y
Fy 7 | 460.46 6.444 4 430.51 431.0 | 5.388 1 7
FH Jee] 4 ga
R ’ » x \ ~~ Mw | MS HPLC
Cmpd | ® AA A Method a 406.49 5.358
H oN
Fy 11-16 HT 458.44 6.083
EICIEEED
J 4857 | 4492
H ol or [HL [oo] / 42249 | 4228 1323 2 7 |G Joel] 7 & 43651 | 4368 1324 2
B 2 11-23 7 45054 | 4508 | 1317 2
Ry
HPLC
Cmpd Ns 2% MW | MS - R,), pr 4
XX 408.461 408.8] 1.431 ~der 4 } 482.59 | 482.8 1.539 2
SY oe]
EXAMPLE 12
SYNTHESIS OF [3-(4-METHOXY-2-METHYL-PHENYL)-2,5-DIMETHYL-PYRAZOLO( 1 ,5-
AJPYRIMIDIN-7-YL]-[1-METHYL-2-(3-METHYL-{ 1,2 4] OXADIAZOL-5-YL)-ETHYL}- AMINE ~ J £5 Je >
RS H < 0 / 0” ACN a. =, NaH, THF a NR ~ 2 122 0 12-1
Pd
Step 12A: (R,S)-Ethyl 3-aminobutyrate (150 mg) was added to a solution of 4d (150 mg) in anhydrous acetonitrile (0.75 mL). The mixture was heated in a sealed tube in a microwave reactor at 150 °C for 35 min. The solvent was evaporated, then the crude residue was purified by silica gel chromatography using 2:1 hexanes/ethyl acetate as eluant to provide Cmpd 12a (170 mg, 76%) as a yellow oil.
Step 12B:
Sodium hydride (21 mg of a 60% suspension in mineral oil) was added to a suspension of acetamide oxime (60 mg) in anhydrous THF (2 mL) at RT. The mixture was stirred at RT for 45 min, then a solution of 12a (160 mg) in anhydrous THF (1.6 mL) was added, the reaction vessel was sealed and the mixture was heated at 80 °C for 1.5 hr.
The mixture was cooled and concentrated, then the residue was purified by silica gel chromatography, using 1:1 hexanes/ethyl acetate as eluant to provide 12-1 (72 mg) as a dark yellow oil.
Depending on the pyrazolo-{1,5a)-pyrimidine, amino acid ester and oxime reagent, the compounds in the following table were prepared:
Table 2. 5
R,, Ry A\ : %
R
$44
A
S@®,),
Ru Ry ’
Cmpd | r ~ MW
AT
HN oN 406.49 | 407.0] 4831 de ‘al 468.56 | 469.0
FC
4
SAT 460.46 4.676
Ry Ray pr
Cm " = A MW
Bd CIEER
Jeo
H. o
F ]
JN
7 12-8 wl oo 406.49 ’ / 12-9 420.51 5.022
H
4 (OH Jo] ° All HPLC employed Analytical Method 1.
EXAMPLE 13
SYNTHESIS OF [3-(4-METHOXY-2-METHYL-PHENYL)-2,5-DIMETHYL-PYRAZOLO[ 1,5-
AJPYRIMIDIN-7-YL}-[(S)-1-(3-METHYL-[1,2,4]0XADIAZOL-5-YL)-BUTYL}-AMINE
O A HO V i “0,” NG \ 0,” NN ad LiOH
LO meme, [10 amp” TN an *oe-g md 0 QO
A / §! 9 A
DIC, HOBT, NN :
DCM/DMF == oy — A 13 C3 13-1 3 h [J /
Step 13A:
A mixture of compounds 10 (416 mg) and 4d (500 mg,), triethylamine (0.35 mL) and acetonitrile (4 mL) was heated at 150 °C in a microwave reactor for 35 min.
The mixture was partitioned between ethyl acetate and aq. sodium bicarbonate, then the organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was chromatographed on silica gel, eluting with 4:1 hexanes/ethyl acetate to provide 13a (340 mg) as a yellow oil.
Step 13B:
Lithium hydroxide hydrate (44 mg) was added to a mixture of Cmpd 13a (320 mg), THF (2 mL), and water (1 mL). The mixture was stirred vigorously at RT for
30 min, then hexanes (5 mL) was added. The layers were separated and the aqueous layer was acidified with 2N hydrochloric acid (0.6 mL, final pH 3-4). The resulting precipitate was collected by filtration, washed with water, co-evaporated with toluene, then dried under vacuum to provide Cmpd 13b (215 mg) as a white solid.
S Step 13C:
A mixture of 13b (160 mg), HOBT (79 mg), acetamide oxime (47 mg),
DCM (2 mL), and DMF (0.25 mL) was cooled to -15 °C. DIC (0.085 mL) was added and the mixture was allowed to warm to RT over 2 hr. The solvents were evaporated, then ethyl acetate (50 mL) was added and the mixture was washed once with saturated aq. sodium bicarbonate, then once with 10% aq. potassium dihydrogen phosphate. The ethyl acetate layer was dried over sodium sulfate, filtered, and concentrated to provide Cmpd 13c.
Step 13D:
Pyridine (1.5 mL) was added to Cmpd 13c prepared in the previous step, 1S then the mixture was heated in a sealed tube at 100 °C for 2.5 hr. The solvent was evaporated. The residue was taken up in ether then filtered to remove DIU, rinsing with several portions of ether. The filtrate was evaporated, then the residue was chromatographed on silica gel, eluting with 3:1 hexanes/ethyl acetate to provide Cmpd 13- 1 as a yellow oil. The free base 13-1 (115 mg) was dissolved in ether (2 mL), then 2 M
HCl in ether (0.205 mL) was added at RT, resulting in formation of a white precipitate.
The supernatant was decanted, the remaining solid was washed twice with ether. Drying under vacuum at 35 °C gave 13-1 hydrochloride salt (121 mg) as a white solid.
Depending on the pyrazolo-[1,5a]-pyrimidine, amino acid ester and oxime reagent, the compounds in the following table were prepared:
Table 3.
Ya
NR),
Ss
Rs, R,, A
HPLC
Cm Re OX MW | MS pd Is, ACR), Method
Sov 42051 | 421.1]209%0 | 3
HN oN ~bnr
YN
132 -— 460.46 cr,
F, % eid 460.46 5991 ) 134 Nels 480.88 14033] 3 ~~ CF, / 3 - ) , oN 480.88 | 4807 | 6215
Fy / 137 es 47646 | 477.1] 13596 3
Ry, Rn HPLC
Cmpd 52 IS 2% MW | MS | Method 7 Ry,
JN
/ 8! 476.46 | 4710
CF,
Fy 4 530.7 6.288
EXAMPLE14
SYNTHESIS OF [3-(4-METHOXY-2-METHYL-PHENYL)-2,5-DIMETHYL-PYRAZOLO] 1,5-
AJPYRIMIDIN-7-YL}-[(S)-1-(3-METHYL-[1,2 4]0XADIAZOL-5-YL)-PROPYL]- AMINE
NH,
Cl xy, > XY en ——————— I “torr” «QQ C10
Hs 14a
S 9!
DIC, HOBT N od y
DCM/DMF a pyridine ne” 141 a ke 0) [)
Step 14A:
A suspension of sodium bicarbonate (28.7 g) and (S)-2-aminobutyric acid (21.7 g) in water (250 mL) was added to a solution of 4d (39.7 g) in dioxane (250 mL).
The mixture was stirred and heated to reflux (102 °C bath) for 14 hr. The mixture was cooled to RT, then concentrated HCl (16 mL) was added over 10 min to final pH4.5. A copious white precipitate formed. The mixture was concentrated to a weight of about 250 g, then the residue was subjected to co-evaporation with several portions of ethyl acetate, resulting in a thick, pasty aqueous slurry. The mixture was filtered, and the filter cake was washed with water (total 350 mL). The filter cake was then dried under vacuum at 35 °C, yielding compound 14a (45.2 g) asa white solid.
Alternate Step 14A:
NaHCO; (97.45 g, 1.16 mol) and (S)-2-aminobutyric acid (74.25 g, 0.72 mol) were suspended in water (900 mL). To this was added a solution of chloropyrimidine 4d (134.4 g) in dioxane (300 mL) and the resulting mixture warmed to reflux and stirred for.2.5 h. The mixture was cooled to rt, and acidified to pH 4 with adding conc. HCI (approx 88 mL) dropwise forming a copious white precipitate. The mixture was concentrated in vacuo and the resulting solid slurried in water (1L), stirred and filtered, washing with water. More product precipitate was observed from the mother liquors and two more crops were obtained. The combined solids were dried in vacuo to give to desired carboxylic acid 14a as a cream colored solid (159.3 g, 0.4 mol, > 93 % purity). In an alternate workup, the reaction mixture is filtered immediately following acidification with the conc. HCI and the solid is dissolved in methylene chloride. The remaining water in the solid was separated and removed and the methylene chloride layer was dried and concentrated to give 14a.
Step 14B:
Cmpd 14a (10 g) was suspended in toluene (50 mL) and evaporated to dryness. Dry DCM (100 mL) was added followed by HOBT (4.8 g) and acetamide oxime (2.7 g). Anhydrous DMF (11 mL) was added, then the reaction mixture was stirred and cooled in an ethylene glycol/dry ice bath to an internal temperature of ~15.5 °C under a nitrogen atmosphere. DIC (5.3 mL) was then added via syringe. The reaction mixture was stirred and allowed to warm over 2 hr, at which time the internal temperature was +16.5 °C. The solvents were evaporated, then ethyl acetate (150 mL) was added and the mixture was washed once with 10% aq. potassium dihydrogen phosphate, twice with saturated aq. sodium bicarbonate, once again with 10% aq. potassium dihydrogen phosphate, and finally with brine. The ethyl acetate layer was dried over sodium sulfate, filtered, and concentrated to provide crude Cmpd 14b.
Alternate Step 14B:
Compound 4a (411.91 g, 0.95 mol) was suspended in CH,CH, (3.8L) and
DMF (300 mL), to which was added acetamidoxime (95.12 g, 1.28 mol) and HOBt (167.56 g, 1.24 mol) under a nitrogen atmosphere. The mixture was cooled to an internal temperature of —30 °C and DIC (194.15 mL, 1.24 mol) was added dropwise so as to maintain the temperature below —20 °C. The reaction was stirred at this temperature for 1 hour and subsequently allowed to warm to 10 °C over the next 3 hours. The mixture was concentrated in vacuo and redissolved in EtOAc (5 L). The EtOAc solution was washed with NaHCO; (3 x 1.5 L, sat. aq.), KH;PO4 (1500 mL, 1M), brine (2 x 1.5 L), dried (MgSO,) and concentrated in vacuo to give 14b as a yellow foam.
Step 14C:
Pyridine (50 mL) was added to Cmpd 14b from Step 14B, then the mixture was heated under nitrogen at 100 °C for 4 hr. The resulting solution was allowed to cool, the solvent was evaporated, and the residue was co-evaporated twice with cthyl acetate and once with heptane. The residue was taken up in 50 mL ether, then filtered to remove
DIU, rinsing with several portions of ether. The filtrate was evaporated, then the residue was chromatographed on silica gel, eluting with 2:1 hexanes/ethyl acetate to provide the partially purified Cmpd 14-1 as a slightly yellow foam. The foam was co-evaporated twice with heptane, then 5:1 heptane/ethyl acetate (60 mL) was added, and the resulting slurry was stirred at RT for 24 hr. The solid was filtered and rinsed with hexanes, providing 14-1 free base (7.3 g) as a white solid. The filtrate was concentrated and a second crop of 14-1 free base (0.7 g) was collected, also as a white solid.
The free base 14-1 (6.0 g) was dissolved in 80 mL acetone and cooled in an ethylene glycol/dry ice bath to —12 °C (internal). Hydrogen chloride B89mLofa20M solution in ether) was added in one portion. The clear yellow solution was stirred for min, then the solvent was evaporated. The residue was co-evaporated with two portions of acetone, then dried under vacuum to produce an amber foam. The foam was pulverized and then dried under vacuum at RT for 24 hr, providing the hydrochloride salt 14-1 (6.7 g) as an amorphous tan powder.
Alternate Step 14C:
Compound 4b from altemate Step 14B was dissolved in pyridine (1.8 L), warmed to 100 °C, stirred for 2 hours and then was concentrated in vacuo to give a brown viscous oil. Purification by flash chromatography eluting with EtOAc:hexane (1:9, 2:8, 3:7, 4:6) gave a cream colored solid. This solid was slurried in heptane (4 L) and ground to a fine powder by stirring to give 14-1 as a white crystalline solid (248.5 g, 98.3 % purity).
Depending on the pyrazolo-[1,5a}-pyrimidine, amino acid ester and oxime reagent, the compounds in the following table were prepared:
Table 4.
Ru Ran AN
R N
(Ya eo,
R,, Ra ? x
C x 406.49 4915
H opr
H
~A
N
14-3 432.52 | 433.1 | 4.987 1 144 42691 | 4270] 2071
EXAMPLE 14A
CHARACTERIZATION OF POLYMORPH FORM 1 OF [3-(4-METHOXY-2-METHYL-PHENYL)-2,5-
DIMETHYL-PYRAZOLO[,5-A}JPYRIMIDIN-7 -YL}-[(S)-1-(3-METHYL-[1 ,2,4JOXADIAZOL-5-YL)-
PROPYL]-AMINE
Free Base 14 -1 prepared as shown in altemate Step 14C affording 248.5 g of 14-1 may be characterized by, for example, X-Ray powder diffraction spectrometry,
Raman spectrometry and/or Differential Scanning Calorimetry (DSC). Free base of 14-1 shows the XPRD pattern of Figure 1 and was identified as polymorph Form 1 of [3-(4-
Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a}pyrimidin-7-yl}-{(S)-1-(3- methyl-[1,2,4]Joxadiazol-5-yl)-propyl}-amine.
Table 1 shows the XRPD angles and d spacings for polymorph Form | of [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1 ,5-aJpyrimidin-7-yl)-[(S)-1 -(3- methyl-{1,2,4]oxadiazol-5-yl)-propyl}-amine.
Table 1 X-Ray Powder Diffraction Spectral Lines of Polymorph Form 1 mem [37
EC meal | 36m [sw | 2¢e7 mee
The X-ray powder diffraction pattern of polymorph Form 1 as shown in
Figure 1 exhibits predominant peaks (expressed in degrees 20 (+/- 0.15 degrees 26) at one or more of the following positions: 6.721, 11.757, 13.323, 18.222, 21.426 and 21.974.
More specifically, such characteristic peaks are at 11.757 and 21.974, and further at 6.721 and further at 13.323, 18.222, and 21.426.
Figure 1 shows X-Ray powder diffraction data obtained for polymorph
Form 1 of (3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a}pyrimidin-7-yl}- [(S)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-propyl]-amine as described before. Form 1 is 10° characterised by having an XRPD pattern with signals substantially as listed in Table 1.
Figure 2 shows the Raman spectrum of polymorph Form 1 of [3-(4
Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a)pyrimidin-7-yI}-{(S)-1-(3- methyl-[1,2,4]oxadiazol-5-yl)-propyl]-amine.
Figure 3 shows a Differential Scanning Calorimetry (DSC) thermogram of polymorph Form 1 of [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolof{1,5- a)pyrimidin-7-yl}-[(S)-1-(3-methyl-[1,2,4]oxadiazol-5-y])-propyl]}-amine.
It will be recognised that spectra and diffraction data will vary slightly according to various factors such as the temperature, concentration and instrumentation used. The skilled person will recognise that XRPD peak positions are affected by differences in sample height. The peak positions quoted herein are thus subject to a variation of +/- 0.15 degrees 2-theta.
As shown in Figure 3, the polymorph Form 1 exhibits a predominant endotherm peak at about 108.3 °C. It should be recognized that that the endotherm peak as measured is dependent under a number of factors including the machine employed, the rate of heating, the calibration standard, humidity and the purity of the sample used.
Accordingly, the term “about 108.3 °C” is intended to encompass such instrument variations.
X-Ray Powder Diffraction
X Ray Powder Diffraction (XRPD) analysis was performed on Bruker
D5005, using Sol-X detector. The acquisition conditions were: radiation: Cu Ko, generator tension: 40 kV, generator current: S0mA, start angle: 2.0 °26, end angle: 45.0 ©20, step size: 0.02 °20 , time per step: 0.5 seconds. The sample was prepared on zero background sample holder.
Raman Spectroscopy
Instrument Configuration: Kaiser RXNI Kaiser Optical System Micro
Raman. Sample on Al sample pan, laser | = 785nm.
Differential Scanning Calorimetry (DSC)
Instrument configuration. PE DSC 7, not ermetic sample pan, run @ 10K/min to 150 °C, sample 1.5-5 mg.
EXAMPLE 14B
SYNTHESIS AND CHARACTERISATION OF POLYMORPH FORM 2 OF [3-(4-METHOXY-2-
METHYL-PHENYL)-2,5-DIMETHYL-PYRAZOLO[ 1,5- AJP YRIMIDIN-7-YL]-[(S)-1-(3-METHYL- [1,2,4JOXADIAZOL-5-YL)-PROPYL]-AMINE
Polymorph Form 2 of [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl- pyrazolo[1,5-a]pyrimidin-7-yl]-[(S)-1-(3-methyl-[1,2,4]Joxadiazol-5-yl)-propyl}-amine was prepared as follows: [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7- yi]-[(S)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-propyl]-amine polymorph Form 1 (0.74 g) was slurried in 50% aqueous isopropanol (4mL). The temperature was cycled between 0 and 40 °C for 24 hours, then the mixture stirred at ambient temperature for 3 days, then the temperature was cycled between 0 and 40 °C for 24 hours. The residual solid was filtered oft and dried at ambient temperature to give 0.70 g of [3-(4-Methoxy-2-methyl-phenyl)- 2,5-dimethyl-pyrazolo[1,5-a)pyrimidin-7-yl}-{(S)-1-(3-methyl-[1,2,4]oxadiazol-5-yi)- propyl]-amine polymorph Form 2.
Preparation of polymorph Form 2 of [3-(4-Methoxy-2-methyl-phenyl)-2,5- dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl}-[(S)-1-(3-methyl-[1 ,2,4]oxadiazol-5-yl)-propyl]- amine was repeated on large scale as follows.
Free Base 14-1 was prepared in an analogous way as described before in
EXAMPLE 14, except for the lack of the chromatographic purification present in Step : 14C. The formation and successive liberation of the mesylate salt afforded a desired compound with a high purity without the necessity of a chromatography.
Free Base 14-1 (2.48 kg, 6.10 mol, chemical purity 90%) was stirred with n-Butyl acetate (12.5 L) for 30 to 45 minutes then Methane sulphonic acid (1.2 eq, 7.32
Mol, 703 g) was added. After stirring for 2-3 hrs at 25-30 %C the mixture was filtered.
The solid was slurry washed with n-Butyl acetate (5 L) followed by Heptane (7.5 L). then dried for 4-6hrs at 50£5 °C under vacuum to give Mesylate salt (2.48 kg, chemical purity 97.37%). :
The mesylate salt was stirred with DM water (12.5 L) for 15 to 30 minutes.
Aq. ammonia was added to a pH of 9.0-10. The suspension was extracted with ethyl acetate (3 x 7.5 L). then the combined extracts were washed with DM water (5 L) and 20%
Brine solution (5 L). The organic solution was concentrated under vacuum at below 5015 °c, removing 85 to 90 % of the solvent, then the residue cooled to 3015 °c. Heptane (15
L) was added and the mixture stirred for 2 to 3 hrs at 25-30 °C then 60 to 70 % of the solvent was distilled off under vacuum at below 50+5 °C. The mixture was cooled to 3015 °C, stirred for 1 to 2 hours, then filtered. The solid was slurry washed with Heptane (5 L) then dried under vacuum at below 505 °C to give polymorph Form 1 of [3-(4- methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a)pyrimidin-7-yl}-[(S)-1-(3-methyl- [1,2,4]Joxadiazol-5-yl)-propyl]-amine (1.70 kg, chemical purity 99.34%).
A mixture of polymorph Form 1 (1.37 kg, 3.37 Mol, purity by HPLC 99.34%) of [3-(4-methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo{1,5-a]pyrimidin-7- yl}-[(S)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-propyl]-amine and ethyl acetate (2.05 L) were heated to 40 to 45 °C (a clear solution was observed). The solution was then cooled to 30+5 °C and Heptane (6.85 L) added before heating to 6042.5 °c. Polymorph Form 2 of
[3-(4-methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-alpyrimidin-7-yl}-{(S)-1-(3- methyl-[ 1,2,.4Joxadiazo}-5-yl)-propyl]-amine seed material prepared as described above (0.5% w/w) was added at 602.5 OC then the mixture was cooled to 40+2.5 °C, then heated back to 5042.5 °C when further seed material (0.5% w/w) was added. The resulting slurry was cooled to 3045 °C and stirred for 12 hrs at 3025 °C. Heptane (2.74 L) was added and the mixture stirred for a further 12 hrs at 30+5 °C. The slurry was filtered and the solid slurry washed with Heptane (2.74 L). The solid was dried under vacuum at 50:5 OC for hrs to give 0.97 kg of polymorph Form 2 of [3-(4-methoxy-2-methyl-phenyi)-2,5- dimethyl-pyrazolo(1,5-alpyrimidin-7-yl]-{(S)-1-(3-methyl-[1,2.4]oxadiazol-5-y)-propyl}- amine (HPLC purity 99.58%).
HPLC method
Column : Zorbax SB-C18(150x4.6 mm), 3.5 micron
Mobile Phase-A : 0.05% TFA (Aqueous)
Mobile Phase -B : 0.025% TFA(Acetonitrile)
Column temperature ~~ : 40 °C
Flow rate : 1.0 ml/min “Wavelength of detection : 225nm
Injection volume : Spl
Run time : 30 mins
Concentration : 0.3 mg/ml
Gradient program : Linear gradient
Time in min Mobile phase-A(%) Mobile phase-B (%) 0 75 25 5 95 29 5 95 75 25
Post run time : 5 min 25 Retentiontime : Form 2 about 9 min
Diluent: Mobile Phase-A: Mobile Phase-B (1:1)
Polymorph Form 2 of [3-(4-methoxy-2-methyl-phenyl)-2,5-dimethyl- pyrazolo[1,5-a} pyrimidin-7-y1]-[(S)-1-(3-methyl-[1,2,4]ox adiazol-5-yl)-propyl]-amine shows the XPRD pattern (Figure 4).
Table 2 shows the XRPD angles and d spacings for polymorph Form 2 of [3-(4-Methoxy-2-methyl -phenyl)-2,5-dimethyl-pyrazolof1 ,S-a]pyrimidin-7-y1}-[(S)-1- (3-methyl-[1 .2,4]oxadiazol-5-yl)-propyl]-amine.
Table 2: X-Ray Powder Diffraction Spectral Lines of Polymorph Form 1
EE LCN
Figure 4 shows X-Ray powder diffraction data obtained for polymorph
Form 2 of [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-alpyrimidin-7-yl)- [(S)-1-(3-methyl-[1,2,4Joxadiazol-5-yl)-propyl]-amine as described before. Form 2 is characterised by having an XRPD pattem with signals substantially as listed in Table 1.
Figure 5 shows the Raman spectrum of polymorph Form 2 of [3-(4-
Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7-yl}-[(S)-1-(3- methyl-[1,2,4]oxadiazol-5-yl)-propyl]-amine.
Figure 6 shows a Differential Scanning Calorimetry (DSC) thermogram of polymorph Form 2 of [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo(1,5- a]pyrimidin-7-yl]-[(S)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-propyl]-amine.
It will be recognised that spectra and diffraction data will vary slightly according to various factors such as the temperature, concentration and instrumentation used. The skilled person will recognise that XRPD peak positions are affected by differences in sample height. The peak positions quoted herein are thus subject to a variation of +/- 0.15 degrees 2-theta.
As shown in Figure 6, the polymorph Form 2 exhibits a predominant endotherm peak at about 115.1 °C. It should be recognized that that the endotherm peak as measured is dependent under a number of factors including the machine employed, the rate of heating, the calibration standard, humidity and the purity of the sample used.
Accordingly, the term “about 115.1 °C” is intended to encompass such instrument variations.
X-Ray Powder Diffraction
X Ray Powder Diffraction (XRPD) analysis was performed on Bruker
D5005, using Sol-X detector. The acquisition conditions were: radiation: Cu Ko, generator tension: 40 kV, generator current: S0mA, start angle: 2.0 °26, end angle: 45.0 20, step size: 0.04 °26 , time per step: 1 second. The sample was prepared on zero background sample holder.
Raman Spectroscopy
Instrument Configuration: Kaiser RXN1 Kaiser Optical System Micro
Raman. Sample on Al sample pan, laser 1 = 785nm.
Differential Scanning Calorimetry (DSC)
Instrument configuration: Q 1000 TA, not ermetic sample pan, run @ 10K/min to 150 °C, N2 Flow =50mL/min, sample 1.5-5 mg.
EXAMPLE 15
SYNTHESIS OF [3-(2,4-DIMETHOXY-PHENYL)-2,5-DIMETHYL-PYRAZOLO[ 1,5-A]PYRIMIDIN-7-
YL}-(2-METHOXY-ETHYL)-(3-METHYL-[1,2,4|OXADIAZOL-5-YLMETHYL)-AMINE we ON > 15a A
QO 8 0 $! 0
Acetamide oxime
NaH de 0 THF ———————— mK Pew
AcCN O— a 15b C3 15.1 8 / \
Step 15A: oo
To a solution of 2-methoxyethylamine (2.9 mL) in THF (40 mL) was added tricthylamine (9.3 mL) followed by methyl bromoacetate (2.8 mL). The mixture was stirred at RT for 16 hr, then the solvent was evaporated. The residue was dissolved in ethyl acetate (100 mL), washed with water (2x 50mL), brine (50 mL), then the organic layer was dried over magnesium sulfate and concentrated. The residue was purified by silica gel chromatography using 95:5 dichloromethane/methanol as eluant to give 15a (1.8 g. 37 % yield) as a colorless liquid. 1H NMR (CDCI3, 300 MHz): 2.78 (1, 2H, J=3Hz), 3.33 (s, 3H), 3.43 (s, 2H), 3.48 (1, 2H, J=3Hz), 3.70 (s, 3H).
Step 15B:
DBU (0.22 mL) and Cmpd 15a (220 mg) were added to a solution of Cmpd
S 4e (400 mg) in acetonitrile (4 mL). The solution was stirred and heated at 80 °C for 16 hr.
The cooled mixture was concentrated, then ethyl acetate (20 mL) was added. The mixture was washed with water (2x 10mL), then brine (10 mL), and the resulting organic layer was dried over magnesium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography using 95:5 dichloromethane/methanol as eluant to provide Cmpd 15b as an oil. Mass: 428.8 (MH); HPLC: Analytical Method 2, retention time 1.46 min.
Step 15C: :
A suspension of acetamide oxime (60 mgin anhydrous THF (5 mL) was stirred at RT as NaH (32 mg of 60% dispersion in oil) was added. The mixture was stirred for 45 min at RT, then a solution of Cmpd 15b (173 mg) in anhydrous THF (5 mL) was added. The mixture was refluxed for 2 hr. The cooled mixture was concentrated, then taken up in ethyl acetate (10 mL) and washed with water (2x 10 mL) and brine (10 mL).
The resulting organic layer was dried over magnesium sulfate, filtered, and evaporated.
The residue was purified by preparative LC/MS to provide Cmpd 15-1. Mass: 452.8 (MH); HPLC: Analytical Method 2, retention time 1.406 min. * Depending on the pyrazolo-[1,5a}-pyrimidine, amino acid ester and oxime reagent, the compounds in the following table were prepared:
Table S.
] 3 : po;
R
Ym
A
; Ra
EE [oe]
Baa FicEER
Baska EEER
EXAMPLE 16
SYNTHESIS OF [3-(2,4-DIMETHOXY -PHENYL)-2,5-DIMETHYL-PYRAZOLO[ 1,5-AJPYRIMIDIN-7-
YLJ-(2-METHOXY-ETHYL)-(3-(3-METHYL-[1.2 4 OX ADIAZOL- 5-YL) PROPYL]-AMINE ~~
Jos NR C. — 5 ae!
J, N O~—
ACN
16 . hi R
DMF “L Y ° ° ~~ N Aceumidc oxime §
JS ny EA
A _— 3
O~ SN = om
Bae T aS
A AP
S Step 16A:
To Cmpd 4e (200 mg) in acetonitrile (5 mL) was added 2- methoxyethylamine (2 mL). The solution was stirred and heated at 80 °C for 16 hr. The mixture was concentrated under vacuum. The residue was dissolved in ethyl acetate (SmL), and the resulting solution was washed with water (2x SmL) and brine (5 mL).
Drying over magnesium sulfate, filtration, and concentration provided a yellow oil, Cmpd 16a, which was used in the following step without purification.
Step 16B:
Sodium hydride (76 mg of a 60% dispersion in oil) was added.to a solution of 16a prepared in Step 16A in DMF (5 mL). After 5 minutes at RT, methyl 4- bromobutyrate (0.21 mL) was added. The mixture was heated for 48 hr at 60 °C in a sealed vial. The cooled mixture was concentrated, taken up in ethyl acetate (25 mL) and washed successively with water (2x 10 mL) and brine. The organic layer was dried over magnesium sulfate, filtered, and concentrated. The crude residue 16b was used without further purification.
Step 16C:
Crude Cmpd 16b, prepared above in Step 16B, was subjected to the procedure of Step 15C. The crude reaction mixture was diluted with methanol, then purified directily by preparative LC/MS to afford Cmpd 16-1. Mass: 480.8 (MH"); HPLC:
S Analytical Method 2, retention time 1.353 min.
EXAMPLE 17
SYNTHESIS OF [3-(4-METHOXY-2-METHYL-PHENYL)-2,5-DIMETHYL-PYRAZOLO[ 1,5-
AJPYRIMIDIN-7-YL}-{(R)- 1-METHYL-2-(5-METHYL-[1,2,4]OXADIAZOL-3-YL)- ETHYL] AMINE
HO sO ; Ho Ad MsCl, TEA ~~ bE A N
Re, a nnorna © NH noma -
DMF 8 Mon. H,0 ¢ oS — d \ A
Ne STs STs
Step 17A:
A mixture of Cmpd 4d (1.0 g), (R)-2-amino-l-propanol (0.5 g), triethylamine (0.91 mL), and acetonitrile (5 mL) was heated with stirring at 90 °C for 4 hr.
The reaction mixture was partitioned between saturated aq. sodium bicarbonate and ethyl acetate. The aqueous layer was extracted with one additional portion of ethyl acetate, then the combined organic layers were dried over sodium sulfate and concentrated to provide
Cmpd 17a as a yellow oil, which was used without further purification.
Step 17B:
A solution of methanesulfony! chloride (0.68 g) in DCM (1.0 mL) was added dropwise to a stirred mixture of crude Cmpd 17a (prepared above), triethylamine (0.91 mL), and DCM. A clear brown solution resulted, and the mixture was stirred at RT for 30 min. Saturated aq. sodium bicarbonate solution was added, and the mixture was extracted with ethyl acetate (2x 25 mL). The combined organic layers were washed once with potassium carbonate solution and were then dried over sodium sulfate, filtered, and concentrated to provide Cmpd 17b as a white foam. This material was used without further purification.
Step 17C:
Powdered sodium cyanide (0.33 g) and potassium carbonate (0.92 g) were added to a solution of Cmpd 17b (prepared above) in DMF (10 mL). The mixture was heated in a sealed tube at 100 °C for 4 hr, forming a thick gel. Saturated aq. sodium bicarbonate solution (25 mL) was added and the mixture was extracted with ethyl acetate (2x 25 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography using 30% ethyl acetate in hexane as eluant, providing Cmpd 17¢ (0.72 g, 62% yield) as a slightly yellow oil.
Step 17D:
A solution of Cmpd 17c (200 mg) in ethanol (4 mL) was treated with hydroxylamine hydrochloride (50 mg) and potassium hydroxide (40 mg). The mixture was stirred and heated at 100 °C in a sealed tube for 4 hr. The cooled mixture was filtered, and the filter cake was washed twice with 5 mL cold ethanol. The combined filtrates were concentrated providing Cmpd 17d as a white solid which was used without further purification.
Step 17E:
Cmpd 17d (prepared above) was dissolved in N,N-dimethylacetamide dimethylacetal (4 mL). The mixture was heated at 100 °C for 2 hr. The mixture was concentarated and the residue was purified by silica gel chromatography, eluting with 30%
ethyl acetate in hexane. The product was converted into the HCI salt following the procedure of Step 14C: 72 mg (28% yield).
Depending on the pyrazolo-{1,5a]-pyrimidine, amino acid ester and oxime reagent, the compounds in the following table were prepared.
Table6. < & Z
BEE EEE
* All HPLC employed Analytical Method 1.
EXAMPLE 18
SYNTHESIS OF [(R)-2-(5-CYCLOPROPYL-[ 1,2 4]OXADIAZOL-3-YL)-1-METHYL-ETHYL]-{3-(4-
METHOXY-2-METHYL-PHENYL)-2,5-DIMETHYL-PYRAZOLO[ 1,5-AJPYRIMIDIN-7-YL]-AMINE
HO. a i > eo}
HN o cyclopropane «TNH ) " carbonyl chioride N 2 a ZINN x A= XN = 174 18-1
A 2 5S Step 18A:
Crude Cmpd 17d (100 mg) was dissolved in 2 mL pyridine and treated with cyclopropanecarbonyl chloride (0.024 mL). The mixture was heated in a sealed tube at 80 °C for 2 hr, then the solvent was evaporated and the residue was purified by preparative
LC/MS.
Depending on the pyrazolo-(1,5a)-pyrimidine and carbonyl chloride reagent, the compounds in the following table were prepared:
Table 7. =
HN N
—~N 3
NN SS
/° (Cmpd| R TMWIMS [te wm] RK es] eo]
CIEE SS Cm * All HPLC employed Analytical Method 1.
EXAMPLE 19
SYNTHESIS OF (3-(4-METHOXY-2-METHYL-PHENYL)-2,5-DIMETHYL-PYRAZOLO(1,5-
AJPYRIMIDIN-7-YL}-[(S)-2,2,2-TRIFLUORO- 1-(5-METHYL-{1,2,4]0X ADIAZOL-3-YLMETHYL)-
ETHYL]-AMINE fea Ie.
Pry iA gy yo wa” er, AN THF, water Pye
McCN Je ) x wy, 44 19a 1% 0
AL ad 1) oxalyl Lipa 1) H.NOH = hlarde NH, { 2) DMA-DMA Boy 2) NH, “" F, ‘NH R or dioxane > 1H _N 3 or F, NH HA
Ty, ART ex x A XY \ 19% 194 191 0 Pa 5 / 0
Step 19A:
A mixture of 4d (565 mg) and 8¢ (400 mg) in acetonitrile (3.5 mL) was heated in a sealed tube in a microwave reactor at 150 °C for 30 min. Aqueous sodium bicarbonate solution was added, and the mixture was extracted once with 3:1 hexanes/ethyl acetate then once with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography using 3:1 hexanes/ethyl acetate as eluant to provide 19a (410 mg, 53 %) as a slightly yellow oil.
Step 19B:
A mixture of 19a (1.1 g), lithium hydroxide (300 mg), THF (10 mL), and water (2 mL) was heated at 90 °C for 2 hr. The cooled reaction mixture was treated with 4M hydrochloric acid (5 mL) and water (25 mL), and the resulting mixture was extracted twice with ethyl acetate. The combined organic layers were dried over sodium sulfate,
filtered, and evaporated to provide crude 19b (1.1 g) as a yellow oil, which was used without further purification.
Step 19C:
A solution of crude 19b (1.1 g) in THF (10 mL) at RT was treated with oxalyl chloride (0.34 g), followed by two drops of DMF. Vigorous gas evolution was observed, and the mixture was stired at RT for lhr. The reaction mixture was concentrated, then ammonia (20 mL of a 2.0 M solution in dioxane) was added, and the resulting suspension was stirred at RT for 16 hr. Aqueous sodium bicarbonate solution was added, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, dried over sodium sulfate, filtered, and concentrated to provide 19¢ (700 mg) as a pale green oil, which was used without further purification.
Step 19D:
A solution of 19¢ (700 mg) and TEA (750 mg) in dioxane (10 mL) was treated at RT with trifluoroacetic anhydride (1.5 g). The reaction mixture was stirred at
RT for 2 hr, then ag. sodium bicarbonate solution was added and the mixture was extracted twice with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography, using 30 % ethyl acetate in hexanes as eluant, providing 19d (400 mg) as a yellow oil.
Step 19E:
To a solution of 19d (400 mg) in ethanol (10 mL) was added hydroxylamine hydrochloride (85 mg) and potassium hydroxide (70 mg). The mixture was heated at 100 °C for 4hr. The reaction mixture was cooled to RT and filtered, and the filter cake was washed with ethanol. The combined filtrates were concentrated, then the residue was dissolved in DMA-DMA (10 mL) and heated at 90 °C for 2hr. The reaction mixture was concentrated, and the residue was purified by silica gel chromatography, eluting with 3:1 hexanes/ethyl acetate to provide 19e free base (70 mg) as a yellow oil.
The free base was dissolved in acetone (5 mL) and treated with hydrogen chloride (2 mL of 2.0 M solution in ether). The mixture was concentrated in vacuo to provide 19-1 HCI salt (75 mg) as a yellow solid. Mass: 461.0 (MH"); HPLC: Analytical Method 1, retention time 5.28 min.
EXAMPLE 20
SYNTHESIS OF ETHYL-[3-(4-METHOXY-2-METHYL-PHENYL)-2,5-DIMETHYL-PYRAZOLO] 1,5-
AJPYRIMIDIN-7-YL] -(3-METHYL-[1 ,2,4]OXADIAZOL-S-YLMETHYL)-AMINE $0Cl, ~NY McOH NYS - 9! a J acetamide oxime
NaH, THF C0
A ; 98
ACN on 3 =O
Step 20A:
Thiony! chloride (0.71 mL) was added carefully to a cold solution of N- ethyl glycine (0.50 g) dissolved in anhydrous methanol (8 mL). The mixture was heated at 60 °C for 14 hr in a sealed tube. The mixture was concentrated then subjected to co- evaporation with toluene (2x) and acetonitrile (3x). Drying under vacuum gave the amino ester hydrochloride salt 20a as a white gummy solid, which was carried on directly without further purification.
Step 20B:
The condensation of Cmpds 20a and 4d by the procedure of Step 11A provided Cmpd 20b (164 mg) as a yellow oil after silica gel chromatography.
Step 20C:
Compound 20b (164 mg) was subjected to the procedure of Step !1B to afford Cmpd 20-1 (105 mg) as a slightly yellow oil after silica gel chromatography employing hexanes/ethy! acetate eluant.
Depending on the pyrazolo-[1,5a)-pyrimidine, amino acid ester and oxime reagent, the compounds in the following table were prepared:
Table 8.
R
0 / \ (Ao
QL
447.1
B — * All HPLC employed Analytical Method 1.
EXAMPLE 21
SYNTHESIS OF [3-(4-METHOXY-2-METHYL-PHENYL)-2,5-DIMETHYL-PYRAZOLO(1,5-
AJPYRIMIDIN-7-YL]-(1-[1,3,4]0XADIAZOL-2-YL-PROPYL)-AMINE
NH,
Jo ow XC 11a 2 21a C3 / Po : i TsCl
Ethyl formate DBU oN LO 21h C3 2111 CY
U 0 /
Step 21A:
Hydrazine hydrate (0.50 mL) was added to a suspension of Cmpd 11a (230 mg) in ethanol (1.5 mL) at RT. The reaction vessel was sealed and heated with stirring at 75 °C forl7 hr. The clear solution was cooled and concentrated to provide the hydrazide
Cmpd 21a as an oil (230 mg).
Step 2]B:
Crude 21a from the preceeding step (70 mg) was dissolved in ethyl formate (2 mL) and heated at 65 °C for 72 hr. The cooled solution was concentrated to provide the crude diacyl hydrazine Cmpd 21b (70 mg) as an oil.
Step 21C:
A mixture of Cmpd 21b from the preceeding step (29 mg), p- toluenesulfonyl chloride (27 mg), DBU (0.053 mL), and THE (0.5 mL) was heated in a microwave reactor at 150 °C for 10 min. Aqueous sodium bicarbonate solution was added, and the mixture was extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered, and evaporated. The residue was purified by preparative thin-layer silica gel chromatography, eluting with 1:2 hexanes/ethyl acetate 10 afford Cmpd 21-1 as an oil (12 mg). Mass: 393.0 (MH"); HPLC: Analytical Method 4, retention time 2.40 min.
EXAMPLE 22
SYNTHESIS OF (3-(4-METHOXY-2-METHYL-PHENYL)-2,5-DIMETHYL-PYRAZOLO[ 1,5
AJPYRIMIDIN-7-YL]-[ 1-(5-METHYL-{1,3,4]0XADIAZOL-2-YL)-PROPYL]-AMINE
H Is
Cr 2 0 11a @ 22a C3 / D o H mJ pe
N H
H TC
DIC. HOBT DBU
DCM/DMF 98 CO (5 =Y 0)
Va
Step 22A.
Compound 11a was subjected to lithium hydroxide hydrolysis according to the procedure of Step 13C giving Cmpd 22a as a white waxy solid.
Step 22B:
Compound 22a (100 mg) and N-acetylhydrazine were subjected to the procedure of Step 14B. The crude ethyl acetate extract was dried over magnesium sulfate; filtered, and concentrated to provide Cmpd 22b (110 mg, 96%) as a white solid.
Step 22C:
Compound 22b (50 mg) was subjected to the procedure of Step 21C with heating in a microwave reactor at 150 °C for 15 min. The resultant was purified by preparative thin-layer silica gel chromatography, eluting with 48:48:4 hexanes/ethyl acetate/methanol to yield Cmpd 22-1 (8 mg, 71%) as a solid. Mass: 407.0 MH"); HPLC:
Analytical Method 1, retention time 4.543 min.
EXAMPLE 23
SYNTHESIS OF [3-(4-METHOXY-2-METHYL-PHENYL)-2,5-DIMETHYL-PYRAZOLO(| ,5-
A]PYRIMIDIN-7 “YL}-[|-METHYL-2-(5-METHYL-[1,3 4JOXADIAZOL-2-YL)-ETHYL]- AMINE / H
D O 3 , Hn b i 0
C Cr
J. & a
OJ Ne Re 0 O 0 O \ 0
R
= NT Gd
Oy *8 Y = 0) oe 0
O
Step 23A: (RS)-Ethyl 3-aminobutyrate (435 mg) was added to Cmpd 4d (500 mg) according to the procedure of Step LIA to afford Cmpd 23a (540 mg) after silica gel chromatography using 2:1 hexanes/ethyl acetate as eluant.
Step 23B: .
Compound 23a (400 mg) was subjected to the procedure of Step 21A to afford Cmpd 23b (367 mg).
Step 23C:
A solution of Cmpd 23b (180 mg) and triethylamine (0.100 mL) in DCM (4 mL) was treated with acetic anhydride (0.53 mL) at RT. After 17 hr, additional triethylamine (0.100 mL) and acetic anhydride (0.53 mL) were added. The solvent was evaporated, then aq. sodium bicarbonate solution was added and the mixture was extracted with DCM (4x 10 mL). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and evaporated. The residue was chromatographed on silica gel eluting with 5% methanol in DCM to afford Cmpd 23c (165 mg).
Step 23D:
Compound 23¢ (50 mg) was subjected to the procedure of Step 21C substituting 1,3,4,6,7,8-hexahydro-1-methyl-2H-pyrimido[1,2-A]pyrimidine in place of
DBU. Purification by preparative thin-layer silica gel chromatography (1:1 hexanes/acetone as eluant) provided Cmpd 23-1 (12 mg).
Depending on the pyrazolo-[1,5a)-pyrimidine, amino acid ester and oxime : reagent, the compounds in the following table were prepared:
Table 9. .
Ny 0
D
/
Cmpd] Rs [MW MS |t
EI Eo
EE CE EX ED
* All HPLC employed Analytical Method 1.
EXAMPLE 24
SYNTHESIS OF [3-(2-CHLORO-4-METHOXY-PHENYL)-2,5-DIMETHYL-PYRAZOLO[ 1,5-
AJPYRIMIDIN-7-YL}-[1-(3-METHYL-{1 ,2,4]0XADIAZOL-5-YL)-PROPYL]-AMINE
O A aN o 1
OH), } x ] .
H, oR 0 . 54 Br - un 8
U
0 / /
Step 24A:
To Cmpd 5d (100 mgl) was added 2-chloro-4-methox yphenylboronic acid (70 mg) followed by potassium carbonate (80 mg) and a solution of dioxane/water 0.9 mL/0.2 mL). The reaction mixture was sparged with nitrogen for 5 min, then tetrakis(triphenyphosphine)palladium(0) (80 mg) was added, and the reaction vessel was sealed and heated at 85°C for 16 hr. The solvent was evaporated, and the residue was purified directly by preparative thin-layer silica gel chromatography using 30% ethyl acetate in hexanes as eluant, providing Cmpd 24a as a solid (31 mg, 26%). LC/MS: 403.0 (MH)
Step 24B:
Compound 24a (31 mg) and acetamidoxime were subjected to the procedure of S1Bb to afford Cmpd 24-1 (5.17 mg) after preparative thin-layer silica gel chromatography (1:1 hexanes/ethyl acetate eluant).
Depending on the pyrazolo-[1,5a)-pyrimidine, amino acid ester and oxime reagent, the compounds in the following table were prepared:
Table 10. bd : 5 R,), wo] Tm [fev
EE EEE
1 a1 464 88 464.9 5.888
Fy
<5 FRE * All HPLC employed Analytical Method 1.
EXAMPLE 25
CRF RECEPTOR BINDING ACTIVITY
The compounds of this invention may be evaluated for binding activity to the CRF receptor by a standard radioligand binding assay as generally described by
Grigoriadis et al. (Mol. Pharmacol vol50, pp679-686, 1996) and Hoare et al. (Mol.
Pharmacol vol63 pp751-765, 2003). By utilizing radiolabeled CRF ligands, the assay may be used to evaluate the binding activity of the compounds of the present invention with any CRF receptor subtype.
Briefly, the binding assay involves the displacement of a radiolabeled CRF ligand from the CRF receptor. More specifically, the binding assay is performed in 96- well assay plates using 1-10pg cell membranes from cells stably transfected with human
CRF receptors. Each well receives about 0.05 mL assay buffer (e.g., Dulbecco’s phosphate buffered saline, 10 mM magnesium chloride, 2 mM EGTA) containing compound of interest or a reference ligand (for example, sauvagine, urocortin I or CRF), 0.05 mL of ['?°T] tyrosine - sauvagine (final concentration ~150 pM or approximately the
Kp as determined by Scatchard analysis) and 0.1 mL of a cell membrane suspension containing the CRF receptor. The mixture is incubated for 2 hours at 22 °C followed by separation of the bound and free radioligand by rapid filtration over glass fiber filters.
Following three washes, the filters are dried and radioactivity (Auger electrons from 57) is counted using a scintillation counter. All radioligand binding data may be analyzed using the non-linear least-squares curve-fitting programs Prism (GraphPad Software Inc) or XLfir (ID Business Solutions Ltd).
EXAMPLE 26
CRF-STIMULATED ADENYLATE CYCLASE ACTIVITY
The compounds of the present invention may also be evaluated by various functional testing. For example, the compounds of the present invention may be screened for CRF-stimulated adenylate cyclase activity. An assay for the determination of CRF- stimulated adenylate cyclase activity may be performed as generally described by
Battaglia et al. (Synapse 1:572, 1987) with modifications to adapt the assay to whole cell preparations.
More specifically, the standard assay mixture may contain the following in a final volume of 0.1 mL: 2 mM L-glutamine, 20 mM HEPES, and i mM IMBX in
DMEM buffer. In stimulation studies, whole cells with the transfected CRF receptors are plated in 96-well plates and incubated for 30 min at 37 °C with various concentrations of
CRF-related and unrelated peptides in order to establish the pharmacological rank-order profile of the particular receptor subtype. Following the incubation, CAMP in the samples is measured using standard commercially available kits, such as cAMP-Screen™ from
Applied Biosystems. For the functional assessment of the compounds, cells and a single concentration of CRF or related peptides causing 50% stimulation of cAMP production are incubated along with various concentrations of competing compounds for 30 min at 37°C, and cAMP determined as described above.
It will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without departing from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.
Claims (29)
1. A compound represented by the following structure: R NP Het Sy Ny xy = mo, or a pharmaceutically acceptable salt, ester, solvate, stereoisomer or prodrug thereof, R, is hydrogen, alkyl, substituted alkyl, haloalkyl, substituted haloalkyl, alkoxyalkyl, substituted alkoxyalkyl, arylalkyl, substituted arylalkyl, heterocyclealkyl, or substituted heterocyclealkyl; Rj, and Ra are independently hydrogen, C;-Ce alkyl, substituted C,-C¢ alkyl, C;-Cs haloalkyl, substituted C,-Ce haloalkyl, arylalkyl, substituted arylalkyl. Ci-Cs alkoxyalkyl, substituted C;-C¢ alkoxyalkyl, alkylsulfonylalkyl, aminoalkyl, monoalkylaminoalkyl or dialkylaminoalkyl; or R; together with the nitrogen to which it is attached and either Ry, or Rx together with the carbon to which Ra and Ry are attached form a 4-7 membered heterocyclic ning; or R,, and Ry, together with the carbon atom to which they are attached form a ring of 3-7 members optionally containing within the ring -O-, -S- or -N(R3)-; R, is alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, acyl, -C(O)ORg, -C(O)NRgR yg, or S(O)XR 11; Y at each occurrence is independently a direct bond or -C(R4aRab)m-; mis 1or2; Re, and Ry, are independently hydrogen, C,-Cs alkyl, substituted C,-Ce alkyl, arylalkyl, substituted arylalkyl, C;-Cs alkoxyalkyl, substituted C,-Cs alkoxyalkyl, alkylsulfonylalkyl, aminoalkyl, monoalkylaminoalkyl or dialkylaminoalkyl; or
Rg, and Ry, together with the carbon atom to which they are attached form a ring of 3-7 members optionally containing within the ring -O-, -S- or -N(Rs)-; Het is Rs SOs Or ral ale R; is hydrogen, halogen, C,-Cs alkyl, substituted C,-Cs alkyl, C,-Ce alkoxy, substituted C;-Cg alkoxy, amino, alkylamino or dialkylamino; Rs at each occurrence is independently halogen, C,-Cs alkyl or substituted C,-Cs alkyl; n is an integer from 0-3 inclusive; Ar is phenyl or pyridyl; R; at each occurrence is independently halogen, alkyl, substituted alkyl, C,- Cs alkoxy, substituted C-Cs alkoxy, -NRgR 0, alkylsulfonyl or substituted alkylsulfonyl; 0 is an integer from 0-3 inclusive; and each of Rg, Re, Rio and Ry is hydrogen, C-C¢ alkyl, substituted C;-C¢ alkyl, arylalkyl, substituted arylalkyl, C-Cs alkoxyalkyl, substituted C;-Cs alkoxyalkyl, alkylsulfonylalkyl, aminoalkyl, monoalkylaminoalkyl or dialkylaminoalkyl.
2. A compound according to claim 1, wherein: R, is hydrogen, C,-Cs alkyl, C,-Cs substituted alkyl, C,-C¢ haloalkyl, substituted C,-Cg haloalkyl or C,-Cs alkoxyalkyl; R,, and Ry are independently hydrogen, C,-Cs alkyl, substituted C-Cs alkyl, C,-Cg haloalkyl or substituted C,-Cs haloalkyl; or R; together with the nitrogen to which it is attached and either Rj, or Ra, together with the carbon to which Ry, and Ry are attached form a 4-7 membered heterocyclic ning; or
R,, and Ry together with the carbon atom to which they are attached form a 3-7 membered carbocyclic ring; Rs is hydrogen, halogen, C,-C¢ alkyl, substituted C;-Cg alkyl, C,-Cs haloalkyl or substituted C,-Cs haloalkyl; Rg at each occurrence is independently Ci-Cs alkyl or substituted C;-C alkyl; nis0, 1or2; R; at each occurrence is independently halogen, C,-Cs alkyl, substituted
C.-C; alkyl, C;-Ce alkoxy, substituted C,-Cs alkoxy, or -NRgR yo; and ois 1or?2.
3 A compound according to claim 2, wherein: R, is hydrogen, C,-C¢ alkyl, C,-Cs haloalkyl or C;-C¢ alkoxyalkyl; Rs and Ra, are independently hydrogen, Ci-Ce alkyl, substituted Cy-Cs alkyl or C;-Cg haloalkyl; or R, together with the nitrogen to which it is attached and either Ra, or Ra together with the carbon to which Ra and Ra are attached form a 4-7 membered heterocyclic ring; or
Ra. and Ry, together with the carbon atom to which they are attached form a 3-7 membered carbocyclic ring; Y is a direct bond or -C(R4sR4p)- Where Ry; and Ry are each hydrogen; Rs is C;-Cs alkyl or C,-Cg haloalkyl; Rg at each occurrence is independently C;-Cs alkyl; nis 1 or2; R; at each occurrence is independently halogen, C,-Cs alkyl, C;-Ce alkoxy, or -NRgR o; and oislor2,
4, A compound according to claim 3, wherein: R, is hydrogen; R, and Ry, are independently hydrogen or C,-Cs alkyl; or R, together with the nitrogen to which it is attached and either Ry, or Ra together with the carbon to which Ry, and Ry, are attached form a 4-7 membered heterocyclic ring; or R,, and Rap together with the carbon atom to which they are attached form a 3-7 membered carbocyclic ring; Rs is C-Cg alkyl or C;-Cs haloalkyl; Rg at each occurrence is independently C,-Cs alkyl; nisl; Ar is phenyl; R; at each occurrence is C;-Cs alkyl, C;-Cq alkoxy, or -NRoRp; and ‘ ois 2.
5. A compound according to claim 4, wherein: R, is hydrogen; R,, and Ry, are independently hydrogen or C;-C¢ alkyl; Rs is C;-Cs alkyl or C;-Cs haloalkyl; Ry at each occurrence is independently C,-C; alkyl; Het is Ry i NO Ve or Ww : ; and R; at each occurrence is C,-Cg alkyl or C,-Ce alkoxy.
6. A compound according to claim 5, wherein:
one of Rz, and Ray is C,-Cg alkyl and the other is hydrogen; Rs is C;-Cg alkyl; and one R; is C,-Cs alkyl and the other is C;-Cs alkoxy.
7. A compound according to claim 1, wherein the compound is selected from the group of: [1-(3-Cyclopropyl-[1 2.4]oxadiazol-5-yl)-propyl]-[3-(4-methoxy-2-methyl- phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a}pyrimidin-7-yl}-amine; [1-(3-Isopropyl-[1,2,41oxadiazol-5-y1)-propyl]-[3-(4-methoxy-2-methyl- phenyl)-2,5-dimethyl-pyrazolo[1,5-alpyrimidin-7-yl}-amine; [3-(4-Methoxy-2-meth yl-phenyl)-2,5-dimethyl-pyrazolof1 ,5-a]pyrimidin-7- yl}-[1-(3-methyl-[1,2,4]Joxadiazol-5-yl)-2-phenyl-cthyl]-amine; [1-(3-Isopropyl-[1,2,4)oxadiazol-5-yl)-propyl]-{3-(4-methoxy-2-methyl- phenyl)-2,5-dimethyl-pyrazolo[1,5-ajpyrimidin-7-yl]-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazoio[ 1,5-a)pyrimidin-7- yl]-[1-(3-methyl-[1,2,4]oxadiazol-5-y})-butyl]-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo{ 1 ,5-a]pyrimidin-7- yl]-(3-methyl-[1 ,2,4]oxadiazol-5-ylmethyl)-amine; (3-Cyclopropyl-[1,2,4]oxadiazol-5-ylmethyl)-[3-(4-methoxy-2-methyl- phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-amine; (3-Isopropyl-[1 ,2,4Joxadiazol-5-ylmethyl)-[3-(4-methoxy-2-methyl- phenyl)-2,5-dimethyl-pyrazolo[1,5-a}pyrimidin-7-yl]-amine; [2-(3-Cyclopropyl-[1.2,4]oxadiazol-5-yl)-(R)-1-methyl-ethyl]-[3-(4- methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolof1 ,5-a]pyrimidin-7-yl}-amine; [3-(4-Methoxy-2-meth yl-phenyl)-2,5-dimeth yl-pyrazolo[1,5-a]pyrimidin-7- yl]-[(R)-1-methyl-2-(3-methyl-[1,2,4]oxadiazol-5-yl)-cthyl]-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-alpyrimidin-7- yl]-[1-(3-trifluoromethyl-[1,2,4Joxadiazol-5-yl)-propyl]-amne; [1-(3-Cyclopropyl-[1,2,4]oxadiazol-5-yl)<cyclopropyl]-{3-(4-methoxy-2- methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a)pyrimidin-7-yl]-amine), [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a] pyrimidin-7- yl]-[1-(3-methyl-[1,2,4]oxadiazol-5-yl)cyclopropyl]-amine;
[1-(3-Ethyl-[1,2 .4)oxadiazol-S-yl)-cyclopropyl]-{3-(4-methoxy-2-methyl- phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7-yl]-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolof 1,5-alpyrimidin-7- yl)-(3-propyl-[1 ,2,4]oxadiazol-5-ylmethyl)-amine; [3-(4-Methoxy-2-methyl-pheny})-2,5-di methyl-pyrazolo{ 1,5-a)pyrimidin-7- yl]}-[ 1-(3-trifluoromethyl-[1 2,4Joxadiazol-5-yl)-cyclopropyl]-amine; [2-(3-Ethyl-[1 2,4)oxadiazol-5-yl)-(R)-1-meth yl-ethyl]-[3-(4-methoxy-2- methyl-phenyl)-2,5-dimethyl-pyrazolo( 1,5-a]pyrimidin-7-yl]-amine; {3-(6-Dimethylamino-4-methy-pyridin-3-yl)-2,5-dimethyl-pyrazolo{1 NE a]pyrimidin-7-y1]-[3-methyl-(R)- 1-(3-methyl-[1,2,4]oxadi azol-5-yl)-butyl]-amine; 3-(2,4-Dimethoxy-phenyl)-2,5-dimeth yl-7-((S)-2-(3-methyl- [1,2,4]oxadiazol-S-yl)-pyrrolidin-1-yl}-pyrazolo{1 ,5-a]pyrimidine; [3-(2,4-Dimethoxy-phenyl)-2,5-dimeth yl-pyrazolo[ 1,5-a]pyrimidin-7-yl]- (1-(3-methyl-(1,2,4}oxadiazol-5-yl)-propyl]-amine; : [3-(2,4-Dimethoxy-phenyl)-2,5-di methyl-pyrazolo(1,5-a]pyri midin-7-yl]- [1-(3-methyl-{1,2,4Joxadiazol-5-yl)-ethyl]-amine; [3-(2,4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo(1 ,5-alpyrimidin-7-yl}- [1-(3-methyl-{1,2,4Joxadiazol-5-yl)-butyl]-amine; [3-(2,4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo[1 ,5-a]pyrimidin-7-yl]- [3-methyl-1-(3-methyl-[1,2 ,4Joxadiazol-5-yl)-butyl]}-amine; [3-(2,4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo{1 ,5-alpyrimidin-7-yl}- methyl-(3-methyl-[1,2,4]oxadi azol-5-ylmethyl)-amine; Benzyl-[3-(6-dimeth ylamino-4-methyl-pyridin-3-y1)-2,5-dimeth yi- pyrazolo[1,5-a)pyrimidin-7 -yl])-(3-methyl-[1,2 4]oxadiazol-5-ylmeth yl)-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolof1 ,5-a]pyrimidin-7- yl]-[1-(3-methyl-[1 ,2,4)oxadiazol-5-yl)-propyl]-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a] pyrimidin-7- yl)-[1-methyl-2-(3-methyl-[1 ,2,4]oxadiazol-5-yl)-ethyl]-amine; Benzyl-[3-(4-methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo [1,5- a)pyrimidin-7-yl}-(3-methyl-(1,2,4] oxadiazol-5-ylmethyl)-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7- y1}-(2,2,2-trifluoro-1-(3-methyl-{1 ,2,4]oxadiazol-5-ylmethyl)-ethyl]-amine;
[2-(3-Cyclopropyl-[1,2,4]oxadiazol-5-y1)-1 -methyl-ethyl}-[3-(4-methoxy- 2-methyl -phenyl)-2,5-dimethyl-pyrazolof 1,5-a]pyrimidin-7-yl]-amine; [2-(3-Isopropyl-[1,2,4] oxadiazol-5-yl)-1-methyl-ethyl]-[3-(4-methoxy-2- methyl-phenyl)-2,5-dimethyl-pyrazolo{ 1,5-a]pyrimidin-7-yl}-amine; [2-(3-Cyclopropyl-[1,2,4]oxadiazol-5 -y1)-(S)-1-methyl-ethyl)-{3-(4- methoxy-2-methyl-phenyl)-2,5-dimeth yl-pyrazolo[ 1,5-a]pyrimidin-7-yl]-amine; [2-(3-Isopropyl-[1,2,4]Joxadi azol-5-yl)-(S)-1-methyl-ethyl]-[3-(4-methoxy- 2-methyl-phenyl)-2,5-dimethyl-pyrazolo(1 ,S-a]pyrimidin-7-yl]-amine; [3-(4-Methoxy-2-meth yl-phenyl)-2,5-dimethyl-pyrazolof1 ,5-a}pyrimidin-7- yi1-[(S)-1-methyl-2-(3-methyl-(1 ,2,4]oxadiazol-5-yl)-ethyl]-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo(1 ,5-a]pyrimidin-7- yl1-[1-(3-methyl-[1 ,2 4]oxadiazol-S-ylmethyl)-propyl]-amine; [1-(3-Cyclopropyl-[1,2,4]oxadiazol-5-ylmeth yl)-propyl}-{3-(2,4- dimethoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a) pyrimidin-7-yl]-amine; [3-(2.4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo[1 ,5-a)pyrimidin-7-yl}- [1-(3-methyl-[1,2,4}oxadiazol-5-ylmeth yl)-propyl]-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo(1,5-a] pyrimidin-7- y11-[(S)-1-(3-methyl-[1 ,2.4]oxadiazol-5-yl)-butyl]-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a] pyrimidin-7- yl]-[2,2,2-trifluoro-(S)-1-(3-methyl-{1 ,2,4]oxadiazol-5-ylmethyl)-ethyl]-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo(1,5-a] pyrimidin-7- yl)-{1-methyl-2-(3-trifluoromethyl-{1 ,2,4]oxadiazol-5-yl)-ethyl}-amine; [3-(2-Chloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pynmidin-7- y1]-[2,2,2-trifluoro-(8)- 1-(3-methyl-[1 ,2,4]oxadiazol-5-ylmethyl)-ethyl}-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7- yl}-[(R)-1-methyl-2-(3-trifluoromethyl-[1 ,2,4]oxadiazol-5-yl)-ethyl]-amine; [3-(2-Chloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7- yl]-[(R)-1-methyl-2-(3-trifluoromethyl-[1 ,2.4]Joxadiazol-5-yl)-ethyl]-amine; [3-(2,4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7-yl]- [(R)-1-methyl-2-(3-triflucromethyl-[ 1,2,4Joxadiazol-5-yl)-ethyl]-amine; [3-(2,4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a)pyrimidin-7-yl]-
[2.2.2-trifluoro-(S)-1-(3-methyl-[1,2,4)oxadiazol-5-ylmethyl)-ethyl}-amine;
[3-(2.4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo[1 ,5-a]pyrimidin-7-yl}-
[2.2.2-trifluoro-(S)-1-(3-trifluoromethyl-[ 1 ,2.4Joxadiazol-5-ylmethyl)-ethyl]-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo( 1,5-a)pyrimidin-7- y1]-[(S)-1-(3-methyl-[1 ,2,4)oxadiazol-5-yl)-propyl]-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7- ylJ-[(R)-1-(3-methyl-[1,2 4]oxadiazol-5-y])-propyl]-amine;
3.(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-7-[(S)-2-(3-methyl- [1,2,4]oxadiazol-5-ylmethyl)-pyrrolidin-1-yl}-pyrazolo[ 1 ,5-a)pyrimidine; [3-(2-Chloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1 ,5-a]pyrimidin-7- yl]-[(S)-1-(3-methyl-[ 1,2 4]oxadiazol-5-yl)-propy!]-amine; [3-(2,4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo{1 ,5-a]pyrimidin-7-yl]- (2-methoxy-ethyl)-(3-methyl-[ 1,2 4]oxadiazol-5-ylmethyl)-amine; (5-{2.5-Dimethyl-7-[(S)-2-(3-methyl-[1,2,4]oxadiazol-5-y})-pyrrolidin-1- yl]-pyrazolo[1,5-a}pyrimidin-3-yl }4-methyl-pyridin-2-yl)-dimethyl-amine; [3-(6-Dimethylamino-4-methyl-pyridin-3-yl)-2,5-dimethyl-pyrazolo{1,5- a]pyrimidin-7-yl]-(2-methoxy-ethyl)-(3-methyl-[1 ,2,4Joxadiazol-5-ylmethyl)-amine; [3-(4-Ethoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-(2- methoxy-ethyl)-(3-methyl-{1,2,4]oxadiazol-5-ylmethyl)-amine; [3-(2.4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a)pyrimidin-7-yl]- (2-methoxy-ethyl)-[3-(3-methyl-[1,2,4]oxadiazol-5-yl)-propyl}-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7- yl-[(R)-1-methyl-2-(5-methyl-[1 ,2,4]Joxadiazol-3-yl)-ethyl]-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo{1,5-a}pyrimidin-7- y1]-[(S)-1-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-propyl}-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a)pyrimidin-7- yll-[(R)-1-(5-methyl-[1,2 4]oxadiazol-3-ylmethyl)-propyl]-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a}pyrimidin-7- y1]-((S)-1-methyl-2-(5-methyl-[1,2,4]oxadiazol-3-yl)-ethyl]-amine; [(R)-2-(5-Cyclopropyl-[1,2,4Joxadiazol-3-yl)-1-methyl-ethyl]-[3-(4- methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-amine; : [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7- y1]-[(R)-1-methyl-2-(S-trifluoromethyl-[1,2,4]oxadiazol-3-yl)-ethyl}-amine;
[3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7- y1}-[(S)-2,2,2-trifluoro-1-(5-methyl-[ 1,2,4]oxadiazol-3-ylmethyl)-ethyl]-amine; Ethyl-[3-(4-methoxy-2-methyl-pheny})-2,5-dimethyl-pyrazolo(1,5- aJpyrimidin-7-yl}-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-amine; 3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-7-{2-(3-methyl- [1,2.4)oxadiazol-5-ylmethyl)-piperidin-1-yl]-pyrazolo{1,5-a]pyrimidine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo{ 1,5-a)pyrimidin-7- yl]-(1-[1,3,4]oxadiazol-2-yl-propyl)-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo{1,5-a]pyrimidin-7- yi]-[1-(5-methyl-[1,3 4]oxadiazol-2-yl)-propyl]-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7- yl]-[1-methyl-2-(5-methyl-[1,3 4]oxadiazol-2-yl)-ethyl]-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[ | ,5-a]pyrimidin-7- ylJ-[ 1-methyl-2-(5-trifluoromethyl-[ 1,3,4]oxadiazol-2-yl)-cthyl]-amine; [3-(2-Chloro-4-methoxy-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7- yl]-[1-(3-methyl-[1,2 4]oxadiazol-5-yl)-propyl]}-amine; . [3-(4-Chloro-2-methoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a}pyrimidin-7- yl]-[1-(3-methyl-[1,2 4]oxadiazol-5-yl)-propyl]-amine; [3-(3-Chloro-4-fluoro-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a}pyrimidin-7- yl]-[1-(3-methyl-[1,2,4]oxadiazol-5-yl)-propyl]-amine; [3-(4-Chloro-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7- yl}-[1«3-methyl-[ 1,2 4]oxadiazol-5-yl)-propyl]-amine; [3-(2-Chloro-4-triflucromethyl-phenyl)-2,5-dimethyl-pyrazolo[1,5- a]pyrimidin-7-yl]-{1-(3-methyl-[1,2,4Joxadiazol-5-yl)-propyl]-amine; and [3-(2-Chloro-4-methyl-phenyl)-2,5-dimethyl-pyrazolo([1,5-a]pyrimidin-7-y1]-[1-(3- methyl-[1,2,4]oxadiazol-S-yl)-propyl]-amine.
8. A compound according to claim 7, wherein the compound is selected from the group of: (3-(2,4-Dimethoxy-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-
[2.,2.2-trifluoro«S)-1-(3-methyl-[ 1,2,4]oxadiazol-5-ylmethyl)-cthyl}-amine;
[3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolol 1,5-a]pyrimidin-7- ylI-[(S)-1-(3-methyl-{1,2,4]oxadiazol -5-yl)-propyl]-amine; [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a}pyrimidin-7- ylI-[(R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-propyl])-amine; [3-(2-Chloro-4-methoxy-phen yl)-2,5-dimethyl-pyrazolo(1,5-a]pyrimidin- 7-yI}-[(S)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-propyl]-amine; and [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a)pyrimidin-7- yl]-[(R)-1-methyl-2-(5-trifluoromethyl-{1,2,4]oxadiazol-3-yl)-ethyl]-amine.
9. A compound according to claim 8, wherein the compound is selected from the group of: [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7- yI]-[(S)-1-(3-methyl-[1,2,4]oxadiazol-5-y!)-propyl]-amine; and [3-(4-Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo{ 1,5-a]pyrimidin-7- yi]-[(R)-1-(3-methyl-{1,2,4]oxadiazol-5-yl)-propyl]-amine.
10. A compound according to claim 9, wherein the compound is [3-(4- Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a]pyrimidin-7-yl]-[(S)-1-(3- methyl-[1,2,4]oxadiazol-5-yl)-propyl]-amine.
11. A compound according to claim 9, wherein the compound is [3-(4- Methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[ 1,5-a}pyrimidin-7-yi]-[(R)-1-(3- methyl-[1,2,4]oxadiazol-5-yl)-propyl]-amine.
12. Polymorph Form 1 of [3-(4-Methoxy-2-methyl-phenyl)-2,5- dimethyl-pyrazolo[1,5-a}pyrimidin-7-yl]-{(S)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-propyl]- amine.
13. The polymorph Form 1 of claim 12 wherein the polymorph exhibits a predominant endotherm at about 108.3 °C.
14. The polymorph Form 1 of claim 12 wherein the polymorph exhibits an X-ray powder diffraction pattern having peaks expressed in degrees 20 (+/- 0.15 degrees 26) at 6.721, 11.757, and 21.974.
15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a pharmaceutically effective amount of a compound according to claim 1.
16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a pharmaceutically effective amount of a compound according to claim 8.
17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a pharmaceutically effective amount of a compound according to claim 10.
18. Use of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to claim | in the manufacture of a medicament for treating an individual having a condition susceptible to treatment with a CRF antagonist.
19. Use of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to claim 8 in the manufacture of a medicament for treating an individual having a condition susceptible to treatment with CRF antagonist.
20. Use of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of claim 10 in the manufacture of a medicament for treating an individual having a condition susceptible to treatment with a CRF antagonist. 105 Amended Sheet
21. A use according to claim 17, wherein said condition is a neuropsychiatric disorder.
22. A use according to claim 18, wherein the neuropsychiatric disorder is selected from the group of anxiety, depression and irritable bowel syndrome.
23. A use according to claim 19, wherein the neuropsychiatric disorder is anxiety.
24. A use according to claim 19, wherein the neuropsychiatric disorder is depression.
25. A use according to claim 19, wherein the neuropsychiatric disorder is irritable bowel syndrome.
26. A compound according to claim 1, substantially as herein described and exemplified and/or described with reference to the accompanying figures.
27. A polymorph of claim 12, substantially as herein described and exemplified and/or described with reference to the accompanying figures.
28. A pharmaceutical composition according to any one of claims 15, 16 or 17, substantially as herein described and exemplified and/or described with reference to the accompanying figures.
29. Use according to any one of claims 18, 19 or 20, substantially as herein described and exemplified and/or described with reference to the accompanying figures. 106 Amended Sheet
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62006004P | 2004-10-19 | 2004-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200702467B true ZA200702467B (en) | 2008-07-30 |
Family
ID=38913138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200702467A ZA200702467B (en) | 2004-10-19 | 2007-03-26 | Pyrazolo[1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor(CRF) receptor antagonists |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN101084219A (en) |
ZA (1) | ZA200702467B (en) |
-
2005
- 2005-10-19 CN CN 200580043716 patent/CN101084219A/en active Pending
-
2007
- 2007-03-26 ZA ZA200702467A patent/ZA200702467B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN101084219A (en) | 2007-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005295353B2 (en) | Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists | |
KR101292348B1 (en) | Pyridine derivatives and their use in the treatment of psychotic disorders | |
US7034153B2 (en) | Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient | |
AU2005299032B2 (en) | Imidazo-benzodiazepine derivatives | |
JP2001511813A (en) | CRF receptor antagonists and related methods | |
CA2584757C (en) | Halogen substituted benzodiazepine derivatives | |
WO2008129007A1 (en) | Benzimidazoles with a hetero spiro-decane residue as npy-y5 antagonists | |
JP2002529465A (en) | CRF receptor antagonists and methods for CRF receptor antagonists | |
US7026317B2 (en) | Pyrazolotriazines as CRF antagonists | |
JP4926720B2 (en) | CRF receptor antagonists and methods related thereto | |
ES2208404T3 (en) | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDOS OF THE 3 GABA RECEIVERS. | |
EP1178048A1 (en) | Azabicycloalkane derivatives for use as serotonin reuptake inhibitors and 5HT2a antagonists | |
EP1697369A1 (en) | Crf receptor antagonists and methods relating thereto | |
US8268854B2 (en) | Aza-beta-carbolines and methods of using same | |
US8088779B2 (en) | Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists | |
FI92203C (en) | Process for the preparation of therapeutically active 4-oxo-imidazo / 1,5-a / quinoxaline derivatives | |
ZA200702467B (en) | Pyrazolo[1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor(CRF) receptor antagonists | |
JP2006525309A (en) | Pyrrolo (1,2-b) pyridazine compounds and their use as CRF-1 receptor antagonists | |
MXPA06007283A (en) | Crf receptor antagonists and methods relating thereto |